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Model-based tools to improve treatment of tuberculosis patients 
Marjorie Zamora Imperial 
Abstract 
Tuberculosis (TB) infects 10 million people each year and kills more than any other 
infectious disease. All current approaches to TB treatment are based on a one-size-fits-all 
approach, which leads to undertreatment of patients with severe forms of disease and entails 
unnecessarily long treatment with potential toxicities for many patients in whom the disease is less 
severe. Shorter, efficacious, and better-tolerated oral regimens for TB are needed. Unfortunately, 
all recent Phase 3 clinical trials aimed to shorten treatment duration from 6 months to 4 months 
for drug susceptible TB failed. The aims of this dissertation were to quantitively characterize 
treatment response in TB patients and develop model-based tools that provide informed 
recommendations on optimal treatment regimens and strategies that: i.) maximize durable cure in 
all patients, ii.) maximize success of late stage regimen development, and iii.) minimize safety 
concerns associated with a highly potent, but toxic, high-dose linezolid-containing regimen.    
In a patient-level pooled analysis of all recent Phase 3 clinical trials evaluating shorter 
treatments for drug susceptible TB , survival analysis identified risk factors of treatment outcomes. 
Based on these risk factors, a risk stratification algorithm and clinical simulation tool were 
developed to provide more individualized predictions of optimal treatment regimens to achieve 
high cure rates in TB patients.   
TB regimen development is plagued with many challenges, the most serious being the inability 
to identify optimal regimens early and efficiently. To facilitate decisions on novel TB regimens 
that move forward through the development process, an integrated model was developed to 
describe the translational link between Phase 2 intermediate biomarkers, treatment characteristics, 
and patient risk factors to Phase 3 clinical outcomes. We provide clinical trial simulation tools to 
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design innovative clinical trial designs that permit evidence-based decisions on moving the best 
regimens forward in late stage clinical development .   
The TB regimen development process is also challenged by the lack of reliable, quantitative, 
non-culture-based biomarkers that inform individual level and trial level treatment response. We 
showed that leveraging longitudinal sputum culture results and drug exposure and applying 
advanced nonlinear mixed effect modeling with machine learning approaches offer insights into 
the response dynamics following anti-TB treatment. We identified candidate proteomic signatures 
that can potentially predict treatment response. 
 Lastly, using modeling and simulation approaches, we quantified the pharmacokinetic-
toxicodynamic relationship of a high-dose linezolid-containing regimen for extensively drug 
resistant TB. We provide practical data-driven recommendations about linezolid dosing 
adjustments to optimize therapeutic effects and minimize adverse events.  
  The quantitative, model-based tools developed in this dissertation contributes to providing 
evidence-based recommendations on optimal treatment strategies for current and novel TB 
regimens.  
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Chapter 1:  A patient-level pooled analysis of treatment-shortening regimens for drug 
susceptible pulmonary tuberculosis*  
Abstract 
Tuberculosis (TB) kills more people than any other infectious disease. Three pivotal trials 
testing 4-month regimens failed to meet non-inferiority margins; however, approximately four-
fifths of participants were cured. Through a pooled analysis of patient-level data with external 
validation, we identify populations eligible for 4-month treatment, define phenotypes that are hard 
to treat and evaluate the impact of adherence and dosing strategy on outcomes. In 3,405 
participants included in analyses, baseline smear grade of 3+ relative to <2+, HIV seropositivity 
and adherence of ≤90% were significant risk factors for unfavorable outcome. Four-month 
regimens were non-inferior in participants with minimal disease defined by <2+ sputum smear 
grade or non-cavitary disease. A hard-to-treat phenotype, defined by high smear grades and 
cavitation, may require durations >6 months to cure all. Regimen duration can be selected in order 
to improve outcomes, providing a stratified medicine approach as an alternative to the ‘one-size-
fits-all’ treatment currently used worldwide. 
  
                                               
* Modified from the publication:  Imperial, MZ, et.al A patient-pooled analysis of treatment-
shortening regimens for drug susceptible pulmonary tuberculosis. Nature Medicine 2018; 
24:1708-15. 
2 
 
Introduction  
Three recent international randomized Phase 3 trials evaluating 4-month fluoroquinolone-
containing regimens in adults with pulmonary, drug-susceptible tuberculosis (TB) failed to achieve 
non-inferiority as compared to the standard 6-month control regimen (OFLOTUB1, 
ClinicalTrials.gov number, NCT00216385; REMoxTB2, NCT00864383; RIFAQUIN3, ISRCTN 
number, 44153044). These trials evaluated later-generation fluoroquinolones (gatifloxacin and 
moxifloxacin), as single substitutions for ethambutol or isoniazid in multi-drug regimens with the 
objective of shortening treatment duration from six to four months. In each of the three trials, the 
4-month regimen did not satisfy the criteria for non-inferiority. However, the experimental four-
month regimens did cure approximately four-fifths of the participants, suggesting that a large 
proportion of global TB cases could be successfully treated with shorter duration.1-3  
Since the introduction of highly effective rifampin-based regimens in the 1970s and 1980s, 
the treatment of TB has been a “one-size-fits-all” paradigm, with a 6-month regimen comprised of 
four drugs (isoniazid, rifampin, pyrazinamide and ethambutol) used for all patients with drug-
susceptible pulmonary TB.4,5 Regimen administration is coupled with various adherence 
interventions at the programmatic level, including directly observed therapy, to ensure regimen 
intake.4 In programs, the one-size-fits-all paradigm leads to undertreatment of patients with severe 
forms of disease, and entails unnecessarily long treatment with potential toxicities for many 
patients in whom there is a lower disease burden, which in turn may result in increased rates of 
loss to follow-up.6 In clinical trials, one-size-fits-all experimental regimens have been consistently 
inadequate to cure the hardest-to-treat TB patients indicating that treatment duration is a critical 
determinant for cure.7 Moreover, even for the standard 6-month regimen, based on the recent trials  
5-8% of patients fail treatment or relapse, and 15-20% experience composite unfavorable 
outcomes.1-3,8 TB is not a uniform clinical entity, and presents with wide variation in severity of 
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disease at the time of diagnosis. Yet, current TB regimen development efforts are aimed at using 
new drugs with increased potency to identify shorter treatments for all patients, regardless of 
severity of disease. This approach places otherwise efficacious drugs and regimens at risk of being 
abandoned, consequently impeding the identification of new TB regimens that are curative if used 
with greater precision.    
In this pooled analysis of individual patient datasets from these high-quality, contemporary 
trials, we sought to identify characteristics of those patients who were cured with 4-month 
regimens and conversely those with hard-to-treat phenotypes of TB who might require longer 
treatment durations. We evaluated both baseline characteristics as well as on-treatment markers of 
risk, including dosing frequency and adherence, for their ability to stratify the study population 
into easy- or hard-to-treat phenotypes of TB.  
Methods 
Study design  
This study utilized individual patient data from four recent, international, randomized 
Phase 3 trials (OFLOTUB1, REMoxTB2, RIFAQUIN3 and DMID 01-0099) that compared 4-
month regimens to standard 6-month WHO and ATS/CDC/IDSA endorsed regimens for drug-
susceptible pulmonary TB.4,5 The OFLOTUB trial compared an experimental 4-month 
gatifloxacin-based regimen to a 6-month standard regimen.1 The REMoxTB trial compared two 
experimental 4-month moxifloxacin-based regimens to a 6-month standard regimen.2 The 
RIFAQUIN trial compared experimental 4-month or 6-month moxifloxacin- and high-dose 
rifapentine-based intermittent regimens to a 6-month standard regimen.3 A fourth independent TB 
treatment-shortening trial sponsored by the National Institute of Allergy and Infectious Diseases 
(NIAID) and conducted by the NIH-funded Tuberculosis Research Unit compared a 4-month 
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standard regimen (with no fluoroquinolone) to a 6-month standard regimen in adults with non-
cavitary disease and 2-month culture negative status (DMID 01-009, NCT00130247).9  The pooled 
analyses are focused on data from participants receiving the 4-month experimental regimens and 
6-month standard regimens, and do not include the once-weekly (in continuation phase) 
fluoroquinolone 6-month experimental regimen in the RIFAQUIN trial. The three trials that 
compared four fluoroquinolone-based tuberculosis regimens to a 6-month standard regimen 
provided data for identifying markers and models for risk stratification, while the DMID 01-009 
trial data were used for external validation. We defined the experimental group as all study 
participants allocated to any of the 4-month experimental regimens and the control group as all 
study participants allocated to the 6-month standard regimen.  The protocol for each study was 
reviewed and approved by ethics committees and regulatory committees described in the original 
publications and all patients provided written informed consent.1-3,9  
Data acquisition, management and harmonization  
Integrated and standardized individual level data in each of the trials were obtained through 
the Platform for Aggregation of Clinical TB Studies (TB-PACTS; https://c-path.org/programs/tb-
pacts/). Data sharing was directed by comprehensive Data Contribution Agreements with sponsors. 
Before data were pooled, we compared trial protocols, case report forms, and data dictionaries to 
harmonize databases. Data queries were resolved through direct consultations with each trial team 
and Critical Path data managers. After pooling data, data inputs were checked for missing or 
duplicated values, for consistency and plausibility. Final dataset specification is available in 
Appendix Table A.1 and Appendix Table A.2, and access to original databases is available through 
TB-PACTS.  Data from the DMID 01-009 were obtained directly from the sponsor.  
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Efficacy outcomes 
The primary efficacy endpoint of the pooled analysis was time to an unfavorable outcome 
for a maximum of 24 months after start of treatment (participants in the OFLOTUB study were 
followed until 24 months after start of treatment and RIFAQUIN and REMoxTB for 18 months), 
as defined according to each trial protocol and described in the original publications. Trial-specific 
definitions of unfavorable outcome were broadly similar but included some differences, which are 
outlined in Appendix Table A.1.  For example, reinfections confirmed by mycobacterial 
interspersed repetitive unit (MIRU) typing were excluded from the composite definition of 
unfavorable outcome in the primary analysis of the REMoxTB and RIFAQUIN trials, whereas 
they were included in the composite definition of unfavorable outcome in the primary analysis of 
the OFLOTUB trial. The secondary efficacy outcome was the non-parametric Kaplan-Meier 
estimate of unfavorable outcome at 24 months after start of treatment.  
Baseline predictors 
The primary analysis set included baseline predictors, which were missing in no more than 
10% of participants: age, race, body mass index (BMI), sex, presence of cavitation on chest 
radiograph and smear grade (Appendix Table A.2). Weight was also considered for inclusion in 
the primary analysis but ultimately was not included due to its moderate correlation with body 
mass index (BMI, Spearman coefficient 0.74). No major covariate imputation was done, with two 
exceptions: (1) black race was assigned for all participants in the OFLOTUB trial, in which race 
information was not available, given that all OFLOTUB sites were in Africa and similar 
demographic characteristics were observed in other studies at their African sites (majority black);  
(2) median height for females and males of available data was used for 291 participants with 
missing height to calculate BMI, defined as the weight in kilograms divided by the squared height 
in meters (additional details available in Appendix Table A.2). Smear grading was specific for 
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each microscopy method, each study, and, in the RIFAQUIN trial, each study center; described in 
study protocols and lab manuals.1-3,9 RIFAQUIN and OFLOTUB trials reported smear grade using 
a negative, 1+, 2+, and 3+ system, while REMoxTB and the validation study reported smear grade 
using a 1+, 2+, 3+ and 4+ system. A conversion chart available in the REMoxTB trial lab manual 
was used to synchronize all smear data to the same grading scale.2 Additional patient 
characteristics (smoking, cough grade, other radiographic measures) were considered but not 
included in the primary analysis due to large proportions of missing data (>10%, Appendix Table 
A.2). 
On-treatment predictors 
On-treatment culture time-point universally applied in all trials was month-two culture 
status on Lowenstein-Jensen (LJ) solid medium or in liquid medium using the Mycobacteria 
Growth Indicator Tube (MGIT) system.  Culture positivity on either media was used for analyses, 
with preference for solid culture if available. Univariate Cox proportional hazard analysis for 
merged MGIT and LJ culture data (as described above), MGIT data only, and LJ data only showed 
similar results in each treatment group (Appendix Table A.3). Treatment adherence was calculated 
as the number of days that doses were taken divided by the prescribed number of days. For 
participants with an unfavorable event during the treatment phase, the adherence calculation was 
adjusted for duration completed, e.g. full adherence was assigned for study participants who took 
all doses up to time of event, if the event appeared during treatment. 
Individuals with missing data between the predefined sets of predictors were excluded from 
the multivariate analysis. There were no major correlations between predefined set of baseline and 
on-treatment predictors.  
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Statistical analysis  
All analyses were conducted using modified intent-to-treat (MITT) and per-protocol 
populations, with the former used for primary analysis (per-protocol results available in published 
manuscript). Definitions for analysis populations are provided in the clinical trial protocols.1-3,9  
To identify risk factors of time to unfavorable outcomes, we performed multivariate Cox 
proportional hazards analysis. Hazard ratios with 95% Wald confidence intervals were reported. 
Analyses were conducted separately for the experimental and control regimens as the hard-to-treat 
phenotypes may be different for different treatment durations.  All multivariate analyses were 
adjusted for study country.  The proportional hazard assumption was tested using Schoenfeld 
residuals, with a p <0.05 for non-proportionality. Model selection for multivariate Cox analysis 
started with a full model (included all predefined predictors) that was followed by a backward 
stepwise approach (p > 0.05 to remove) then a forward stepwise approach to test predictors that 
were removed in the backward step (p < 0.01 to include). Predictors were included using linear 
relationships. Non-inferiority analyses were performed in study participant subgroups, according 
to identified risk factors in the multivariate Cox analysis. The test for interaction for each subgroup 
was performed prior to non-inferiority sub-group tests.10 The absolute difference in proportion of 
unfavorable outcomes was calculated using inverse probability study-weighted Kaplan-Meier 
estimates at 24 months after start of treatment to include maximal patient-years of follow up and 
retain maximal data.11 Non-inferiority was assessed using the upper bound of the two-sided 90% 
confidence interval, determined by bootstrapping 500 samples, and a non-inferiority margin of 6 
percentage points, which was used in all the parent trials.1-3  
Further analyses were performed to assess impact of 7/7 (REMoxTB and RIFAQUIN) and 
6/7 weekly (OFLOTUB) dosing strategies on outcomes. First, we compared Kaplan-Meier 
estimates for 7/7 and 6/7 weekly dosing strategies in study participants who completed their 
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prescribed treatment.  Second, we performed separate Cox proportional hazards analyses for trials 
with different weekly dosing strategies and assessed total number of days that the drugs were taken 
(total doses) and treatment duration (time between first and last dose dates) as predictors of 
treatment outcomes. To allow for pragmatic interpretation, hazard ratios were reported for total 
doses of 156 to 181 (on average 6/7 doses per week) and 112 to 155 (on average 5/7 doses per 
week) relative to 182 (on average 7/7 doses per week) for the REMoxTB and RIFAQUIN analysis 
(7/7 weekly dosing strategies for 26 weeks). For the OFLOTUB analysis (6/7 weekly dosing 
strategy for 24 weeks), hazard ratios were reported for total doses of 112 to 143 (on average 5/7 
doses per week) relative to 144 (on average 6/7 doses per week). We have used an arbitrarily lower 
cutoff of 112 total doses as it coincides with 4 months of treatment on 7/7 dosing strategy and most 
of the data were clustered above this cutoff point. We have performed sensitivity analysis with 
cutoffs of at least 130 (exact number of doses if participant took 5/7 doses for 26 weeks) for the 
REMoxTB and RIFAQUIN analysis and 120 (exact number of doses if participant took 5/7 doses 
for 24 weeks) for the OFLOTUB analysis.  Each analysis was adjusted for study country.   
All data management, analyses and visualization were performed using R Statistical 
Software (version 3.4.3, https://www.r-project.org/).  
Data availability  
The standardized data for the OFLOTUB (ClinicalTrials.gov number, NCT00216385) , 
REMoxTB (NCT00864383), and RIFAQUIN (ISRCTN number, 44153044) trials that support the 
findings of this study are publicly available to qualified researchers through the Platform for 
Aggregation of Clinical TB Studies (TB-PACTS, https://c-path.org/programs/tb-pacts/). The 
DMID 01-009 (NCT00130247) data that support the findings of this study are available from the 
Tuberculosis Research Unit at Cape Western Reserve University but restrictions apply to the 
availability of these data, which were used under agreement for the current study. Data are however 
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available from the authors upon reasonable request and with permission from the Tuberculosis 
Research Unit.   
Results  
Study participants  
A total of 3411 study participants treated for drug susceptible tuberculosis with one of four 
fluoroquinolone-containing 4-month regimens (n=2001) or the standard 6-month regimen 
(n=1404) were included in the modified intention-to-treat (MITT) analyses of the OFLOTUB1, 
REMoxTB2, and RIFAQUIN3 trials; six  participants were excluded from the current analyses due 
to inability to verify treatment allocation in source databases. The external validation data set 
(DMID 01-0099) includes 193 study participants treated with a 4-month experimental regimen (no 
fluoroquinolone) and 193 study participants treated with the standard 6-month regimen (Figure 
1.1). Baseline characteristics of participants did not differ across the experimental and control 
groups within analysis datasets with exception of race and Senegal country (both p < 0.001, Table 
1.1); 12% of the participants were HIV-infected. 
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Figure 1.1 Analysis and validation populations. Individual patient data from three trials were pooled for 
analysis. The original results were published in ref. 1 (OFLOTUB), ref. 2 (REMoxTB), and ref. 3 
(RIFAQUIN). Data from a fourth trial, DMID 01-009, were used for external validation and previously 
published in ref. 9. The modified intent-to-treat population was used for the analysis. aFor the validation 
dataset, the time to event analysis population in the original publication was used. bREMoxTB consisted 
of two 4-month experimental groups. 
  
Analysis dataset 
3411 Study participants were included in     
modified intent-to-treat anlayses in original 
publications
 Validation dataset
 386 Study participants were included in the 
modified intent-to-treat analysis in original     
publicationa
Analysis dataset
2001 Assigned to 4-month experimental groups 
were included in modified intent-to-treat      
analysis
1119 REMoxTBb
689 OFLOTUB
193 RIFAQUIN
Validation dataset 
193 Assigned to 4-month experimental group were 
included in the intent-to-treat validation 
193 DMID 01-009
6 Were excluded from the analysis 
dataset due to untraceable regimen
assignment in source database 
Analysis dataset
1404 Assigned to control groups were          
included in modified intent-to-treat analysis
555 REMoxTB
661 OFLOTUB
188 RIFAQUIN
Validation dataset 
193 Assigned to control group were included in 
the modified intent-to-treat validation*
193 DMID 01-009
Analysis dataset 
150 Were excluded due to 
per-protocol violations as       
defined per clinical trial 
81 REMoxTBb
41 OFLOTUB
28 RIFAQUIN
Validation dataset 
8 Were excluded due to  
per-protocol violations as       
defined per clinical trial 
8 DMID 01-009
Analysis dataset 
133 Were excluded due to 
per-protocol violations as       
defined per clinical trial 
45 REMoxTB
63 OFLOTUB
25 RIFAQUIN
Validation dataset 
8 Were excluded due to  
per-protocol violations as       
defined per clinical trial 
8 DMID 01-009
Analysis dataset 
1851 Were included in the per-protocol      
analysis 
1038 REMoxTBb
 648 OFLOTUB
 165 RIFAQUIN
Valildation dataset
185 Were included in per-protocol validation
185 DMID 01-009
Analysis dataset
1271 Were included in the per-protocol       
analysis 
510 REMoxTB
598 OFLOTUB
163 RIFAQUIN
Validation dataset
185 Were included in per-protocol validation
185 DMID 01-009
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Table 1.1 Baseline characteristics of study participants in modified intent-to-treat analysis.  
  
  
Analysis Dataset  
(OFLOTUB, REMoxTB, 
RIFAQUIN) 
Validation Dataset 
(DMID 01-009) 
Experimental 
Group   
Control  
Group  
Experimental 
Group   
Control  
Group  
Characteristic  (N = 2001) (N = 1404) (N = 193) (N=193) 
Country - no. (%)       
 Benin 122 (6) 108 (8) - - 
 Botswana 11 (<1) 12 (<1) - - 
China 12 (<1) 8 (<1) - - 
Guinea 191 (10) 184 (13) - - 
India 228 (11) 114 (8) - - 
Kenya 165 (8) 122 (9) - - 
Malaysia 43 (2) 20 (1) - - 
Senegal 129 (6) 138 (10) - - 
South Africa 811 (41) 516 (37) - - 
 Tanzania 122 (6) 67 (5) - - 
Thailand 65 (3) 34 (2) - - 
Zambia 35 (2) 21 (1) - - 
Zimbabwe 67 (3) 60 (4) - - 
Brazil - - 67 (35) 68 (35) 
Philippines  - - 46 (24) 46 (24) 
Uganda - - 80 (41) 79 (41) 
Female sex - no. (%)  592 (30) 415 (30) 76 (39) 76 (39) 
Race - no. (%)a        
 Black or African American  1326 (66) 1066 (76) - - 
 Asian  349 (17) 178 (13) - - 
 Other  326 (16) 160 (11) - - 
Age- yrsb        
 Median  30 29 29 27 
 Interquartile range  24-39 24-38 23-38 22-36 
Weight- kg        
 Median  52 52 54 55 
 Interquartile range   46-58 47-58 49-62 49-61 
Body mass indexc       
 Median  18.4 18.3 20.3 19.5 
 Interquartile range  16.9-20.2 16.9-20.1 18.7-22.2 18.5-22.0 
HIV positivity - no. (%)d 248 (12) 220 (16) 0 (0) 0 (0) 
CD4 cell count e       
 Median 363 317 - - 
 Interquartile range   265-493 241-444 - - ≤ 300 - no. (%)  74 81 - - 
> 300 - no (%)  135 99 - - 
Cavitation- no. (%)f 1247 (62) 847 (60) 0 (0) 0 (0) 
Smear- no. (%)g       
 Negative 151 (8) 85 (6) 85 (44) 85 (44) 
 1+ 332 (17) 232 (17) 26 (14) 30 (15) 
 2+ 503 (25) 404 (29) 32 (17) 36 (18) 
 3+ 988 (49) 667 (48) 50 (26) 42 (22) 
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aRace was missing for all OFLOTUB study participants, black race was assigned to all study participants 
given all OFLOTUB sites were in Africa.  
bAge was missing for 5 study participants.    
cBody mass index was defined as the weight in kilograms divided by the squared height in meters. Height 
was missing for 291 study participants, median height for females and males were used to calculate body 
mass index.  
dHuman immunodeficiency virus (HIV) status was missing for 9 study participants. 
eCD4 cell count cutoff was variable across trials (described in Supplementary Table 2). CD4 cell counts 
summary statistics was based only on study participants co-infected with HIV, but were missing for 79 
HIV co-infected study participants. 
fCavitation status was missing for 200 study participants.  
gSmear grade was based on clinical trial defined grading, but readjusted so all data was on the same scale. 
Smear grade was missing for 43 study participants. 
 
Primary outcome analysis 
Multivariate Cox analysis of baseline risk factors for unfavorable outcomes included 
3154/3405 (93%) participants with no missing baseline covariates; 1843/2001 (92%) participants 
were allocated to one of the 4-month experimental regimens and 1311/1404 (93%) participants 
were allocated to the control regimens. In participants assigned to 4-month experimental regimens, 
baseline smear 3+ relative to smear negative or 1+ grade and HIV seropositivity were the two 
major baseline clinical risk factors for unfavorable outcomes with an adjusted hazard ratio of 1.4 
(95% confidence interval [CI],1.1-1.9) and 1.4 (95% CI 1.1-1.9), respectively, adjusted also for 
age and sex. Higher risk was shown in older participants (adjusted hazard ratio [HR], 1.1 per 10 
years increase; 95% CI, 1.0-1.2) and male sex (HR, 1.6; 95% CI 1.3-2.1) study participants. After 
inclusion of on-treatment culture and adherence as risk factors, 1668/2001 (83%) experimental 
arm participants were available for analysis. Non-adherence was the most significant risk factor 
for unfavorable outcome with adjusted hazard ratios of 5.7 (95% CI, 3.3-9.9) for participants who 
missed 10% or more prescribed doses and 1.4 (95% CI, 1.0-1.9) for participants who missed less 
than 10% of prescribed doses relative to participants who completed treatment without any missed 
doses. Month-2 culture positivity was significantly associated with unfavorable outcome (HR, 2.2 
(95% CI, 1.7-2.9)). After adjustment for on-treatment factors, lower body mass index (BMI, 
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representative of malnutrition) was a risk factor for unfavorable outcome (HR, 1.4 per 5 kg/m2 
decrease; 95% CI 1.1-1.7) (Figure 1.2). 
In the 1311/1404 (93%) participants allocated to the 6-month control regimen, HIV 
seropositivity was the most significant baseline risk factor for unfavorable outcomes with an 
adjusted hazard ratio of 2.3 (95% CI, 1.6-3.3).  Older age (HR, 1.3 per 10 years increase, 95% CI, 
1.1-1.4), male sex (HR, 1.5; 95%CI, 1.1-2.1), and lower BMI (HR, 1.3 per 5 kg/m2 decrease; 95% 
CI, 1.0-1.7) at study entry had higher risk of unfavorable outcomes. 1186/1404 (84%) control arm 
participants contributed data both for baseline and on-treatment risk factors. Non-adherence was 
the most significant on-treatment risk factor for unfavorable outcomes with adjusted hazard ratio 
of 5.9 (95% CI, 3.3-10.5) for participants who missed 10% or more and 2.4 (95% CI, 1.6-3.6) for 
participants who missed less than 10% of prescribed doses relative to participants who completed 
treatment without any missed doses. On-treatment culture positivity was also identified as a 
significant risk factor for unfavorable outcomes (month-2 HR, 1.8; 95% CI, 1.3-2.7). After 
adjustment for on-treatment factors, HIV positivity (HR, 3.1; 95% CI, 2.0-4.6), male sex (HR, 1.5; 
95% CI, 1.0-2.4), and lower BMI (HR, 1.5 per 5 kg/m2 decrease; 95% CI, 1.0-2.0) remained as 
factors associated with high risk (Figure 1.3). In the per-protocol analysis, results were similar in 
the experimental and control groups when compared to the primary modified intent-to-treat 
analysis (data not shown).   
14 
 
 
Figure 1.2 Multivariate Cox regression analysis for experimental group with baseline predictors (top) and 
baseline and on-treatment predictors (bottom). aAge <30 years, 179/916 (20%) unfavorable outcomes and 
age ≥30 years, 237/927 (26%) unfavorable outcomes. bAge <30 years, 136/830 (16%) unfavorable 
outcomes and age ≥30 years, 181/838 (22%) unfavorable outcomes; BMI ≥17 kg/m2, 226/1,247 (18%) 
unfavorable outcomes and BMI <17 kg/m2, 91/421 (22%) unfavorable outcomes. 
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Figure 1.3 Multivariate Cox regression analysis for control group with baseline predictors (top) and 
baseline and on-treatment predictors (bottom). aAge <30 years, 92/657 (14%) unfavorable outcomes and 
age ≥30 years, 121/654 (19%) unfavorable outcomes; BMI ≥17 kg/m2, 156/989 (16%) unfavorable 
outcomes and BMI <17 kg/m2, 57/322 (18%) unfavorable outcomes. bBMI ≥17 kg/m2, 102/901 (11%) 
unfavorable outcomes and BMI <17 kg/m2, 36/285 (13%) unfavorable outcomes. 
Noninferiority test 
The proportion of unfavorable outcomes at 24 months for study participants with a baseline 
smear negative or 1+ grade was similar in experimental and control regimens, indicating 
noninferiority (difference in study adjusted Kaplan-Meier estimate of unfavorable outcome, 2.6; 
90% CI, -0.4 to 5.6; P=0.05 for interaction). Additionally, study participants with non-cavitary 
disease had a similar proportion of unfavorable outcomes between experimental and control 
regimens (difference in study adjusted Kaplan-Meier estimate of unfavorable outcome, 3.1; 90% 
CI, 0.9 to 5.4; P=0.06 for interaction). In an easy-to-treat phenotype of TB consisting of patients 
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with 1+ or negative smear or non-cavitary disease that comprised 47% (1591/3405) of the study 
population, the 4 month regimens were noninferior to the 6-month control regimen (Figure 1.4). 
In a hard-to-treat phenotype of TB consisting of patients with 3+ smear and cavitary disease that 
comprised 34% (1162/3405) of the study population, the 4-month regimens were clearly inferior. 
External validation 
Using an independent data set available from the DMID 01-009 trial in patients with non-
cavitary disease, the patient population eligible for a 4-month rifampin-containing regimen was 
validated, confirming that for study participants with low-to-moderate smear grade, a standard 
regimen shortened to 4 months was noninferior to standard 6-month regimen. We confirmed that 
the driver of high rates of unfavorable outcomes in the 4-month DMID 01-009 regimen was due 
to study participants with high smear grade (Figure 1.4). 
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Figure 1.4 Difference in proportion of unfavorable outcomes between the experimental group and control 
group, overall and according to subgroups. a. Non-inferiority tests based on analysis dataset. b. Validation 
of non-inferiority tests in panel a based on an independent validation dataset. The 90% confidence interval 
of the difference in proportion of unfavorable outcomes were determined by bootstrapping 500 samples.  
Red squares denote experimental subgroups that were non-inferior to the control subgroups and blue 
squares denote subgroups that did not show non-inferiority. Study participants in the validation dataset were 
HIV-uninfected adults with non-cavitary disease and 2-month culture negative status. 
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Impact of dosing frequency 
Kaplan-Meier estimates show that study participants who fully adhered to a 6/7 weekly 
dosing treatment had a higher probability of unfavorable outcome than those who adhered to and 
completed a 7/7 weekly dosing treatment (HR 2.7, 95% CI 1.1-6.7, after adjustment for treatment 
duration and country) (Figure 1.5).  
To assess the impact of partial adherence on standard of care under a 7/7 or 6/7 dosing 
strategy, 1285 participants who completed at minimum 4 months of treatment (112 total doses) 
were included in the Cox regression analysis. This analysis set included 687 participants who were 
prescribed treatment with a 7/7 weekly dosing strategy for 26 weeks (REMoxTB and RIFAQUIN 
trials) and 598 participants prescribed under a 6/7 weekly dosing strategy for 24 weeks 
(OFLOTUB trial). On a 7/7 weekly dosing strategy for 26 weeks, participants who took 156 to 
181 total doses (corresponding to an average of 6 doses per week or missing up to 14% pills) or 
112 to 155 total doses (corresponding to an average of 5 doses per week or missing 14-33% pills) 
had significantly higher risk of unfavorable outcomes relative to those who took all 182 prescribed 
doses (7 doses per week), with hazard ratios of 2.4 (95% CI, 1.3-4.3) and 28.9 (95% CI, 10.5-
80.0), respectively, adjusted for treatment duration and country (Figure 1.5). Similarly, participants 
receiving 112 to 143 doses (average of 5 doses per week) had a higher risk of unfavorable 
outcomes relative to those who took the complete 144 prescribed doses (6 doses per week) for 24 
weeks, with hazard ratio of 2.4 (95% CI 1.2 to 4.8), adjusted for treatment duration and country 
(Figure 1.5).  
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Figure 1.5 Analysis of 7/7 and 6/7 dosing strategies and impact of adherence in the control group. a. 
Kaplan–Meier estimates for fully adherent study participants (n = 996) after treatment with 7/7 or 6/7 dosing 
strategies. b. Multivariate analysis with total number of doses taken for study participants who took at least 
4 months of treatment under 7/7 dosing strategies for 26 weeks (REMoxTB and RIFAQUIN trials), after 
adjustment for country and treatment duration. c. Multivariate analysis with total number of doses taken for 
study participants who took at least 4 months of treatment under 6/7 dosing strategies for 24 weeks 
(OFLOTUB trial), after adjustment for country and treatment duration. Effect sizes for country are available 
in Supplementary Table 7. In b and c, the HRs with 95% Wald CI are reported. aHazard ratio with 95% 
Wald CI for 6/7 dosing strategy relative to 7/7 dosing strategy for fully adherent population after adjustment 
for country and treatment duration. bTreatment duration <182 days, 21/110 (19%) unfavorable outcomes 
and treatment duration ≥182 days, 40/577 (7%) unfavorable outcomes. cTreatment duration <169 days, 
21/155 (14%) unfavorable outcomes and treatment duration ≥169 days, 42/443 (9%) unfavorable outcomes. 
Discussion 
In this individual patient pooled analysis of recent phase 3 treatment shortening trials, we 
have shown that adult patients with minimal disease, as defined by low smear grade or the absence 
of cavitation were at lower baseline risk for unfavorable outcomes; in this population the 
experimental 4-month regimens are effective. Patients with either of these low-risk characteristics, 
which define an easy-to-treat phenotype of TB, comprised 47% (1591/3405) of the total study 
population. Conversely, we have shown that a smear grade of 3+ and the presence of cavitation on 
chest radiograph at baseline define a hard-to-treat phenotype, comprising 34% (1162/3405) of the 
population, and this group may require longer durations of treatment than the current standard 6-
month regimen to achieve the highest cure rates feasible. In our analyses, other baseline 
characteristics associated with unfavorable outcomes included being HIV-infected and having a 
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lower BMI at study entry. Male sex was consistently and independently linked with poor likelihood 
of cure in both control and experimental regimens.  The etiology for this association is not clear, 
particularly given the association persists after adjusting for severity of disease and adherence.  
Our definitions of TB phenotypes were validated in an independent trial dataset of patients with 
non-cavitary disease. Whereas this trial was stopped early due to higher rates of unfavorable 
outcomes in the experimental 4-month regimen, we confirmed that a 4-month regimen would be 
effective for patients with negative, 1+ or 2+ smears in non-cavitary disease at baseline.  We also 
confirmed that patients with high smear grade (smear 3+) at baseline were more likely to fail 
treatment regardless of receiving 4-month or 6-month regimens, as compared to those with lower 
smear grades at baseline.  Given the established importance of cavitation in disease prognosis and 
treatment response5,12,13, we included this characteristic in the analyses of non-inferiority for 
various sub-groups, despite the fact that cavitation was not a significant variable in the multivariate 
analysis and only marginally significant in the univariate analysis.  In analyses limited to the trials 
providing detailed chest radiograph readout data, specifically OFLOTUB and RIFAQUIN, we 
confirmed that cavity size, bilateral disease and disease extent measured by zone scores were all 
significant risk factors for unfavorable outcome  (Appendix Figure A.1 and Appendix Figure A.2), 
confirming that disease severity determined by chest radiograph remains an important tool for the 
definition of hard-to-treat phenotypes and prediction of treatment outcome. Overall, we show that 
the combination of smear grading and cavitary status adequately define easy-to-treat and hard-to-
treat groups, however, we also show subgroups that allow for stratification when chest 
radiographic information is not available.    
In this study, we also found that across both experimental and standard control regimens, 
minimal non-adherence and missed doses were associated with significantly increased risk for 
unfavorable outcome. Missing as few as 1 in 10 doses of a regimen was associated with a five-
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fold increase in risk. Missed doses had a stronger association with poor outcome than failure to 
achieve culture conversion at 2 months. Consistent with our analyses of non-adherence, dosing 
frequencies of less than 7 of 7 days increase the chances of unfavorable outcome, even if 
participants were fully adherent (Figure 1.5).  Current U.S. TB treatment guidelines state, on the 
basis of clinical experience and program practicality, that 5-days-a-week drug administration is an 
acceptable alternative to 7-days-a-week administration, and that either approach may be 
considered as meeting the definition of “daily” dosing.5 Our findings suggest otherwise and 
provide data-driven evidence to support using 7 of 7 dosing.14,15 The finding that the current 
rifampin-based regimen used worldwide has “low forgiveness” for non-adherence or missed doses 
has important implications for TB care as well as for future design and conduct of clinical trials.  
A regimen with excellent efficacy under rigorous clinical trial settings that is otherwise 
unforgiving of missed doses will fail in the field. New and improved adherence interventions for 
TB have been introduced to facilitate treatment completion, however, such tools can be limited by 
issues of scale-up, generalizability and cost.16,17  A more durable and patient-centered solution is 
the targeted development of regimens comprised of drugs with long half-lives and steady 
pharmacokinetic profiles that will accommodate less than perfect adherence patterns in the field, 
without penalty to the efficacy of the regimen. Our findings in this regard highlight the critical 
value of additionally conducting pragmatic clinical trials that assess the effectiveness and 
robustness of regimens under programmatic conditions.   
In this study, we found that the 4-month fluoroquinolone containing regimens met the 
margin for non-inferiority in participants with a baseline smear negative or 1+ grade or non-
cavitary disease. Conversely, we found that a hard-to-treat phenotype of TB defined by high smear 
grades and cavitation on baseline chest radiograph was associated with unfavorable outcomes. 
Randomized trials conducted by the British Medical Research Council largely in the pre-HIV era 
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have previously illustrated that the majority of patients do not need six months of standard 
therapy.18,19 Our analyses support this position and suggest that the current “one-size-fits-all” 
model of care leads to under-treatment of patients with severe forms of disease, and unnecessarily 
long treatment (with unjustified risk of drug toxicity) for many patients with less extensive disease.   
We believe our results provide justification to evaluate a stratified approach to TB therapeutics.  
Using baseline markers to determine the optimal stratum for a given patient, with decisions for 
treatment extension further enhanced by use of on-treatment measures of adherence and clinical, 
microbiologic and radiographic markers, the feasibility of achieving cure in all patients with TB, 
rather than a majority, is enhanced. Pursuit of the highest possible cure rates in TB is an important 
public health priority, and perhaps more important than treatment shortening, as suggested by 
recent modelling work that shows increases in treatment efficacy will have the greatest impact on 
reducing mortality and burden of disease worldwide.20 The tools necessary for using stratified 
medicine approaches to TB care at the programme level are already in use in many settings, 
including HIV testing, CD4 cell counts for HIV-positive patients, chest radiography, smear 
microscopy, and scales for measuring height and weight for calculation of BMI. Future trials that 
test stratified medicine approaches to TB care should also evaluate newer tools (e.g., GeneXpert 
cycle threshold), which in turn would allow for algorithms for selecting duration to be further 
refined, offering additional characteristics and options for determining risk. Nonetheless, some 
patients will have limited access to these diagnostics and in such settings, either a simpler 
stratification algorithm can be developed (for example, smear grade and BMI, as shown in  ) or 
the currently used “one-size-fits-all” approach may still remain the most practical and 
implementable option.  
Our study has limitations. Data sharing principles are supported in the TB therapeutics 
field, however, data collection was not standardized across the included trials.21,22 Future protocols 
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should use minimum data set standards, compliant with CDISC standards (https://www.cdisc.org), 
to allow robust pooled analyses in the future. Second, chest radiograph interpretation was not 
uniform, as such we could not analyze size and number of cavities in all three studies (Appendix 
Figure A.1 and Appendix Figure A.2).  Third, very limited pharmacokinetic data were available, 
hampering our ability to explore dosing, drug-exposure and outcome relationships. We advocate 
for the inclusion of population pharmacokinetics in phase 3 trials to address the variability in 
responses across geographic regions and populations. Our comparison of 6/7 with 7/7 dosing was 
a comparison between trials rather than within trials, and therefore may be confounded by other 
study differences. Finally, only 12% of participants had HIV-coinfection and many were not on 
effective ART regimens, thus, caution should be used in generalizing our findings to 
immunocompromised populations. Strengths of our analyses include the inclusion of large data 
sets from four international registration-quality phase 3 trials conducted across diverse human 
populations in high TB burden settings in South America, sub-Saharan Africa and Asia, 
performance of microbiologic assays by quality-controlled laboratories, and the careful recording 
of study treatment under direct observation. 
In sum, our validated analyses of individual patient data from contemporary randomized 
clinical trials provide three major findings. First, we show that low smear grades at baseline or the 
absence of cavitation identifies a population at low risk for recurrence in whom 4-month rifampin 
containing regimens may be effective. Conversely, high sputum smear grade at baseline in 
conjunction with the presence of cavities defines a hard-to-treat phenotype that may require longer 
durations of treatment than the current standard of care, in order to achieve high cure rates. There 
is also a third phenotype made up of the remaining patients for whom treatment shortening may 
also be possible. Second, we show that minor degrees of non-adherence or missed doses 
significantly increase the risk for poor outcomes. Third, we show that simple baseline and on-
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treatment markers could be used to select treatment duration with greater precision, providing a 
programmatically viable alternative to the “one-size-fits-all” paradigm used worldwide. Our 
results indicate that stratified medicine principles should be further evaluated in clinical trials of 
TB therapeutics.   
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Chapter 2:  Predicting optimal treatment durations for tuberculosis patients: a risk 
stratification algorithm and clinical simulation tool  
Abstract  
Background No evidence-based tools exist to guide decisions on the optimal treatment duration 
for tuberculosis. We developed (1) survival models to predict individual risk of unfavorable 
outcomes, (2) a quantitative risk stratification algorithm that stratifies individuals into risk groups, 
and (3) a clinical tool that predicts optimal treatment duration for each patient receiving  rifampin 
containing regimens. 
Methods Data from four Phase 3 trials, each evaluating treatment duration shortening from 6 
months to 4 months, were obtained from a public repository. Parametric survival models were used 
to describe time to unfavorable outcomes. Regimen, baseline, and on-treatment characteristics 
were evaluated as predictors of outcomes. Exact regression coefficients of significant predictors 
were used to calculate individual risk scores and a target cure rate of 93% was used to predict 
optimal treatment duration.  
Results A six-item risk score (HIV status, smear grade, sex, cavitation, BMI and month 2 culture 
status) successfully grouped patients into low (794/3405, 23%), moderate (1624/3405, 48%), and 
high (987/3405, 29%) risk, requiring treatment durations of 4, 6 and greater than 6 months, 
respectively, to reach 93% target cure rates. Of the 393/3405 patients who had TB-related 
unfavorable events, 49% (194/393) were identified as high risk, 38% (151/393) as moderate risk 
and 12% (48/393) as low risk.  
Conclusions Our results show that stratified medicine approaches, where duration is selected with 
precision based on patient risk, is feasible and safely achieves high cure rates in tuberculosis 
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patients.  A validated, interactive, evidence-based tool for selection of optimal treatment durations 
is provided.  
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Introduction  
Innovation in and simplification of tuberculosis (TB) therapy is desperately needed. There 
is an increase in the number of new and repurposed compounds undergoing evaluation as part of 
novel treatment regimens. Current TB drug development programs are focused on identifying 
shorter TB treatment regimens that maximize treatment completion without compromising on 
overall cure rates.1,2  However, numerous translational gaps hinder the developmental pathway and 
improved tools and approaches are necessary to accelerate the identification of optimal treatment 
regimens for TB patients.1,3  
Whereas current practice guidelines highlight individual risk factors that based on post-hoc 
analyses suggest an extension in treatment duration may be warranted (bacterial burden, extent of 
cavitary disease, culture positivity at 8 weeks, etc.), there have been no tools developed that 
indicate likelihood of achieving cure based on an integrated suite of baseline and on-treatment risk 
factors.4,5 Such tools could provide for individualized prediction of optimal treatment regimens for 
TB patients. Moreover, there have been no tools to date that could estimate likelihood of durable 
cure when treatment is shortened to durations less than 6 months.  
As short and ultrashort duration regimens, such as those evaluated by TB Trials 
Consortium (TBTC) Study 31/A53496 and TRUNCATE TB7, are now being evaluated in the 
treatment of TB patients, stakeholders are increasingly seeking to integrate innovative clinical trial 
approaches and tools into their decision making to facilitate early and effective deployment of the 
best regimens. In this study, we leveraged data from three large contemporary Phase 3 trials to 
develop a data-driven framework and clinical tools that can be used to recommend optimal 
treatment durations for stratified patient subgroups with the aim to provide equal likelihood of 
durable cure in all patients. Specifically, we developed: (1) parametric survival models to predict 
individual risk of unfavorable outcomes, (2) a quantitative risk stratification algorithm that defines 
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stratification groups using individual patient risk scores, and (3) a clinical simulation tool that 
predicts optimal treatment duration of rifampin-containing regimens based on individual patient 
risk and target cure rates. We externally validated our models and tools using data from a fourth 
Phase 3 trial. Our tools can be used to alert clinicians to patients with high risk of unfavorable 
outcome who may need longer treatment, to identify patients that may be able to be treated with 
shorter durations, and finally to inform a priori decisions regarding optimal durations for new 
regimens being considered for phase 3 clinical trials.   
Methods  
Study design and data collection  
Individual participant data (n=3405) from three recent international, randomized phase III 
trials (OFLOTUB8, REMoxTB9, and RIFAQUIN10) that compared 4-month fluoroquinolone 
containing regimens to the standard 6-month regimen was used for model development. A fourth 
trial, DMID 01-00911 (n = 386), was used for external validation and tested a 4-month standard 
regimen (no fluoroquinolone). Additional information on study design for these trials are available 
in the original publications and described in Chapter 1 Methods Section. 
Efficacy outcomes  
The primary efficacy endpoint was time to an unfavorable outcome for a maximum of 18 
months after start of treatment. Participants who were not followed for at least 18 months were 
censored at their last available timepoint. Due to the composite definitions used to label 
unfavorable outcomes, we developed two separate models for: a.) time to TB-related outcomes 
and b.) time to non-TB-related outcomes. TB-related outcomes included treatment failures, deaths 
due to TB, relapse, and exogenous reinfection (for the OFLOTUB study only). Non-TB-related 
outcomes included dropouts, withdrawal of consent, lost to follow up, adverse events, other deaths, 
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and inadequate treatment. For each of the models, time was censored at time of alternative outcome 
(i.e. when modelling time to TB-related outcomes, non-TB-related outcomes were censored at 
time of event). This approach requires independent censoring, meaning that we are assuming 
censoring does not change the probability of the event of interest for each model.12  
Predictors of efficacy outcomes 
Variables collected in all studies and missing in less than 10% of participants were tested 
as potential predictors of risk of unfavorable outcomes. Covariate search was performed in a 
stepwise manner. First, exposure and regimen composition factors were tested. Due to limited 
pharmacokinetic data collected in each trial (83% of population without pharmacokinetic data), 
exposure of drugs was described by: i.) treatment duration, defined as the duration of days the 
participant was on treatment, ii.) number of treatment days, defined as the total number of 
treatment days drugs were administered, and iii.) cumulative rifampin dose, defined as number of 
treatment days taken multiplied by individual rifampin daily dose. Actual treatment duration, 
number of treatment days, and cumulative rifampin dose were all determined based on complete 
dosing histories that were recorded during the trial with distributions shown in Figure 2.1. Number 
of treatment days was adjusted for the intermittent schedule used with high dose rifapentine in the 
RIFAQUIN 4-month experimental arm during the continuation phase. The 900 mg rifapentine 
twice weekly administration (total of 1800 mg weekly) was translated to 3 treatment days per week 
if both doses were administered (1800 mg per week/600 mg per day). Isoniazid and moxifloxacin 
inclusion were tested as regimen composition predictors of unfavorable outcome.  
Second, baseline characteristics and month 2 culture conversion were tested as potential 
predictors of risk of unfavorable outcomes. The baseline analysis set included age, race, BMI, sex, 
presence of cavitation on chest radiograph and smear grade. Major imputations for baseline 
characteristics and more information on data specification and harmonization is available and has 
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been reported in our previous publication (Chapter 1).4 For missing categorical data, the mode 
value for the entire population was assigned. For missing continuous data, the median value for 
the entire population was assigned. Finally, the effect of study and region of clinic site (African 
vs. non-African) were tested and the final model was adjusted if found significant.  
 
 
Model development and evaluation  
Two separate parametric survival models were developed to describe time to TB-related 
unfavorable outcomes and time to non-TB-related unfavorable outcomes. To describe time to 
event for each model, a parametric survival function was used, according to the following survival 
equation:  "# = %&∫ ((#)+(#),-  
where survival at time	/, "#, is a function of the cumulative hazard risk from time 0 to time /. The 
hazard, ℎ(/), describes the instantaneous risk of having an event at time /. The hazard distribution 
of each of the models were evaluated by testing different functions that best described the risk of 
having an event including the exponential, Gompertz, Weibull, and surge functions.  
Figure 2.1 Distribution of treatment duration (days), number of treatment days and cumulative rifampin 
dose (mg) for patients in the model development dataset. 
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Identification of predictors were tested on all model parameters of the best fit hazard risk 
function (i.e. baseline hazard risk and shape parameters) for each TB-related unfavorable outcome 
model and non-TB-related unfavorable outcome model. An automated procedure with Stepwise 
Covariate Model software (PsN, SourceForge, Slashdot Media, San Francisco, CA, USA) was 
used. This method involves stepwise testing of linear and nonlinear relationships with forward 
inclusion (change in objective function value, DOFV, of 6.63, p < 0.05 to include for 1 degree of 
freedom) and backwards exclusion (DOFV of 10.83, p < 0.01 to remove for a degree of freedom). 
In case of categorical covariates, DOFV at the respective p-values may be different depending on 
the degrees of freedom. Linear, sigmoidal EMAX, and sigmoidal EMAX with hill coefficients 
relationships were assessed when testing exposure predictors on hazard function parameters. 
Linear relationships were tested for all other predictors. The final models contained covariates that 
met the predefined statistical criteria. 
Model development was performed using the nonlinear mixed effect approach available in 
the NONMEM program (version 7.4). The Laplacian estimation method was employed for the 
time to event variable. The model building procedure was guided by likelihood testing and internal 
validation techniques, including Kaplan-Meier visual predictive checks to assess calibration and 
area under the receiver operating characteristic curve (AUROC) for discrimination. Kaplan-Meier 
visual predictive checks involved performing 800 simulations with the analysis datasets and final 
model, then comparing the observed Kaplan-Meier curve with 95% prediction interval of the 
simulated data. AUROC for discrimination was determined by calculating the c-index at 6-months 
post end of treatment. After final model development, external validation with the DMID 01-009 
dataset was also evaluated using the same calibration and discrimination techniques.  
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Derivation of individual risk scores and optimal treatment durations  
Exact regression coefficients for significant baseline and on-treatment (month 2 culture 
status) predictors of TB-related unfavorable outcomes in the final model were used to derive a 
continuous risk score , 3456	"789%:, for each individual,	4. The individual risk scores, which take 
into account all significant baseline and on-treatment predictors, and the final predictive model for 
time to TB-related outcome were used to calculate the number of treatment days required to reach 
a specified target cure rate, ;<3=#>?@A# . The optimal treatment duration for each individual, B3B_D<3EBFGH:,	can then be determined based the number of treatment days required to reach 
a target cure rate and the weekly dosing schedule. Optimal treatment duration calculations in this 
manuscript are based on a 7/7 weekly dosing schedule and full adherence. Full derivation of 3456	"789%: and B3B_D<3EBFGH: are described in the Chapter 2 Supplemental Results.  
Validation of risk stratification algorithm and treatment duration 
The risk stratification algorithm to define low, moderate, and high risk patients were based 
on the predicted optimal treatment duration of the control regimen (isoniazid, rifampin, 
pyrazinamide, and ethambutol) required to reach less than or equal to 7% TB-related outcomes 
(;<3=#>?@A# = 0.93) at 18 months follow-up from the start of treatment.  Low risk group was 
defined as patients requiring less than or equal to 18 weeks of treatment, moderate risk group 
requiring 19 to 24 weeks of treatment, and high risk group requiring more than 24 weeks of 
treatment. To validate the calibration of our risk stratification algorithm, we first calculated the 
individual risk scores for all individuals in the derivation cohort (REMoxTB, RIFAQUIN and 
OFLOTUB) and grouped patients into low, moderate, and high risk groups. Then, we compared 
the observed Kaplan Meier rates of TB-related unfavorable outcome after treatment of 4-month 
and 6-month regimens for each risk group. For good calibration, we expected that the low risk 
group would be treated successfully (Kaplan Meier rates at or above 93%) by the 4 or 6-month 
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regimens, moderate risk groups treated successfully only by the 6-month regimen, and the high 
risk group not treated successfully with neither the 4- or 6-month regimens. Additionally, we 
calculated the hazard ratio based on Cox regression analysis to compare success rates in the 4-
month and 6-month regimens for each risk group. For external validation of the risk stratification 
algorithm, we used the independent dataset available from DMID 01-009. The same statistical 
methods used for interval validation was also used to externally validate the calibration of our risk 
stratification algorithm.  
Clinical simulation tool  
An interactive clinical simulation application based on the final parametric survival model 
for TB-related unfavorable outcomes was developed using the Shiny package in the R 
programming language (version 1.3.2). The tool allows evaluation by simulation of different 
treatment strategies in various population groups based on predictors included in the final models. 
All simulations of virtual populations are based on the available model development and external 
validation populations used in this analysis. This means that the uncertainty of simulated 
populations reflects the distribution of patients available in the development and external 
validation population and the global TB burden included in these clinical trials.  
Results  
Data characteristics  
The model development population included 3405 patients with drug susceptible TB. As 
described previously, baseline characteristics did not differ between experimental and control 
groups (Table 2.1).4 In the 4-month experimental group, 1257/2001 (63%) of patients were treated 
with a regimen that included isoniazid. The median number of treatment days was 114 in the 4-
month experimental group and 169 in the 6-month control group (Table 2.1). Month 2 culture 
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conversion rates were higher in the 4-month experimental group than 6-month control group 
(Table 2.1, P = 0.01). Of the 3405 patients, 656 patients had an unfavorable outcome during follow-
up (up to 18 months), with shorter time to unfavorable outcome when treated with 4-month 
experimental regimens [univariate hazard ratio [HR]: 1.6 (95% confidence interval [CI]:1.3-1.8)]. 
Of the 656 patients with unfavorable outcomes, 393 had a TB-related outcome, with shorter time 
to TB-related outcome when treated with 4-month experimental regimens [HR: 2.5 (95% CI: 2.0-
3.1)], and 263 had a non-TB-related outcome (145 in the 4-month experimental group and 118 in 
the 6-month experimental group), with no evidence of difference in time to non-TB-related 
outcome among 4-month and 6-month regimens [HR: 0.87 (95% CI: 0.68-1.1)] (Figure 2.2).  
Table 2.1 Baseline, on-treatment and regimen characteristics of study participants included in the model 
development population. 
  
4-month experimental 
group    
6-month 
control group   
Characteristic  (N = 2001) (N = 1404) 
Site Region      
Sub-Saharan Africa  1653 (83)  1228 (88) 
India  228 (11) 114 (8) 
Asia 120 (6) 62 (4) 
Female sex - no. (%)  592 (30) 415 (30) 
Age- yrsa     
Median  30 29 
Interquartile range  24-39 24-38 
Range 16-81 17-77 
Weight- kg      
Median  52 52 
Interquartile range   46-58 47-58 
Range 35-98 35-137 
Body mass indexb     
Median  18.4 18.3 
Interquartile range  16.9-20.2 16.9-20.1 
Range 12.0-40.7 12.1-50.9 
HIV positivity - no. (%)c 248 (12) 220 (16) 
Cavitation- no. (%)d 1247 (62) 847 (60) 
Smear- no. (%)e     
Negative or 1+  483 (24) 317 (23) 
2+ 503 (25) 404 (29) 
3+ 988 (49) 667 (48) 
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Table 2.1 continued. 
  
 Characteristic 
4-month experimental 
group    
6-month 
control group   
 (N = 2001) (N = 1404) 
Regimen Composition   
Isoniazid 1257 (63) 1404 (100) 
Rifapentine 193 (10) 0 (0) 
Moxifloxacin 1312 (66) 0 (0) 
Gatifloxacin 689 (34) 0 (0) 
Treatment duration (days)f   
Median 119 175 
Interquartile range 114-119 169-182 
Range 2-202 4-239 
Number of treatment daysg    
Median  114 144 
Interquartile range 96-119 144-182 
Range 1-120 1-189 
Cumulative rifampin dose (mg)h   
Median 57600 86400 
Interquartile range 51600 - 71400 79200 - 108600 
Range 450 -72000 450-113400 
Number of daily doses takeni    
Median  114 144 
Interquartile range 96-119 144-182 
Range 1-120 1-189 
Month 2 culture positivityi  336 (17) 285 (20) 
aAge was missing for 5 study participants.    
bBody mass index was defined as the weight in kilograms divided by the squared height in meters. Height was 
missing for 291 study participants, median height for females and males were used to calculate body mass 
index.  
cHuman immunodeficiency virus (HIV) status was missing for 9 study participants. 
dCavitation status was missing for 200 study participants.  
eSmear grade was based on clinical trial defined grading, but readjusted so all data was on the same scale. 
Smear grade was missing for 43 study participants. 
fTreatment duration, defined as the number of days the participant was on treatment, was missing for 106 
study participants.  
gNumber of treatment days, defined as the total number of treatment days drugs were administered, was 
missing for 38 study participants.  
hCumulative rifampin dose, defined as number of treatment days multiplied by individual rifampin daily dose, 
was missing for 38 study participants.  
iMonth 2 culture was missing for 308 study participants.  
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Figure 2.2 Kaplan-Meier estimates of time to unfavorable outcomes, TB-related outcomes and non-TB-
related outcomes. (A) All unfavorable outcomes as defined according to each trial protocol. (B) TB-related 
outcomes including treatment failures, deaths due to TB, relapse, and reinfection (OFLOTUB study only). 
(C) Non-TB-related outcomes including dropouts, withdrawal of consent, lost to follow up, adverse events, 
other deaths, and inadequate treatment. Each plot was stratified by assigned regimen duration.   
Model development and evaluation  
The hazard risk for TB-related outcomes was best described with a surge function:  ℎ(I:, /) = J(I:)/K%IL(−N/) 
where J(I:)	is the baseline hazard risk dependent on the covariate values,	I:, for each individual,	4; N and O are the surge function shape parameters; and / is time in months from start of treatment. 
Decreased number of treatment days and exclusion of isoniazid increased hazard risk of TB-related 
outcomes (29% (relative standard error, RSE = 9) increase per 28 day decrease in number of 
treatment days, 32% (48) increase for exclusion of isoniazid, Table 2.2). Baseline factors that 
increased hazard risk included HIV co-infection (86% (RSE = 29) increase), higher smear grade 
(68% (36) increase for smear 3+ relative to smear 1+ or negative), male sex (64% (32) increase), 
cavitary disease (26% (57) increase), and lower BMI (18% (41) increase per 5 kg/m2 decrease). 
Inclusion of month 2 culture status improved discrimination with an increase in AUROC from 
0.69 (95% CI, 0.66-0.72)  to 0.72 (0.69-0.75) (Table 2.2). Calibration of the final predictive model 
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was good, as shown in the visual predictive checks (Figure 2.3 and Appendix Figure A.3 and 
Appendix Figure A.4) 
To model probability of non-TB-related outcomes, a Gompertz function was used to 
describe the hazard risk: ℎ(I:, /) = 	J(I:)exp(−N/) 
where J(I:)	is the baseline hazard risk dependent on the covariate values,	I:, for each individual,	4; N is the Gompertz function shape parameter; and / is time in months from start of treatment. 
Increasing age was the sole factor that increased the hazard risk of non-TB-related 
outcomes (23% (RSE = 29) increase per 10 year increase; Table 2.2, Figure 2.3 and Appendix 
Figure A.5). Because the final model for non-TB-related outcomes were independent of treatment 
specific factors, derivation and prediction of subsequent risk scores and optimal treatment 
durations were based solely on the final model for TB-related outcomes.  
  
Figure 2.3 Kaplan-Meier visual predictive checks and receiver operating characteristic curves. (A) Visual 
predictive check (left) and ROC curve (right) for final model describing time to TB-related outcome. (B) 
Visual predictive check (left) and ROC curve (right) for final model describing time to non-TB-related 
outcome.    
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Risk stratification algorithm and optimal treatment durations  
Optimal treatment duration was predicted based on a six-item hazard risk score: month 2 
culture, HIV status, baseline smear grade, sex, baseline cavitation, and baseline BMI. The 
derivations and final formulas to calculate individual risk scores and optimal treatment durations 
are presented in Chapter 2 Supplemental Results. Based on the predicted optimal treatment 
durations for each individual to reach a 93% target cure rate, 794/3405 (23%) patients in the model 
development population were assigned to a low risk group (≤ 18 weeks required for 93% cure 
rate) with risk scores ranging from 0 to 1.67,  1624/3405 (48%)  patients were assigned to a 
moderate risk group (19-24 weeks required for 93% cure rate) with risk scores ranging from 1.68 
to 3.20, and 987/3405 (29%) patients were assigned to a high risk group (> 24 weeks required for 
93% cure rate) with risk scores ranging from 3.21 to 14.73. The distribution of individual risk 
scores and predicted optimal treatment durations in the model development population are shown 
in Figure 2.4A and Figure 2.4B, respectively. Figure 2.4C illustrates the distribution of different 
risk factors across the three risk strata. Patients with individual risk factors are still distributed 
among low, moderate, and high risk groups showing that risk group assignment is dependent on a 
patient’s combination of risk factors, rather than a single variable.     
The performance of the risk stratification algorithm is presented in observed Kaplan-Meier 
rates shown in Figure 2.5 and Appendix Figure A.4. Of the 393 patients who had TB-related 
outcomes, 49% (194/393) were defined as high risk according to our risk stratification algorithm 
identified, 38% (151/393) as moderate risk and 12% (48/393) as low risk. Patients in the low risk 
group treated with either a 4- or 6-month regimen had similar risk of TB-related outcomes [HR: 
1.7 (95% CI: 0.9-3.1)], with cure rates above or approximately at the 93% target cure rate 
threshold. In the moderate risk group, only patients treated with a 6-month regimen resulted in 
cure rates above 93%, with 4-month regimens leading to significantly more risk of TB-related 
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outcomes than the 6-month regimens [HR: 3.4 (95% CI: 2.2-5.2)]. Finally, in the high risk group, 
cure rates after treatment with a 4- or 6-month regimen were below the 93% threshold, with the 4-
month regimens leading to significantly higher risk than the 6-month regimen [HR: 2.5 (95% CI: 
1.8-3.4)]. No interaction between regimens and risk groups were identified, suggesting that risk of 
TB-related outcomes increases in higher risk groups independent of treatment duration (P value 
for interaction = 0.4).  
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Figure 2.4 Distribution of individual risk scores, optimal treatment durations for target cure of 93% and 
risk factors in the model development population. (A) Distribution of individual risk scores stratified by 
low, moderate, and high-risk group. (B) Distribution of individual optimal treatment durations for target 
cure rate of 93% at 18 months since start of treatment stratified by low, moderate, and high-risk groups. (C) 
Heat map distribution of identified risk factors among low, moderate, and high-risk groups. All individuals 
are arranged on the x-axis from lowest risk score to highest risk score and each column in each row (risk 
factor) represents a single individual. Low risk group was defined as patients requiring less than or equal 
to 18 weeks of treatment, moderate risk group requiring 19 to 24 weeks of treatment, and high-risk group 
requiring more than 24 weeks of treatment for a target cure rate of 93%.  
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External validation 
The final TB-related outcome model and stratification algorithm were externally validated 
using an independent dataset available from the DMID 01-009 trial that includes 386 patients with 
non-cavitary disease at baseline and culture conversion at month 2. This external dataset represents 
a sub-population of primarily lower risk patients with 266/386 (69%) patients in the low risk group, 
116/386 (30%) in the moderate risk group, and 4/386 (1%) in the high risk group (Figure 2.6). The 
final TB-related outcome model had similar model discrimination and calibration with the external 
dataset as compared to the model development dataset (AUROC of 0.78 (95% CI, 0.65-0.90)), 
Figure 2.7). The observed Kaplan-Meier estimates of TB-related outcomes confirm that patients 
in the low risk group can be treated with a 4-month regimen and patients in the medium risk group 
require at least 6 months of treatment to reach 93% target cure rates. No TB-related outcomes were 
reported in the four patients categorized in the high risk group (Figure 2.8).  
Figure 2.5 Kaplan-Meier estimates to validate calibration of risk stratification algorithm using model 
development population for (A) low risk group stratified by regimen duration, (B) moderate risk group 
stratified by regimen duration, (C) high risk group stratified by regimen duration. Dashed line shows target 
cure rate of 93% at 18 months since start of treatment.  
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Figure 2.6 Distribution of risk scores for external validation population. Risk groups are defined by target 
cure rate of 93% at 18 months since start of treatment. 
 
Figure 2.7 Kaplan-Meier visual predictive checks and receiver operating characteristic curves for 
external validation dataset. Visual predictive check (left) and ROC curve (right) for final model 
describing time to tuberculosis related outcome. 
 
Figure 2.8 Kaplan-Meier estimates to validate calibration of risk stratification algorithm using external 
validation population for (A) low risk group stratified by regimen duration and (B) medium risk group 
stratified by regimen duration. Only 3 individuals in the 4-month experimental group and 1 individual in 
the 6-month control group, none of which had a Tuberculosis related unfavorable outcome, were 
categorized as high risk in the external validation dataset so Kaplan-Meier graph is not shown. Dashed line 
shows target cure rate of 93% at 18 months since start of treatment.  
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Clinical simulation tool  
We developed a clinical simulation tool based on the final model for TB-related outcomes 
to provide recommended treatment interventions in stratified groups with the aim to maximize TB 
clinical cure rates. This interactive tool can generate critical knowledge essential for regimen 
optimization in a clinical or research setting by highlighting those subgroups of patients who are 
at higher risk of unfavorable outcomes and may require treatment adjustments. Input parameters 
for the application include arguments about regimen of interest (composition, duration, and dosing 
frequency), baseline characteristics, month 2 culture conversion, and patient adherence. Users can 
assess predicted proportions of patients without TB-related outcomes following 8 to 36 weeks of 
treatment, patient risk scores (at baseline and when on-treatment data becomes available) to stratify 
patients, and optimal treatment durations of standard rifampin dose regimens for a target cure rate 
in specified subgroups. A snapshot of the application is shown in Figure 2.9.  
 
 
Figure 2.9 Interactive clinical simulation tool. A page in the clinical simulation tool that displays the 
predicted proportions of patients without TB-related unfavorable outcomes following 8 to 36 weeks of 
treatment. In this tab, the user can investigate the optimal treatment duration for various stratified 
populations. 
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Discussion 
In this study, we developed and validated a clinical tool that successfully stratified TB 
patients into low (794/3405, 23%), moderate (1624/3405, 48%), and high (987/3405, 29%) risk 
groups.  In conjunction, through risk stratification, we are able to predict the optimal treatment 
durations of standard rifampin dose (10mg/kg) regimens for each stratum, where low risk patients 
can be treated with a 4-month regimen, moderate with a 6-month regimen, and high likely 
requiring regimens exceeding 6 months without compromising on cure rates. Based on our results, 
we have developed interactive clinical tools that provide quantitative evidence-informed 
recommendations on optimal treatment interventions in stratified populations.  
Our risk stratification algorithm uses six pragmatic markers of risk that are routinely 
collected in the clinic: HIV status, baseline bacterial burden, sex, cavitation, BMI, and month 2 
culture status. The risk stratification algorithm successfully grouped low risk patients eligible for 
4-month standard rifampin dose regimens, moderate risk patients requiring at least 6 months, and 
high risk patients with suboptimal relapse rates with 6-month standard rifampin dose regimens. 
Because our external validation dataset only included non-cavitary patients with month 2 culture 
conversion treated with 4- or 6-month durations, it was only capable of validating the optimal 
durations for low and medium risk groups. For high risk patients, it was not validated whether 
standard rifampin dose regimens exceeding six months will result in better treatment outcomes. 
However, we learned that this high risk group indeed require more effective regimens to reach 
target cure rates and are likely the cause of unsuccessful shortening of TB treatments when using 
one-size-fits-all regimens. For example, observed cure rates for this group treated with the 6-month 
control was 88% (378/428) compared to the low and moderate risk group of 96% (936/976) (Figure 
2.5). Possible alternative interventions that can be tested to improve efficacy in these patients 
include increasing daily rifamycin doses or substituting drugs for those with better lesion 
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penetration properties and/or more potent bactericidal or sterilizing activity.5,13,14 These potentially 
more effective regimens may also allow for ultrashort treatments for low and moderate risk groups.  
Presently, only two separate studies have investigated the relationship between treatment 
duration and rates of relapse. In one study, a meta-regression model was developed based on 
published historical data to predict rates of relapse using treatment duration and month 2 culture 
conversion rates as predictors.15 The model was capable of predicting the expected rates of relapse 
in the 4-month experimental regimens from the REMoxTB and RIFAQUIN trials, and found that 
the tested regimens can indeed shorten TB treatment, but only to 5 months. This model predicted 
wide confidence and prediction intervals suggesting that other important factors were likely 
unaccounted for in the model making it difficult to make appropriate treatment recommendations 
in individuals or patient subgroups, particularly in high risk groups who are the main drivers of 
relapse. In a second study, a translation pharmacokinetic-pharmacodynamic model derived from 
preclinical mice data was used to predict the results of a number of clinical trials with reasonable 
success, including the observed 4-month experimental and 6-month control regimens tested in the 
REMoxTB and RIFAQUIN study.16 Although, this translational model is valuable in informing 
regimen optimization and predict outcomes of future and on-going trials, particularly in early 
stages of regimen development, it also does not take into account established major high risk 
factors that may influence cure rates. Our model now provides an evidence-based tool developed 
from individual patient data from four large randomized controlled trials and accounts for 
established patient and disease specific risk factors. We are now capable of quantitatively 
predicting, with good precision, rates of TB-related outcomes and provide recommendations on 
optimal treatment durations in stratified groups to maximize cure.  
We developed separate parametric survival models for TB-related and non-TB-related 
outcomes to determine whether different risk factors affect each outcome. Indeed, treatment and 
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disease specific risk factors only affected TB-related outcomes and proposed treatment 
interventions would only improve relapse, treatment failures, and TB-related deaths. Still, non-
TB-related outcomes are undesirable because of risk of disease transmission and emergence of 
drug resistant strains.17 To improve non-TB-related outcomes, possible interventions include well-
informed patients of potential risk of inadequate treatment, use of all efforts (i.e. phone calls, home 
visits) by clinicians and researchers to contact participants that miss routine visits, and closely 
monitoring adverse events.    
Our study has limitations. First, with modest model discrimination, our risk score still has 
room for improvement if more quantitative and sensitive measures of disease burden and severity 
are used. Smear grade to measure baseline bacterial burden and month 2 culture as a putative 
surrogate biomarker of clinical endpoint both have been proven to have low sensitivity.18-20 
Promising new techniques showing association with baseline and longitudinal bacterial burden 
include cycle threshold in Gene Xpert assays and quantification of sputum or urine 
lipoarabinomannan levels.21-26 Our model can be continually revised to account for more 
information as additional data become available and reliable relationships between current and 
promising new markers become established and routinely collected. Second, all tested regimens 
in the studies included in our analysis used rifampin-based regimens at standard-suboptimal doses. 
Predicted optimal treatment durations will likely be underestimated when high dose rifamycin 
regimens are considered, potentially allowing even shorter regimens to be tested. As clinical data 
on high-dose rifamycin regimens become available this model can be revised. Caution is also 
advised if generalizing our findings to regimens of other compositions as predictors of relapse may 
be different. Third, although the proposed six risk factors are routinely collected at baseline or 
during treatment (month 2 culture), missing values may arise. Our model can predict a risk score 
for patients with missing values by using a simplified model (without missing factor) or imputing 
51 
 
the missing value based on observed patient distributions. Strengths of our analyses include the 
inclusion of four large datasets from phase 3 trials conducted across diverse populations in high 
TB-burden settings; the predictive model is evidence-based and fully parametric with minimal 
assumptions about the shape of hazard risk; the stratification algorithm is based on pragmatic and 
routinely available makers; an interactive clinical tool has been developed to handle complex 
calculations; and our predictive model had similar discrimination and calibration in the model 
development and validation cohort and that of other predictive models of risk of relapse.   
In conclusion, we have developed and validated a risk stratification algorithm capable of 
categorizing patients into low, medium, and high risk groups. Additionally, an interactive clinical 
simulation tool has been developed to predict the optimal treatment duration for standard-dose 
rifampin regimens in stratified populations. Our validated interactive clinical tools allow for more 
informed decision making and could be used to accelerate regimen development and decision 
making while maximizing expected cure rates. Finally, our tool can also greatly benefit 
tuberculosis patients who can now be assigned optimal treatment duration based on their 
phenotype. 
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Supplemental results: Full derivation of individual risk scores and optimal treatment 
durations 
The surge hazard function, ℎ(I:, /),	 best described the instantaneous risk of TB-related outcomes:   ℎ(I:, /) = J(I:)/K%IL(−N/) 
where J(I:)	is the baseline hazard risk dependent on the covariate values,	I:, for each individual,	4; N and O are the surge function shape parameters; and / is time in months from start of treatment. 
The cumulative hazard from 0 to time, t, can be analytically derived using the following:  
;efℎgh(I:, /) = 	i ℎ(I:, /)j(/)#k = J(I:) l/K(N/)&K[Γ(O + 1) − Γ(O + 1, N/	)]N p= J(I:)q(/, N, O)	 
where Γ(g) is the gamma function and Γ(g, r) is the incomplete gamma function. The second term 
in the cumulative hazard can be grouped, q(/, N, O) and is independent of I:.  
 
Survival (proportion not experiencing a TB-related outcome or proportion cured), ", can then be 
determined by the cumulative hazard with the following: " = exp(−;efℎgh(I:, /)) = 	exL	(−J(I:)q(/, N, O))	 J(I:) is defined as the product of the typical value (median of population) of the baseline hazard, B]J, and linear relationships with individual covariate values, I::  J(I:) = B]Js(I:)= B]J t(1 + =uuvwxyz)(1 + =uu{|})(1 + =uu~cA>?)(1 + =uu~A)_1
+ =uuÄA@:[\d(1 + =uuxÅ})(1 + =uuYv| Ç18.375 + àâF:5 ä)(1 + =uu|Z{)(1
+ =uuÄ	ã>åç Ç11928 − H8. 8s	/9%g/f%ê/	jgë528 ä)í 
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where the effect parameters, =uuì, for each covariate, h, are described in Table 2.3, and àâF: is 
the invidual’s BMI value (kg/m2) and H8. 8s	/9%g/f%ê/	jgë5 is the total number of days drugs 
are administered .  
Table 2.3 Covariate effect parameters to calculate individual risk scores.  
Parameter Value  îïïñóòôö  
 Month 2 culture negative 0 
 Month 2 culture positive  1.45 îïïõúT  
 Negative  0 
 Positive 0.86 îïïùûü†°  
 Negative or 1+  0 
 2+  0.18 
 3+ 0.68 îïïùü¢  
 Female  0 
 Male  0.64 îïï£ü§•¶ß  
 Sub Saharan African  0 
 Non-Sub Saharan African 0.54 îïïò®T  
 Negative  0  
 Positive  0.26 îïï©ñú (©ñú•= individual patient’s 
BMI value) 
0.18 îïïú™õ  
 Included 0  
 Excluded 0.26 îïï£¢	´†¨≠  0.29 
 
Individual risk scores, 3456	"789%:, were defined as the product of the B]J and the six identified 
baseline and on-treatment risk factors (excluding regimen characteristics) and adjusted for region 
of clinical site. A scaling factor of 104 was added. The following formula was used:  3456	"789%: = 10ÆB]J(1 + =uuvwxyz)(1 + =uu{|})(1 + =uu~cA>?)(1 + =uu~A)_1
+ =uuÄA@:[\d(1 + =uuxÅ})(1 + =uuYv| Ç18.375 + àâF:5 ä) 
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The baseline hazard risk can then be redefined as:  
J(I:) = 3456	"789%:10Æ (1 + =uu|Z{)(1 + =uuÄ	ã>åç Ç11928 − H8. 8s	/9%g/f%ê/	jgë528 ä) 
And survival can be redefined as: −ln(") = 	J(I:)q(/, N, O)
= 	3456	"789%:10Æ (1 + =uu|Z{)(1+ =uu±:≤≤	≥[¥\# Ç11928 − H8. 8s	/9%g/f%ê/	jgë528 ä)q(/, N, O) 
 
Predicted optimal treatment durations are based on the standard regimen that includes isoniazid, 
rifampin, pyrazinamide, and ethambutol, therefore, =uu|Z{= 0 and =uu±:≤≤	≥[¥\#  = 0.29 (Table 
2.3). Rearranging and solving for optimal H8. 8s	/9%g/f%ê/	jgë5 required for a target cure rate, " = ;<3=#>?@A#, we have:  
H8. 8s	/9%g/f%ê/	jgë5 = 	119 − ⎣⎢⎢
⎢⎡28∏ − ln_;<3=#>?@A#d(3456	"789%: 10Æ)⁄ (q(/, N, O)) − 1∫=uu±:≤≤	≥[¥\# ⎦⎥⎥
⎥⎤ 
Predicted optimal treatment duration (weeks), B3B_D<3EBFGH: , for a 7/7 weekly dosing 
schedule is then defined as:  B3B_D<3EBFGH:(æ%%65) = H8. 8s	/9%g/f%ê/	jgë5 B9%g/f%ê/	jgë5	L%9	æ%%6⁄ =
ø¿ ⎣⎢⎢
⎡119 − ¡w¬∏ √ ƒ≈∆«»… ,ÀÃÕŒ,œ(…–—“	”‘’ÃŒ– ÷-◊)⁄ (Õ(,,ÿ,Ÿ))&ø∫⁄¤¤‹–››	‘’fifl, ‡⎦⎥⎥
⎤
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Chapter 3:  Development and Application of an Integrated Biomarker Clinical Endpoint 
Tool for Late Stage Tuberculosis Regimen Development and Innovative Clinical Trial 
Designs 
Abstract  
Background TB regimen development is plagued with many challenges, the most serious being 
the inability to identify optimal regimens early and efficiently. We developed integrated models 
that described the translational link between sputum-based Phase 2B intermediate biomarkers 
(time to culture conversion, culture conversion status after 8 weeks of treatment, and slope of time 
to detection profiles from MGIT system after 8 weeks of treatment), patient risk factors, and 
treatment characteristics to Phase 3 clinical outcomes at an individual level. We applied our tool 
to recommend minimum Phase 2B treatment efficacy targets and to design innovative late stage 
trials that maximize success of TB regimen development with the most promising regimens. 
Methods Data from four Phase 3 trials that compared six novel regimens to the 6-month standard 
of care for treatment of drug susceptible TB was used to develop and evaluate integrated 
parametric models. Simulations were performed to assess cure rates of novel regimens with culture 
conversion hazard ratios of 2 and 3 for treatment durations between 2 and 6 months. Cure rates for 
adjuvant immunotherapeutic strategies were also assessed. Phase 3 trial designs with the standard 
one-duration-fits-all approach or stratified medicine approaches were evaluated to maximize trial 
success. The simulation process involved individual level predictions of Phase 2B outcomes that 
were sequentially used as input for individual level predictions of Phase 3 outcomes. 
Results Time to culture conversion better predict Phase 3 outcomes compared to culture 
conversion status at 8 weeks or slope of time to detection at 8 weeks [AUROC=0.72 (95% CI: 
0.68-0.77) vs. 0.67 (0.62-0.71) vs. 0.66 (0.62-0.71)]. Potent regimens with culture conversion 
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hazard ratios of 3 or more are required to shorten treatment durations to 4 months using a one-
duration-fits-all approach. With these potent regimens, a stratified medicine approach may allow 
for low risk populations to be treated with ultrashort 2-month durations, but high risk populations 
will still require durations of at least 5.5 months to maximize cure rates. Adjuvant therapies have 
the potential to reduce relapse by 50% with culture conversion hazard ratios above 1.5.  Phase 3 
designs with innovative stratified medicine approaches or adjuvant therapeutic strategies have 
potential to introduce a paradigm shift to the TB regimen development process that include 
superiority tests.  
Conclusions We provide a clinical trial simulation tool that can be used to design optimal Phase 
2 and Phase 3 trials that permit informed decisions about moving the best regimens forward in the 
TB regimen development process. 
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Introduction  
Shorter, efficacious, and better-tolerated oral regimens for tuberculosis (TB) are needed to 
meet the ambitious goals of the WHO End TB Strategy.1 The TB research community has 
identified several new chemical entities with promising preclinical data and are now evaluating 
novel regimen compositions in the clinical phases.2 However, the developmental process of new 
TB regimens remains slow and costly and is plagued by many challenges, the most serious being 
the inability to identify optimal regimens early and efficiently.3 Phase 3 trials that recently failed 
to shorten TB treatment duration from 6 to 4 months using fluoroquinolones has led to a thorough 
review on how decisions are made to move novel regimens through the developmental process.4-6   
Late stage TB regimen development rely on sputum-based culture conversion in Phase 2B 
trials as an intermediate biomarker to predict Phase 3 clinical endpoints of treatment failure and 
relapse up to 24 months following treatment completion. Predominately, Phase 2B studies have 
relied on a dichotomous measure of culture conversion after 8 weeks of treatment due to its 
simplicity and abundance of historical data showing its modest association with long term 
outcomes.7,8 New approaches to Phase 2B designs are now being adapted where more quantitative 
measures are used for early treatment response over the first 8 weeks of treatment with more 
intensive sampling of sputum at earlier timepoints, such as time to culture conversion or slope of 
longitudinal quantitative cultures (i.e. time to detection from the Mycobacteria Growth Indicator 
Tube, MGIT, system; or colony-forming units from the Lowenstein-Jensen, LJ, medium). These 
endpoints permit smaller trials and are thought to be more reliable by capturing an element of time 
on treatment.9,10 However, the translational link between these intermediate biomarkers, treatment 
duration and Phase 3 clinical outcomes is not fully understood and the minimum treatment effect 
required in Phase 2B trials  (i.e. minimum hazard ratio for time to culture conversion) for novel 
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regimens to shorten TB treatment is unknown making it difficult to decide which regimens to 
advance to late stage clinical development.  
Epidemiologic models strongly suggest that novel regimens to end the TB epidemic require 
high cure rates, even more so than treatment shortening. In one study, increasing efficacy from 
94% to 99% was predicted to have the greatest impact on reducing mortality, transmission, and 
burden of disease.11 Additionally, only a modest population-level effect on 10-year transmission 
and mortality was predicted for a 4-month regimen with non-inferior cure rates to a 6-month 
standard of care.12 Therefore, unless TB treatment is radically shortened to 2 months or less, 4-
month regimens that are non-inferior to the 6-month standard regimen will be inadequate to reach 
the all goals outlined in the WHO End TB Strategy. Rather, superior regimens are required. 
However, novel regimens are unlikely to achieve higher cure rates than the 93% observed in 
standard regimens.4-6 Even if possible, very large sample sizes would be required for Phase 3 trials 
that are already expensive and time consuming.13-15 Therefore, innovation to curing TB is required. 
Stratified medicine approaches where duration is based on patient risk factors or adjuvant 
immunotherapeutic strategies with host-directed therapies or therapeutic vaccines administered 
with standard regimens are promising innovative approaches to increase efficacy of treatment 
regimens.16,17 However, the optimal clinical trial design of incorporating these innovative 
approaches have not been evaluated. In this study, we developed integrated parametric models that 
describe the translational link between sputum-based Phase 2B intermediate biomarkers (time to 
culture conversion, culture conversion status after 8 weeks of treatment, and slope of time to 
detection profiles from the MGIT system after 8 weeks of treatment), patient risk factors, and 
treatment characteristics (composition and duration) to Phase 3 clinical outcomes at an individual 
level. Then, we applied our tool to recommend minimum Phase 2B treatment efficacy targets and 
to design innovative late stage trials that maximize success of TB regimen development with the 
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most promising regimens. Our goal was to provide a clinical trial simulation tool to design optimal 
Phase 2 and Phase 3 trials that permit informed decisions about moving the best regimens forward 
to Phase 3 clinical trials.  
Methods 
Data 
Individual participant data (n = 4003) from four Phase 3 trials (OFLOTUB, REMoxTB, 
RIFAQUIN, and DMID 01-009)4-6,18 that compared six 4- or 6-month novel regimens to the 6-
month standard regimen for treatment of drug susceptible TB was used to develop integrated 
parametric models. The OFLOTUB trial tested a 4-month gatifloxacin-containing regimen, 
REMoxTB tested two 4-month moxifloxacin-containing regimens, RIFAQUIN tested a 4-month 
and a 6-month moxifloxacin- and high-dose-rifapentine-containing intermittent regimen, and 
DMID 01-009 tested a 4-month regimen with standard drugs.  Additional information is available 
in the original publication. 4-6,18 
OFLOTUB, RIFAQUIN, and DMID 01-009 collected sputum samples every one or two 
months during treatment. REMoxTB serially collected sputum samples weekly to 8 weeks and 
monthly to end of treatment. In each trial, participants were followed for up to one or two years 
post treatment with sputum samples collected monthly, 3-monthly, or 6-monthly. For analysis in 
this study, participants were censored at 18 months after start of treatment.  
Integrated model development 
Model development involved two parts: 1. integrated model development to predict Phase 
3 clinical outcomes and 2. parametric model development for Phase 2B intermediate biomarkers. 
In part 1, treatment characteristics, observed individual level Phase 2B outcomes, and patient 
phenotypes were tested as predictors of Phase 3 clinical outcomes. In part 2, the best Phase 2B 
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outcome that predicted Phase 3 clinical outcomes from part 1 was modeled with treatment 
characteristics and patient phenotypes tested as predictors.  
Integrated model development for Phase 3 clinical outcomes  
The Phase 3 clinical outcome used for parametric survival modeling was time to a TB-
related outcome; a composite endpoint of treatment failure at the end of treatment, relapse during 
follow up for 18 months from start of treatment, deaths due to TB, and exogenous reinfection (for 
the OFLOTUB study only). The definitions of each outcome were taken from the original 
publications. 4-6,18 Defaults and deaths from a non-TB cause were classified as a missing endpoint 
and censored in our analysis. Hereafter, a patient who experienced a TB-related outcome is referred 
to as experiencing a poor outcome and a patient who does not experience a TB-related outcome is 
referred to have been cured. Cure rates are defined as the proportion of cured patients.  
Phase 2B outcomes investigated to be predictors of poor outcomes were culture status after 
8 weeks of treatment, time to culture conversion up to 6 months after start of treatment, and slope 
of time to detection profiles from the MGIT system after 8 weeks of treatment. Time to culture 
conversion was defined as the time from start of treatment to the first of two negative sputum 
cultures at different visits without an intervening positive culture, irrespective of whether there 
were subsequent positive cultures. Slope of time to detection profiles from the MGIT system after 
8 weeks of treatment was defined as the difference in time to detection at 8 weeks vs baseline 
(pretreatment) in days divided by treatment time in days; the slope had units of detection days per 
treatment days.  
  Separate analysis was performed based on available data from the five trials. Data from all 
four trials were pooled to assess the universally available culture status after 8 weeks of treatment 
as a predictor of poor outcomes. Culture status on LJ solid medium was used because it was 
available in all four trials. Serially collected sputum samples from the REMoxTB trial was further 
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analyzed separately to assess culture status after 8 weeks of treatment, time to culture conversion 
up to 6 months, and slope of time to detection profiles after 8 weeks of treatment all on MGIT 
liquid medium. In the REMoxTB trial, MGIT liquid cultures and LJ solid cultures were available 
but MGIT data was used because it is believed to be more sensitive and current trials are more 
commonly beginning to shift to the use of liquid media.  
Predictors of poor outcomes were tested in the following manner:  1) treatment 
characteristics (treatment duration defined as total number of treatment days drugs were 
administered and regimen composition) were tested independently and significant factors (P < 
0.01) were retained; 2) Phase 2B outcomes were added independently and the single most 
significant factor with the highest area under the receiver operating characteristic curve (AUROC) 
was retained; and 3) patient risk factors were tested as additional predictors and significant factors 
were retained using a stepwise covariate search (p < 0.05 to include and p < 0.01 to remove).  
Parametric model development for Phase 2B intermediate biomarkers  
Time to culture conversion was described with a parametric survival model. Regimen 
composition and patient risk factors were tested as predictors of time to culture conversion using 
a stepwise covariate search. The final model was adjusted for geographical region of clinical site 
(Africa, India, East Asia, South America).  
Model building of Phase 2B and Phase 3 outcomes was guided by Kaplan-Meier visual 
predictive checks to assess calibration and AUROC for discrimination. Model development was 
performed using the nonlinear mixed effect approach available in the NONMEM program (version 
7.4). 
Clinical trial simulations  
The final models that describe Phase 2B and Phase 3 outcomes were integrated to perform 
clinical trial simulations. The simulation process involved individual level predictions of Phase 2B 
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outcomes that were sequentially used as input for individual level predictions of Phase 3 outcomes 
(Figure 3.1). Input parameters for clinical trial simulations include:  
i. sample size per treatment arm, 
ii. recruitment/enrollment strategies (enriched for low risk patients, enriched for high risk 
patients, or distributions that reflect current Phase III trials), 
iii. sampling intervals and study duration for Phase 2B trials or sample intervals and follow 
up duration for Phase 3 trials,  
iv. individual level patient characteristics,  
v. expected improvement in Phase 2B outcomes for novel experimental regimens relative 
to standard regimen (culture conversion hazard ratio adjusted for risk factors),  
vi. expected improvement in poor outcomes after adjusting for improvement in Phase 2B 
outcomes (percent decrease in relapse after adjusting for culture conversion 
improvements),  
vii. treatment duration with 7 of 7 daily dosing, and  
viii. patient adherence (full adherence assigned in this study).  
Hereafter, improvements in Phase 2B outcomes described by culture conversion hazard ratios and 
improvements in poor outcomes described by decrease in relapse are referred to as adjusted 
improvements after accounting for other identified risk factors in the final models. Low, moderate, 
and high risk patients were defined based on risk stratification algorithms described in Chapter 2.  
Simulations were performed to assess cure rates of novel regimens with culture 
conversation hazard ratios of 1, 2, and 3 and decreases in poor outcomes between 0 to 33% for 
treatment durations of 2 to 6 months. A target cure rate of 93%, the observed cure rate in 6-month 
standard regimen data, was used to compare regimens and inform minimum culture conversion 
targets required to shorten treatment duration. Simulations were also performed to predict cure 
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rates for adjuvant immunotherapies (with host-directed therapies or therapeutic vaccines) that are 
given in combination with the 6-month standard regimen with culture conversion hazard ratios of 
1, 2, and 3. A prolonged duration effects between 1 to 2 weeks was also included to describe the 
prolonged immunological response from adjuvant immunotherapies. For adjuvant 
immunotherapies, a target of 50% reduction in poor outcomes compared to the standard regimen 
alone was used. The effect of enriched recruitment strategies, uncertainty in effect size of Phase 
2B outcomes, and uncertainty in the translational link between Phase 2B and Phase 3 outcomes on 
predicted cure rates was assessed.   
Via simulation study, we evaluated operating characteristics of Phase 3 trial designs for 
novel regimens. The performance of Phase 3 trials was characterized by cure rates of novel 
regimens at 18 months after start of treatment, power to detect non-inferior results relative to the 
6-month standard regimen with a non-inferior margin of 6%,4-6 and power to detect superior results 
relative to 6-month standard regimen. Performance was compared between one-duration-fits-all 
and stratified medicine approaches for novel regimens with culture conversion hazard ratios of 2 
and 3. For one-duration-fits-all approaches, a 4-month treatment duration was used. For stratified 
medicine approaches, low risk patients were treated with 2 months, moderate risk patient with 4 
months, and high risk patients with 6 months. Designs were also characterized by i.) sample sizes 
of 250 and 500 patients per arm and ii.) recruitment/enrollment strategies that are consistent with 
current Phase 3 trial populations, are enriched for 80% low risk patients, or are enriched for 80% 
high risk patients. 
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Figure 3.1 Clinical trial simulation workflow. Clinical trial simulations involved individual level 
predictions of Phase 2B outcomes using Model 8 described in Table 3.4 that were sequentially used as input 
for individual level predictions of Phase 3 outcomes using Model 7 described in Table 3.3. For Phase 2B 
outcomes, individual level patient characteristics, regimen characteristics, and trial design characteristics 
were specified for model simulations. For Phase 3 outcomes, simulated Phase 2B outcomes (or observed 
values can be used if available), individual patient characteristics, regimen characteristics, and trial design 
characteristics were specified for model simulations. Output for each simulation are individual level Phase 
2B or Phase 3 outcomes.  
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Results  
Data characteristics  
Data was pooled from four Phase 3 trials (N = 4003) that compared six novel experimental 
regimens (one 6-month regimen and five 4-month regimens) to the 6-month standard regimen. In 
solid medium, 643 of 4003 pooled study participants (16%) had positive culture after 8 weeks of 
treatment. For REMoxTB participants, 764 of 1674 study participants (46%) had positive culture 
after 8 weeks of treatment, median time to culture conversion was 56 days and median slope of 
time to detection was 3.3 detection days per treatment day, all in liquid medium (Table 3.1).   
Table 3.1 Data characteristics 
Characteristic  N = 4003 
Treatment regimen N (%)a  
6-month regimens  
2HRZE/4HR (standard regimen) 1597 (40) 
2EMRZ/4P1M1 212 (5) 
4-month regimens   
2HRZE/2HR 193 (5) 
2HRZG/2HRG 689 (17) 
2HRZM/2MHR 568 (14) 
2EMRZ/2MR 551 (14) 
2EMRZ/2P2M2 193 (5) 
Geographical region of clinical site   
Africa  3228 (81)  
India  342 (9) 
East Asia 274 (7) 
South America 159 (4) 
Female sex - no. (%)  1234 (31) 
Age- yrsb    
Median  29 
Interquartile range  24-38 
Range 16-81 
Weight- kg    
Median  52 
Interquartile range   47-58 
Range 32-137 
Body mass indexc   
Median  18.5 
Interquartile range  16.0-20.4 
Range 12.0-50.9 
HIV positivity - no. (%)d  517 (13) 
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Table 3.1 continued.  
Characteristic  N = 4003 
Cavitation- no. (%)e  2219 (55) 
Smear- no. (%)f    
Negative or 1+  1118 (28) 
2+ 1009 (25) 
3+ 1833 (45) 
Culture positivity after 8 weeks in solid mediumg  643 (16) 
Culture positivity after 8 weeks liquid medium 
(REMoxTB only)h 196  
764 (46)  
Time to culture conversion (days) (REMoxTB only)h    
Median  56 
Interquartile range   42-90 
Range  1-168 
Slope of time detection profiles after 8 weeks 
(detection days/treatment days) (REMoxTB only)h  
 
Median 3.3 
Interquartile range   1.5-4.7 
Range  -4.9-5.4 
aH = isoniazid, Z = pyrazinamide, E = ethambutol, R = rifampin, P = rifapentine, M =moxifloxacin, 
G=gatifloxacin. Subscripts on P and M define rifapentine and moxifloxacin weekly dosing; 1, once weekly 
rifapentine (1200 mg) and moxifloxacin (400 mg); 2, twice weekly rifapentine (900 mg) and moxifloxacin (400 
mg). All other drugs were administered daily according to published guidelines. First set of drugs represent 2-
month intensive phase regimen and second set of drugs represent 4-month or 2-month continuation phase 
regimen.   
bAge was missing in 5 participants (<1%). 
cBody mass index was defined as the weight in kilograms divided by the squared height in meters.  
dHIV status was missing in 9 study participants (<1%).  
eCavitation status was missing for 215 study participants (5%).  
fSmear grade was missing for 43 study participants (1%). 
g Culture status in Lowenstein-Jensen solid medium. Culture status after 8 weeks of treatment was missing for 
340 study participants (8%).  
h Culture data from Mycobacterial Growth Indicator Tube (MGIT) liquid medium used in separate analysis 
with REMoxTB trial data only. Based on N=1674. Culture status after 8 weeks of treatment was missing for 
196 study participants (12%). Time to culture conversion was missing for 142 study participants (8%). Slope of 
time to detection after 8 weeks of treatment was missing for 196 study participants (12%).  
 
Integrated model development 
Culture status after 8 weeks of treatment had modest AUROC for predicting poor outcomes 
in the pooled data from four Phase 3 trials (0.67 (95% confidence interval, CI, 0.63-0.70); Table 
3.2) and in the REMoxTB data only (0.67 (0.62-0.71) (Table 3.3). Comparing more quantitative 
Phase 2B outcomes, time to culture conversion had higher AUROC for predicting poor outcomes 
than the slope of time to detection profiles after 8 weeks of treatment (0.72 (0.68-0.77) vs. 0.66 
(0.62-0.71), Table 3.3). Integrating time to culture conversion, treatment duration and identified 
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patient risk factors (HIV status, sex, and cavitation at baseline) further improved the prediction of 
poor outcomes (Table 3.3 and Figure 3.2).    
A time to culture conversion model was developed to link to the Phase 3 clinical outcome 
model. Patient risk factors that prolonged risk of culture positivity were higher smear grade at 
baseline (60% (relative standard error, RSE=9%) decrease in culture conversion hazard for smear 
3+ relative to smear 1+ or negative) and older age (8% (RSE = 21) decrease in culture conversion 
hazard per 10 year increase in age). The final model that predicts time to culture conversion had 
an AUROC of 0.73 (0.70-0.75) (Table 3.4). Calibration of the final integrated models were good, 
as shown in the visual predictive checks (Figure 3.2 and Figure 3.3).   
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Table 3.2 Model parameter estimates for time to poor outcome in data pooled from four trials (DMID 01-
009, OFLOTUB, REMoxTB, RIFAQUIN).  
 Model 1 
Treatment Duration  
Model 2 
Treatment duration and 
culture status 
AUROC (95% confidence interval) 0.60 (0.58-0.64) 0.67 (0.63-0.70)  
Parameter Description  Estimate (RSEc)  Estimate (RSEc)  
Baseline hazarda, STU 10-3.6 (13) 10-3.7 (12) 
Shape parametera, V	 0.52 (24) 0.52 (24) 
Shape parameter 2a, W 3.9 (26) 3.9 (26) 
Linear effect on baseline hazard (%) b 
Per 28 day decrease in treatment duration  27 (10)  30 (8)  
For culture positivity after 8 weeks in solid 
medium 
- 190 (16) 
aHazard of poor outcomes was described with the surge function, ℎ(/) = J(I)/K%IL(−N/) . J(I)  is the 
baseline hazard risk and is dependent on the typical value,	B]J, and covariate vector,	I. O and N are shape 
parameters. 
bCovariate effects added using linear relationships. For continuous covariates, the following relationship was 
used: ^(I) = 	B]^_1 + b(;G] − ;G]cA+:>\)d, where B]^ is the typical value for parameter ^, b is the 
reported covariate effect centered around the covariate median value (;G]cA+:>\) and ;G] is the individual 
covariate value. For binary covariates, the following relationship was used: ^(I) = 	B]^_1 + b(;G])d 
where B]^ is the typical value for parameter ^, b is the reported covariate effect for the individual covariate 
value ;G] (value of either 0 for reference or 1 for test group). Increased effect (positive covariate effect) on 
baseline hazard refers to increased hazard risk of poor outcomes in this model.  
cRSE = relative standard error standardized to parameter estimate (typical value or median), units in %  
-Parameter not included in model. 
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Table 3.4 Model parameter estimates for time to culture conversion. a 
 Model 8 
Patient risk factors 
AUROC (95% confidence interval) 0.73 (0.70-0.75) 
Parameter Description  Estimate (RSEd)  
Baseline hazardb, STU 1.0 (14) 
Shape parameterb, V	 0.93 (10) 
Shape parameter 2b, W 2.2 (7) 
Linear effect on baseline hazard (%)c 
For smear 3+ relative to smear negative or 1+ -60 (9) 
For smear 2+ relative to smear negative or 1+ -18 (71) 
For 10-year increase in age   -8 (21) 
Linear effect on shape parameterc 
For smear 3+ relative to smear negative or 1+ -30 (17) 
a The final model was adjusted for geographical region of clinical site (Africa, India, 
East Asia, South America). 
bHazard of poor outcomes was described with the surge function, ℎ(/) =J(I)/K%IL(−N(I)/). J(I) is the baseline hazard risk and is dependent on the typical 
value,	B]J, and covariate vector,	I. N(I) is the shape parameter and is dependent on 
the typical value,	B]N, and covariate vector,	I. O is the second shape parameter. 
cCovariate effects added using linear relationships. For continuous covariates, the 
following relationship was used: ^(I) = 	B]^_1 + b(;G] − ;G]cA+:>\)d, where B]^ is the typical value for parameter ^, b is the reported covariate effect centered 
around the covariate median value (;G]cA+:>\) and ;G] is the individual covariate 
value. For binary covariates, the following relationship was used: ^(I) =	B]^_1 + b(;G])d where B]^ is the typical value for parameter ^, b is the reported 
covariate effect for the individual covariate value ;G] (value of either 0 for reference 
or 1 for test group). Decreased effect (negative covariate effect) on baseline hazard 
and shape parameters refers to prolonged culture conversion in this model.  
dRSE = relative standard error standardized to parameter estimate (typical value or 
median), units in %  
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Figure 3.2 Receiver operating characteristic curves and Kaplan Meier visual predictive checks for time to 
poor outcome models. (A) ROC curves for predicting time to poor outcome according to pooled data from 
four Phase 3 trials (DMID 01-009, OFLOTUB, REMoxTB, RIFAQUIN). (B) ROC curves for predicting 
time to poor outcome according to data from REMoxTB trial only. (C) VPC for final integrated poor 
outcome model (Model 7). Model 1 and 3 included treatment duration only, Model 2 and 4 included 
treatment duration and culture status after 8 weeks of treatment (solid medium for Model 2 and liquid 
medium for Model 4), Model 5 included treatment duration and slope of time to detection profiles after 8 
weeks of treatment, Model 6 included treatment duration and time to culture conversion, and Model 7 
included treatment duration, time to culture conversion, and patient risk factors.   
 
 
Figure 3.3 Receiver operating characteristic curves and Kaplan-Meier visual predictive checks for final 
time to culture conversion model. (A) ROC curve for predicting time to culture conversion and (B) VPC 
for final time to culture conversion model  
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Phase 2B treatment efficacy targets  
Via simulation study, the final integrated models were used to inform treatment durations 
required for novel regimens with culture conversion hazard ratios of 1, 2, and 3 relative to standard 
regimen. For a one-duration-fits-all approach, as would be expected, treatment durations of 6 
months are required for regimens with a culture conversion hazard ratio of 1 (i.e. the same as the 
standard regimen) to reach target cure rates of 93%. More potent regimens with culture conversion 
hazard ratios of 2 and 3 were predicted to require treatment durations of 4.5 to 5.5 and 4 to 5.5 
months to reach target cure rates, respectively (Figure 3.4A). Stratifying patients by risk group 
showed potential for the low risk subgroup to be treated for as low as 2 months with highly potent 
regimens (i.e. hazard ratio of 3). However, the moderate risk subgroup requires durations of at 
least 3.5 months to reach target cure rates and the high risk subgroup requires at least 5.5 months 
(Figure 3.4B).  For adjuvant immunotherapies that are co-administered with the standard 6-month 
regimen, a minimum culture conversion hazard ratio of 1.5 is required to reach a 50% reduction 
in poor outcomes compared to the standard regimen alone (Figure 3.5).  
The effect of enrollment/recruitment strategies, uncertainty in culture conversion hazard 
ratios, and uncertainty in the translational link between Phase 2B to Phase 3 outcome on predicted 
cure rates was assessed for a 4-month regimen with a culture conversion hazard ratio of 2. 
Recruitment strategies had the largest effect on predicted cure rates. Compared to recruitment 
reflecting recent Phase 3 trials, enrichment for 80% low risk patients led to 4.2 percentage points 
above the true cure rate and enrichment for 80% high risk patients led to 4.8 percentage points 
below the true cure rate. Uncertainty in culture conversion hazard ratios also had large effects on 
predicted cure rates. If the estimated culture conversion hazard ratio from a Phase 2B trial is at the 
5th percentile of the uncertainty distribution, the estimated cure rate can be as low as 3.3 points 
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below the expected true cure rate. The uncertainty in the translational link between Phase 2B to 
Phase 3 outcomes had marginal effects on predicted cure rates (Figure 3.6).   
 
Figure 3.4 Optimal treatment durations for novel regimens. Cure rates for novel regimens with Phase 2B 
culture conversion hazard ratios (HR) of 1 (left), 2 (middle), and 3 (right) administered for 2 to 6 month 
durations. (A) Simulations for one-duration-fits-all approach. (B) Simulations by risk group for a stratified 
medicine approach. Shaded areas represent regimens with 0 to 33% decrease in relapse after adjusting for 
culture conversion improvements.  
 
Figure 3.5 Optimal culture conversion hazard ratios for adjuvant immunotherapeutic strategies. Cure rates 
for adjuvant immunotherapies co-administered with the standard 6-month regimen for Phase 2B culture 
conversion hazard ratios (HR) of 1 to 3 are shown. Shaded area represents adjuvant therapies with 
prolonged duration effects of 1 to 2 weeks.   
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Figure 3.6 Effect of enrollment/recruitment strategies, uncertainty in culture conversion hazard ratio, and 
uncertainty in the model parameter that links Phase 2B to Phase 3 outcomes on predicted cure rates for a 
novel 4-month regimen with a culture conversion hazard ratio (HR) of 2 relative to the 6-month standard 
regimen. Reference recruitment reflected distributions observed in recent Phase 3 trials. Predicted cure rates 
for enriched enrollment/recruitment strategies with 80% low risk patients or 80% high risk patients, the 5th 
and 95th percentile of culture conversion HR uncertainty with standard deviations of 0.1, 0.2, 0.3, and 0.4 
for log(HR), and the 5th and 95th percentile of the estimated model parameter uncertainty that links Phase 
2B to Phase 3 outcomes (median = 0.29, relative standard error of 15%, see Table 3.3 Model 7)were 
compared to true cure rates.  
Phase 3 clinical trial simulations  
The clinical trial simulation tool was used to identify Phase 3 clinical trial designs and novel 
regimens that maximize trial success and cure rates with current one-duration-fits-all and 
innovative stratified medicine approaches. Simulations showed that one-duration-fits-all 
superiority trial designs for novel 4-month regimens with culture conversion hazard ratios of 2 or 
3 are unlikely to be successful, with powers below 10% (Figure 3.7A and Figure 3.7B, bottom 
panels). However, stratified medicine designs with a highly potent regimen that has a culture 
conversion hazard ratio of 3 is predicted to have 80% power to show superiority if the trial has 500 
participants per arm and is enriched for high risk patients (Figure 3.7D, bottom panel). For the 
same potent regimen, one-duration-fits-all and stratified medicine trial designs with 500 
participants per arm had at least 90% power to show non-inferiority (Figure 3.7B and Figure 3.7D, 
middle panels). Comparing enrollment/recruitment strategies, one-duration-fits-all non-inferiority 
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designs with enrichment for high risk patients had decreased power compared to enrichment for 
low risk patients (Figure 3.7A and Figure 3.7B, middle panels). However, for stratified medicine 
non-inferiority trial designs, enrichment for high risk patients had increased power compared to 
enrichment for low risk patients (Figure 3.7C and Figure 3.7D, middle panels).   
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Discussion  
In this study, we have developed a clinical trial simulation tool that integrates Phase 2B 
outcomes, treatment duration, and patient risk factors to predict Phase 3 clinical outcomes. 
Applying the tool, we predicted that highly potent regimens with culture conversion hazard ratios 
of 3 or higher are required to reach target cure rates. With highly potent regimens, a stratified 
medicine approach may allow for low risk subgroups to be treated with ultrashort 2-month 
durations but high risk subgroups may still require durations of at least 5.5 months to maximize 
cure rates. Adjuvant immunotherapeutic strategies that prolonged immune response when co-
administered with the 6-month standard regimen may also have the potential to increase cure rates 
with culture conversion hazard ratios above 1.5. We found that clinical trial designs with these 
innovative approaches have potential to introduce a paradigm shift to the TB regimen development 
process that include superiority tests.  
Our data shows that time to culture conversion, a summary measure of the longitudinal 
profile of culture results over time, had higher AUROC for predicting long-term poor outcomes 
compared to culture status after 8 weeks of treatment or slope of time to detection profiles after 8 
weeks of treatment (Table 3.3 and Figure 3.2). However, the ability of time to culture conversion 
to discriminate between favorable and poor outcomes is still modest with a maximum AUROC of 
0.74 after adjusting for patient risk factors and treatment duration. This level of discrimination 
agree with previously published analysis with REMoxTB data using a logistic regression approach 
compared to the parametric survival modeling we performed to predict Phase 3 clinical 
outcomes.19  We also found that the uncertainty in the translational link between Phase 2B and 
Phase 3 outcomes had marginal effects on predicted cure rates further highlighting the low 
sensitivity of culture-based intermediate markers to predict long-term poor outcomes (Figure 3.6). 
However, this may also be explained, in part, by the low-unvarying culture conversion hazard 
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ratios for the two regimens tested in the REMoxTB trial (1.17 for both novel fluoroquinolone-
containing regimens compared to standard regimen)5 that were included in the final integrated 
model. Sputum samples were not collected serially at earlier timepoints than 1 or 2 months in the 
OFLOTUB, RIFAQUIN, and DMID 01-009 trial, therefore, not included in the final integrated 
model. As more longitudinal culture and long-term outcome data become available from Phase 3 
clinical trials that test novel potent regimens (i.e. SimpliciTB, NCT0333862120 and TBTC Study 
31, NCT0241077215), our clinical trial simulation tool can be validated to confirm the translational 
links identified.  
Although potentially imperfect, the integrated relationship between intermediate culture-
based biomarkers, treatment duration, patient risk factors and clinical outcomes, was used to 
inform the minimum efficacy targets required in Phase 2B trials to maximize cure rates and success 
in late stage TB regimen development. Our simulations suggest that culture conversion hazard 
ratios of 3 or more are required to maximize cure rates for shorter durations than 6 months. In a 
Phase 2B study, a very promising regimen that includes bedaquiline, pretomanid, moxifloxacin, 
and pyrazinamide (BPaMZ) was shown to have a culture conversion hazard ratio of 3.3 in patients 
with rifampin-resistant TB.10 In the current Phase 3 trial (SimpliciTB), the BPaMZ regimen is 
being tested for 4 months in drug-susceptible and 6 months in drug-resistant patients.20 
Prospectively, our clinical trial simulation tool predicts that a regimen with a culture conversion 
hazard ratio of 3, similar to the BPaMZ regimen, can potentially shorten drug susceptible TB 
treatments to 4 to 5.5 months using a one-duration-fits-all approach. However, low risk subgroups 
may only require 2 months of the BPaMZ regimen and therefore may be over treated with a 4-
month duration; potentially exposing patients to unnecessarily long and toxic treatments. In 
contrast, we predict that high risk subgroups may be undertreated requiring durations longer than 
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the 4 months currently investigated. These predictions will need to be confirmed when longitudinal 
culture data and long-term outcome data become available from the clinical trial.  
Noninferiority has been the design of choice for all recent Phase 3 trial for drug susceptible 
TB because the very high success rates with the standard regimen making it unlikely to find an 
experimental regimen showing superior outcomes without exceptionally large sample sizes. In 
addition, some loss of efficacy because of shorter treatments in exchange for more effectivity in 
programmatic terms, such as improved adherence, improved patient management, and reduced 
exposure to toxic drugs, is deemed beneficial to the TB community.4-6,13-15,20-22 Unfortunately, all 
recent Phase 3 trials with non-inferiority designs testing 4-month experimental regimens failed.4-6 
In previous analysis, high risk subgroups (i.e. patients with high bacterial burden and cavitary 
disease) were shown to require regimens longer than the standard 6 months and are likely the 
reason for failed non-inferiority trials (Chapter 1 and 2).16 In this study, we found that innovate 
stratified medicine approaches, where duration is selected based on patient phenotypes, not only 
improves success of non-inferiority trials but also introduces potential to design and conduct 
unprecedented superiority trials in TB regimen development with increased cure rates. However, 
success rates of Phase 3 trials using a stratified medicine approach was dependent on enrollment 
strategies. In TB, the high risk subgroup is a curable population with the most potential for 
improved efficacy compared to the low risk subgroup that already have high cure rates even with 
shorter standard regimens.16 Therefore, designs with stratified medicine approaches have more 
power to detect non-inferiority or superiority between experimental and standard regimens when 
enrollment is enriched for high-risk patients and designs with one-duration-fits-all approaches 
have more power to detect non-inferiority between experimental and standard regimens when 
enrollment is enriched for low-risk patients; as high risk patients will likely still be under treated. 
Enrichment in confirmatory Phase 3 trials is limited and unlikely to be acceptable by regulators; 
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as evidence of proven efficacy and safety in all patients is required for approval. Innovative 
approaches that include stratified medicine and strata level objectives may be an alternative 
approach to show efficacy and safety in all patients. For example, strata level objectives may 
involve showing superiority for high risk subgroups treated with regimens 6 months or longer and 
non-inferiority for low risk groups treated with shorter regimens. This approach may allow for 
maximized cure rates all patients and reduced toxicity concerns in at least low risk subgroups but, 
with treatment durations based on patient phenotypes, improvement of effectivity in programmatic 
terms will need to be assessed.  
Adjuvant immunotherapeutic strategies, where host-directed therapies or therapeutic 
vaccines are administered with standard regimens, are another attractive approach to increase TB 
cure rates.17 However, efficacy of adjuvant immunotherapies in patients is difficult to quantify 
because of the lack of clinical data, as clinical trials are still in the design and development 
stages.23,24 In our tool, we added a prolonged duration effect from the standard regimen to 
quantitatively describe the long-lasting immune response because of immunotherapies. We 
predicted that adjuvant therapies with long-lasting immune response require culture conversion 
hazard ratios of 1.5 compared to the standard regimen alone to reduce poor outcomes by 50%. 
Prospective Phase 3 trials that test adjuvant immunotherapies to treat TB will need to confirm these 
predictions and will help better quantify the prolonged duration effect.  
In conclusion, we provide a clinical trial simulation tool that can be used to design optimal 
clinical trials that permit informed decisions about moving the most promising regimens forward 
in the TB regimen development process. The tool integrates the most studied and broadly 
acceptable intermediate biomarkers assessed in Phase 2B trials, treatment duration, and patient 
risk factors to predict Phase 3 clinical outcomes. Model simulations provided Phase 2B efficacy 
targets for novel regimens and optimal trial designs for innovative stratified medicine approaches 
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and adjuvant immunotherapeutic strategies. We have developed a framework that can be extended 
and adapted to provide more precise predictions of cure rates and further facilitate decisions when 
more quantitative and sensitive biomarkers are discovered and more data from Phase 3 trials that 
testing novel regimens become available.   
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Chapter 4:  Identification of novel proteomic signatures as predictors of tuberculosis 
treatment response  
Abstract 
Background Traditionally, sputum-based culture status after 8 weeks of treatment is used to 
monitor tuberculosis (TB) treatment response. Robust, quantitative, non-culture-based biomarkers 
of treatment outcomes represent an advance for individual monitoring of TB patients. Here, we 
leverage serially-collected sputum culture results and drug exposure in clinical trial participants to 
identify proteomic signatures that predict response to TB treatment.  
Methods Blood samples collected at enrollment and week 8 of treatment from 538 participants 
from two Phase 2B trials were screened for 70 markers of infection, inflammation, and 
metabolism. Biomarker assays were quantified using a multiplexed electrochemiluminescence 
assay. Nonlinear mixed effect modeling and classification and regression tree analysis was used 
to integrate proteomic, drug exposure, and clinical risk factor data for prediction of longitudinal 
treatment response profiles from the Mycobacteria Growth Indicator Tube assay. An independent 
dataset of TB patients with confirmed durable cure 12 months post-treatment completion was used 
to validate identified proteomic signatures.  
Results We identified SAA1, CD40L, and RANTES as candidate proteomic biomarkers with 
early, dynamic treatment response profiles.  By integrating the proteomic signatures with drug 
exposure, and clinical risk factors we predicted week 8 and week 12 culture conversion status with 
an AUROC of 0.82 (95% CI: 0.76-0.87) and 0.85 (0.78-0.92), respectively. Fast and moderate 
responders, as predicted by proteomic biomarker levels, had shorter time to culture conversion 
compared to slow responders (3.1, 95% CI 1.9-5.2, and 2.0, 1.2-3.4, respectively). In the 
independent dataset of cured participants, 80% (24/30) were predicted to be fast to moderate 
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responders. Longitudinal proteomic levels suggest treatment response may be predicted with levels 
after 2 weeks of treatment.  
Conclusions In a rigorously followed cohort of diverse TB patients enrolled in two Phase 2B 
clinical trials, we identified and validated proteomic signatures that predict early treatment 
response dynamics. Further investigation is warranted with novel non-rifampin-based regimens, 
more long-term outcomes and biomarker levels at earlier timepoints.   
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Introduction  
Establishing the efficacy of newer regimens has been a major challenge in tuberculosis 
(TB) drug development because of the lack of reliable surrogate markers.1 Sputum-based markers, 
predominately culture status after 8 weeks of treatment or time to culture conversion, are the most 
frequently used intermediate markers to quantify early drug response and predict clinical outcomes 
of treatment failure and relapse up to 24 months of follow up. Unfortunately, despite their historical 
use as a measure of bacterial burden, they have shown to have poor surrogate properties at the 
individual and trial level with low sensitivity and modest specificity.2-4 New biomarkers and 
technologies are needed to both monitor treatment response in individual patients and to support 
innovation in TB clinical trials. 
Discovery of robust, quantitative, non-culture-based biomarkers of anti-TB treatment 
outcomes that can be measured early in treatment would represent a major advance for the TB 
therapeutics field.1,5,6 Blood-based markers are promising as they are easy to collect, available 
throughout treatment, quantitative, thereby providing opportunity to improve predictive power, 
and can lead to development of cost-effective point-of-care assays that don’t require sophisticated 
mycobacteriology laboratory infrastructure. A number of studies have identified several blood-
based host biomarkers that change during TB treatment or are associated with culture status after 
8 weeks of treatment.7-18 However, most of these studies are single center studies, assess single 
markers, use convenience samples, have modest sample sizes or rely on case-control or 
observational designs. In seeking to overcome such limitations,  70 different markers of infection, 
inflammation, and metabolism were previously investigated in over 300 participants enrolled in 
an international Phase 2B clinical trial conducted across nine countries (TB Trial Consortium 
Study 29, NCT00694629)19. A subset of biomarkers were shown to be associated with disease 
severity and bacterial burden at baseline and strongly modulated by tuberculosis treatment with 
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greater modulation in early culture converters than late culture converters.19-21 Although the 
rigorous analyses identified promising novel biomarkers that could be useful for evaluating disease 
severity and treatment monitoring, these biomarkers alone or in combination with clinical risk 
factors only had modest predictive power to discriminate individual treatment status 
dichotomously using culture status after 8 weeks of treatment (area under the receiver operating 
characteristic curve, AUROC, 0.66).20 Longitudinal information from sputum culture results in 
conjunction with population-based pharmacokinetics (PK) and drug exposure were not fully 
leveraged in the previous analyses, warranting further investigation into the response dynamics to 
better understand treatment response heterogeneity between individuals.    
Here, we aimed to improve predictive power of proteomic biomarkers by maximizing the 
use of the rich, longitudinal time to detection data collected from the Mycobacteria Growth 
Indicator Tube (BACTEC MGIT 960) assay throughout treatment to describe individual treatment 
response. In addition, we pooled additional data from participants enrolled in a second clinical trial 
that tested higher rifamycin doses (TB Trial Consortium Study 29X, NCT01043575)22.  High 
interindividual variability of rifamycin PK (more than 4-fold variation of exposure for a given 
dose) have been highly predictive of individual culture conversion,22,23 therefore was integrated 
with the search for proteomic biomarkers, along with other identified clinical risk factors (i.e. HIV 
status, smear grade, and cavitation), to predict of individual treatment response. Nonlinear mixed 
effect methodology was used to model longitudinal time to detection profiles and empirical 
Bayesian estimates were obtained from the final model to describe patient-specific treatment 
response parameters. Machine learning approaches with classification and regression tree (CART)  
analysis were then used to examine the role of 70 biomarkers as predictors of the patient-specific 
treatment response parameters.24 Our proposed candidate biomarkers of treatment response were 
then validated as predictors of long-term outcomes from an independent dataset.  
92 
 
Methods  
Data 
We pooled data from adults, 18 years and older, with pulmonary tuberculosis enrolled in 
two randomized Phase 2 clinical trials (TB Trial Consortium Studies 29 and 29X) that compared 
efficacy and safety of rifampin to rifapentine during the 8-week intensive phase of treatment.19,22 
These trials were conducted in Brazil, Hong Kong, Kenya, Peru, South Africa, Spain, Vietnam, 
Uganda, and the United States. In Study 29, participants were randomized to receive rifapentine 
(10 kg/mg/dose) or rifampin (10 mg/kg/dose) 5 days per week for 8 weeks. In Study 29X, 
participants received rifapentine (10, 15, or 20 mg/kg/dose) or rifampin (10 mg/kg/dose) daily for 
8 weeks. Isoniazid, pyrazinamide, and ethambutol were also administered during the 8-week 
intensive phase and rifampin and isoniazid were administered during the 4-month continuation 
phase in accordance to published guidelines.25,26 Sputum specimens for culture were collected at 
baseline (enrollment) for pretreatment levels and weeks 2, 4, 5, 6, 8, 12 and monthly thereafter 
during treatment for Studies 29 and 29X participants. Study design and results for both trials have 
been previously published.19,22  
In Studies 29 and 29X, 546 protocol correct participants (319 from Study 29 and 227 from 
Study 29X) had paired baseline (pretreatment) and week 8 blood samples for biomarker testing. 
Eight participants had missing baseline smear grade or chest radiograph data and were excluded 
from the analysis. In total, 538 participants irrespective of dose were included in the analysis of 
proteomic biomarkers that account for drug only (rifampin vs rifapentine) to predict treatment 
response. This analysis would inform if regimen composition and proteomic biomarkers are 
adequate for predictions. For 335 participants treated with rifapentine, a second analysis was 
performed by integrating proteomic biomarkers, drug exposure and clinical risk factors to predict 
treatment response. Rifampin PK data was not collected in the studies therefore not included in 
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the second analysis. Comparing the results of these two analyses would inform the level of drug 
exposure and clinical data necessary to maximize predictive value of proteomic biomarkers. A 
population pharmacokinetics-pharmacodynamic model for the Studies 29 and 29X dataset have 
been previously developed and were used in this analysis for post-hoc estimates of individual 
rifapentine PK parameters (area under the concentration time curve, AUC).23  
An independent dataset for external evaluation of potential biomarkers was obtained from 
the multi-network partnered Consortium for TB Biomarkers (CTB2; 
https://www.tbbiorepository.org  funded through U.S. Food and Drug Administration, U.S. 
National Institutes of Allergy and Infectious Diseases and Bill & Melinda Gates Foundation) and 
included 21 cured participants from the Phase 3 REMoxTB trial (NCT00864383) and 9 cured 
participants enrolled and managed through the National Tuberculosis Program at the same sites at 
which REMoxTB was conducted.27 Cured was defined as confirmed durable cure 12 months post-
treatment completion. In the REMoxTB trial, adults with pulmonary TB received the standard 6-
month regimen or one of two experimental 4-month regimens that replaced isoniazid or ethambutol 
with moxifloxacin. Adults with pulmonary TB from the National Tuberculosis Program are 
presumed to have received the standard 6-month regimen. All participants in the independent 
dataset received standard rifampin doses. Blood for proteomic analysis was collected at baseline 
and weeks 2, 4, 8, 17, 26, and 52 and sputum was collected at baseline and weeks 2, 4, 8, 17, 26, 
and 52 for REMoxTB participants and at baseline, and weeks 4, 8, 26, and 52 for National 
Tuberculosis Program participants. 
Longitudinal treatment response variables 
Treatment response for each individual was characterized using the longitudinal sputum 
culture results from the MGIT assay to describe 1.) time to detection profiles which reflect bacterial 
burden over time, 2.) time to first negative culture status defined as time from start of treatment to 
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the first culture conversion from positive to negative, irrespective of whether there were any 
subsequent positive results, and 3.) time to stable culture conversation defined as time from start 
of treatment to the first of two negative cultures at different visits without an intervening positive 
result. Time to detection profiles were used to identify proteomic biomarkers of treatment response 
that grouped participants into slow, moderate, and fast responders. Time to first culture negative 
status and time to stable culture conversion were used to compare responder groups in Cox 
regression analysis, with the former being the primary marker because it is less impacted by study 
design (i.e. how often sputum is collected) and better aligns with time to detection profiles as it 
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such that culture becomes negative.  
Nonlinear mixed effect modeling was used to describe time to detection profiles with the 
following empirical logistic model:  
/+A#A≥#:[\ = 	àE"= +	 âEÂ − àE"=1 + %&Ê(X,ÃŒÀ,„Œfl,&XÁ-) 
where /+A#A≥#:[\ is the time to bacterial detection in the MGIT assay at treatment time, B#?A>#cA\#; àE"= is baseline time to bacterial detection; MAX  is the model derived time to bacterial detection 
maximum value (artifact of modeling due to assay censoring at 44 days); N is the slope of the 
profile; and BËk is the treatment time to reach 50% of MAX. /+A#A≥#:[\, àE"=, and âEÂ are in the 
units of days and represent assay times;	B#?A>#cA\# and BËkare in the units of weeks and represent 
treatment times; and N is in the units 1/week.  A publication for this model in currently in progress. 
Figure 4.1 shows the effect of covariates on each of the model parameters while holding all other 
parameters constant. Covariates on BËk has the most pronounced effect on the treatment time when 
time to detection profiles reach censored values of 44 days such that culture becomes negative. In 
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this study, we aimed to identify proteomic biomarkers that describe empirical Bayesian estimates 
of unexplained interindividual variability of  BËk. The BËk parameter is described by the following:  BËk = B]BËk(I) ∗ exp(Í) 
where B]BËk(I)  is the typical value of  BËk  for individuals with covariates, I , and Í  is the 
empirical Bayesian estimate of unexplained interindividual variability of BËk with a mean of zero 
and variance of ÎÏw, which is estimated in population modeling. Hereafter, the empirical Bayesian 
estimates, Í, of unexplained inter-individual variability of  BËk is referred to as an individual’s 
response time. A positive value for response time increases BËk and represents a slower response 
(longer time on treatment to convert culture) for an individual relative to a typical patient with the 
same covariates, while a negative value for response time decreases BËk and represents a faster 
response (shorter time on treatment to convert culture) for an individual relative to a typical patient 
with the same covariates. A zero value for response time represents an individual with no variation 
compared to the typical patient with the same covariates. Drug or drug exposure and clinical risk 
factors of smear grade, geographic site (Africa vs non-Africa) and cough before treatment 
(productive vs. nonproductive) were covariates included for determination response time.  
 
Figure 4.1 Covariate effects on time to detection parameters. Covariate effects are shown on the (A) àE"= 
parameter, (B) âEÂ parameter, (C) N parameter, and (D) BËk parameter. Black curves represent a typical 
patient, red curves represent a 25% increase in parameter values due to a covariate, and blue curves 
represent a 25% decrease in parameter values due to a covariate. /+A#A≥#:[\, time to bacterial detection in 
the MGIT assay; B#?A>#cA\# , treatment time; àE"=, baseline time to bacterial detection; MAX, model 
derived maximum time to bacterial detection; N, slope of the profile; and BËk, treatment time to reach 50% 
of MAX.  
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Proteomic methods  
Proteomic assays have been described in a precious publication.20 Briefly, a total of 70 
biomarkers were measured in 14 multiplexed assay panels using sandwich immunoassay format 
(proteins) or a competitive immunoassay format (neopterin), using electrochemiluminescence 
(ECL) detection.28 The ECL assays employed consumables and instrumentation from Meso Scale 
Diagnostics, LLC (MSD). The assay components for each panel included an MSD MULTI-
ARRAY® 96- well plate having an array of capture antibodies in each well, a set of labeled 
detection antibodies for each analyte in the panel (labeled with the MSD SULFO-TAG™ ECL 
label), a combined calibration standard containing a mixture of the target analytes, an assay diluent 
and a detection antibody diluent. For the neopterin competitive assay, a labeled neopterin analog 
was used in the place of the labeled detection antibody. In total, 14 biomarker panel assays were 
tested, six MSD commercial kits and eight custom assay panels that were newly developed for 
analysis of this data. 
MSD received 500 μL of each sample at their core facility (Gaithersburg, MD) where 
assays were conducted with investigators and technicians blinded to participant data. Each sample 
was tested in duplicate with each of the 70 assays. Concentrations were reported as the average 
value of the duplicate measurements; values below the limits of detection were assigned a 
concentration equal to the limits of detection. Coefficient of variations were determined for the 
biomarker levels measured in the control samples run on each assay plate; the median control 
coefficient of variation (and in quantitation range) across the different assays was 10% (9%–13%). 
Serum levels were quantified for 69 proteins and one metabolic marker. As described 
previously, 8 of 70 markers that provided levels greater than twice the limit of detection for <25% 
of the samples were excluded from further analysis.20 In addition, one marker, IL12P40, was 
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excluded from analyses in this study because it was not available from the panel of assays for 
Study 29X participants.  
Statistical methods  
Statistical analysis was conducted using the R statistical programming language (version 
3.4). We performed CART analysis to examine proteomic biomarkers that predict response time 
after adjusting for drug or drug exposure and clinical risk factors. Baseline, week 8 and ratio of 
week 8 to baseline proteomic biomarker levels (61 biomarkers, 183 variables total) were tested 
simultaneously as predictors of response time. CART uses nonparametric techniques that examine 
both linear and nonlinear interactions simultaneously in the whole dataset and creates a hierarchy 
of predictors, starting with the most predictive to the least predictive.24 The CART algorithm 
model works by repeatedly splitting predictor variables into multiple nodes, so that the outcomes 
in each final node is as homogenous as possible. The split cutoff for each predictor is defined so 
that the residual mean squared error is minimized across the samples that fall within the sub 
partition. Tree pruning, where decisions trees are simplified to remove splits that do not 
significantly improve overall quality of the model, as described by the root mean squared error, 
was performed by automatically assessing 10 values of the complexity parameter in CART 
analysis using the caret and rpart packages in R.29,30 The complexity parameter imposes penalties 
for having too many splits and the best model with the optimal complexity parameter value was 
chosen that minimized the 10-repeated 10-fold cross validation root mean squared error. A random 
selection of 70% of participants in Studies 29 and 29X was used to train the model, while the 
remaining 30% was used to test the model. Following CART analysis, the final decision tree was 
used to define slow, moderate, and fast responders using the identified proteomic signatures. Cox 
regression analysis was performed to assess adjusted hazard ratios between slow, moderate, and 
fast responders for time to first negative culture conversion and time to stable culture conversion. 
98 
 
Hazard ratios were adjusted for drug or drug exposure and clinical factors. Using the linear 
predictor from the Cox regression results, area under the receiver operating characteristics curve  
(AUROC) analysis was applied to assess discrimination of culture conversion after 8 and 12 weeks 
of treatment.   
Funding  
Written informed consent was obtained from all study participants for collection of serum 
for TB-related research. In addition, the institutional review board at University of California, San 
Francisco approved this ancillary study to assess putative biomarkers of treatment response 
(approval #12-10360).   The substudy was supported through a Partnerships for Biodefense RO1,  
funded by the NIH, NIAID (R01AI104589). 
Results  
Data 
Table 4.1 shows demographic and clinical data of 538 participants included in the train and 
test datasets and 30 participants included in the independent dataset. In the train and test datasets, 
203 participants were treated with the standard regimen (rifampin at 10 mg/kg) and 335 were 
treated with rifapentine at 10 mg/kg, 15 mg/kg or 20 mg/kg as substitution for standard-dose 
rifampin during the 8-week intensive phase. In the independent dataset, 17/30 (57%) participants 
received the 6-month standard regimen and 13/30 (43%) received a 4-month experimental 
regimen. Of 538 participants in the train and test dataset, 53 (10%) were HIV co-infected. No HIV 
co-infected participants were included in the independent dataset. At the time of modeling, smear 
grade, cavitation and other clinical factors were not available for the independent.  
 
 
99 
 
Table 4.1 Regimen and participant characteristics 
 Training Dataset  Testing Dataset  Independent Dataset  
N  379 159 30 
Treatment regimen N (%)a    
2HRZE/4HR 143 (38) 60 (38) 17 (57) 
2HP10ZE/4HR 158 (42) 68 (43) - 
2HP15ZE/4HR 40 (11) 22 (14) - 
2HP20ZE/4HR 38 (10) 9 (6) - 
2HRZM/2MHR - - 3 (10) 
2EMRZ/2MR - - 10 (33) 
Enrolled at African Site N (%)b 214 (57) 96 (60) 20 (67) 
Female N (%) 123 (33) 46 (29) 12 (40) 
Age (years)  
Median [interquartile range] 
32 (24-44) 30 (25-44) 28 (23-35) 
Weight at baseline (kg)  
Median [interquartile range] 
55 (50-61) 54 (49-62)  52 (47-60) 
BMI at baseline (kg/m2) 
Median [interquartile range] 
20 (18-22) 19 (18-21) 19 (17-22) 
HIV positive N (%) 39 (10) 14 (9) 0 (0) 
History of smoking N (%) 161 (43) 61 (38) Not available 
Smear grade at baseline    
Negative 24 (6) 13 (8) Not available  
1+ 119 (31) 49 (31) Not available  
3+ 91 (24) 34 (21) Not available  
4+ 145 (38) 63 (40) Not available  
Cavitation at baseline  268 (71) 113 (71) Not available  
Cough before treatment    
Productive 345 (91) 140 (88)  Not available 
Nonproductive 22 (6) 14 (9) Not available 
No cough  12 (3) 5 (3) Not available 
Rifapentine AUC  
Median [interquartile range]c  
264 (174-417) 250 (157-369)  Not available 
aH, isoniazid; Z, pyrazinamide; E, ethambutol; R, rifampin; P, rifapentine;M, moxifloxacin at 400 
mg/dose. Subscripts on P define rifapentine dose (10 mg/kg/dose, 15 mg/kg/dose, or 20 mg/kg/dose). All 
other drugs were administered according to published guidelines. First set of drugs represent drugs 
included in 2-month intensive phase and second set of drugs represent drugs included in 4-month or 2-
month continuation phase of regimen.   
cRifapentine area under the curve estimated from previously published population pharmacokinetic model 
for Studies 29 and 29X . 1 
HIV, human immunodeficiency virus; BMI, body mass index; AUC, area under concentration time curve   
 
Proteomic signature after adjusting for rifamycin drug  
Week 8 SAA1 and RANTES levels were the top proteomic biomarkers that predict 
response time after adjusting for rifamycin drug (rifampin vs rifapentine) (Figure 4.2A). The 
distribution of response times and longitudinal time to detection profiles by response group as 
defined by the week 8 SAA1 and RANTES proteomic signature are shown in Figure 4.2B and 
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Figure 4.2C.  Time to first negative culture status was not available for three participants. Among 
those participants who are fast responders, 88% (273/311) culture converted before week 8 and 
12% (36/311) after week 8; among those who are moderate responders, 83% (75/90) culture 
converted  before week 8 and 17% (15/90) after week 8; and among those who are slow responders, 
50% (68/137) culture converted before week 8 and 50% (68/137) after week 8 (Figure 4.2A). The 
adjusted hazard ratios for time to first culture negative status of fast and moderate responders 
compared to slow responders were 2.6 (95% CI, 2.1-3.2) and 1.9 (1.4-2.5), respectively, for the 
combined train and test dataset (Table 4.2 and Figure 4.2D). The AUROC for this proteomic 
signature to predict week 8 and week 12 culture conversion status was 0.77 (95% CI, 0.73-0.82) 
and 0.77 (0.71-0.84), respectively, for the combined train and test dataset; an improvement when 
compared to models without proteomic biomarkers (AUROC ≤	0.60, Table 4.3). Similar hazard 
ratios and AUROC were observed for predicting time to stable culture conversion (Appendix Table 
A.4 and Appendix Table A.5). 
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Figure 4.2 Proteomic signature that predicts response time after adjusting for drug (rifampin vs rifapentine). 
(A) Decision tree that predicts fast, moderate, and slow responders based on week 8 SAA1 and RANTES 
levels. (B) Distribution of response time (unexplained interindividual variability of  BËk ) stratified by fast, 
moderate, and slow responders as defined by proteomic signature. Vertical lines represent the median 
response time for each group. (C) Individual time to detection profiles (thin lines) and median time to 
detection profiles (thick lines) color coded by fast, moderate, and slow responders as defined by proteomic 
signature and stratified by drug (rifampin vs rifapentine) and dataset. (D) Time to first culture negative 
status color coded by fast, moderate, and slow responders as defined by proteomic signature and stratified 
by drug (rifampin vs rifapentine) and dataset. 
Table 4.2 Adjusted hazard ratios for time to first negative culture status. P value for interaction between 
response groups and drug or drug exposure not significant at a P = 0.01 level.   
 
Train 
Dataset 
Test 
Dataset 
Train + Test 
Dataset 
Independent 
Dataset 
Proteomic signature adjusted for drug (rifampin vs rifapentine)  
N 379a 158a 538a 30 
First Negative Culture  
Hazard Ratio  
Median (95% CI)   
  
Moderate responders relative to 
slow responders  1.8 (1.3-2.5) 2.3 (1.3-3.9) 1.9 (1.4-2.5) 1.7 (0.5-5.1) 
Fast responders relative to slow 
responders  2.5 (1.9-3.2) 2.9 (1.9-4.3) 2.6 (2.1-3.2) 2.3 (0.8-6.5) 
Proteomic signature adjusted for drug exposure and clinical risk factors  
N  236a 99a 335a - 
First Negative Culture  
Hazard Ratio  
Median (95% CI)  
  
 
Moderate responders relative to 
slow responders  2.0 (1.0-3.9) 1.7 (0.7-4.1) 2.0 (1.2-3.4) - 
Fast responders relative to slow 
responders  3.6 (1.9-6.7) 2.3 (0.9-5.7) 3.1 (1.9-5.2) - 
aTwo participants in train dataset and one participant in test dataset missing time to first negative culture 
status 
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In the independent dataset of 30 cured participants, 16 (53%) were categorized as fast 
responders, 8 (27%) as moderate responders, and 6 (20%) as slow responders. Among those 
participants who are fast responders, 81% (13/16) culture converted before week 8 and 19% (3/16) 
converted after week 8; among those who are moderate responders, 63% (5/8) culture converted 
before week 8 and 38% (3/8) after week 8; and among those who are slow responders, 50% (3/3) 
culture converted before week 8 and 50% (3/3) after week 8 (Figure 4.3A) Although the confidence 
interval was wide, as expected in this small independent dataset, the adjusted hazard ratio point 
estimates for first culture negative status between responder groups were consistent with the train 
and test datasets (Table 4.2).       
The longitudinal profiles of SAA1 and RANTES levels was available for up to 52 weeks 
after start of treatment for the 30 cured participants in the independent dataset. Fast responders 
were qualitatively shown to have the steepest decline in SAA1 levels compared to moderate and 
slow responders that can already be observed after only 2 weeks of treatment (Figure 4.3B). 
Furthermore, at 2 weeks fast responders had a median level of SAA1 below the week 8 split 
threshold identified in the CART analysis above (Week 8 SAA1 levels = 10.1x106).  The median 
RANTES level for the slowest responders did not decline during the first 8 weeks of treatments 
but the median RANTE level for moderate responders declined after only 4 weeks of treatment 
before beginning to plateau (Figure 4.3C). Data from participants that failed treatment were not 
included in this analysis but data acquisition is on-going and analysis will be updated when data 
becomes available.  
 
105 
 
 
Figure 4.3 Validation of drug adjusted proteomic signature in independent dataset. (A) Proportion of 
participants with culture conversion before or after week 8 for fast, moderate, and slow responders as 
defined by week 8 SAA1 and RANTES proteomic signature. (B) SAA1 profiles color coded by fast, 
moderate, and slow responders as defined proteomic signature. (C) RANTES profiles color coded by 
moderate, and slow responders as defined by proteomic signature. 
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Proteomic signature after adjusting for rifapentine exposure and clinical risk factors 
Week 8 SAA1 and CD40L levels were the top proteomic biomarkers that predict response 
time after adjusting for rifapentine drug exposure and clinical risk factors (Figure 4.4A). The 
distribution of response times and time to detection profiles by response group as defined by the 
week 8 SAA1 and CD40L proteomic signature are shown in Figure 4.4B and Figure 4.4C. 
Participants with rifapentine exposure below the median had slower response compared to 
participants with rifapentine exposure above the median in the same response groups (solid vs 
dashed lines, Figure 4.4C). Time to first negative culture status was not available for three 
participants. Among those participants who are fast responders, 90% (189/231) culture converted 
before week 8 and 9% (20/231) after week 8; among those who are moderate responders, 65% 
(55/84) culture converted  before week 8 and 33% (28/84) after week 8; and among those who are 
slow responders, 55% (11/20) culture converted before week 8 and 45% (9/20) after week 8 
(Figure 4.4A). The adjusted hazard ratios for time to first culture negative status of fast and 
moderate responders compared to slow responders were 3.1 (95% CI, 1.9-5.2) and 2.0 (1.2-3.4), 
respectively, for the combined train and test dataset (Table 4.2 and Figure 4.4D). The integration 
of rifapentine exposure, clinical risk factors, and proteomic biomarkers had an AUROC to predict 
week 8 and week 12 culture conversion of 0.82 (95% CI: 0.76-0.87) and 0.85 (0.78-0.92), 
respectively, for the combined train and test dataset; higher than models including drug exposure 
and clinical factors or proteomic biomarkers only (Table 4.3). Similar hazard ratios and AUROC 
were observed for predicting time to stable culture conversion (Appendix Table A.4 and 
Appendix). 
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Figure 4.4 Proteomic signature that predict response time after adjusting for rifapentine exposure and 
clinical risk factors. (A) Decision tree that predicts fast, moderate, and slow responders based on week 8 
SAA1 and CD40L levels (B) Distribution of response time (unexplained interindividual variability of  BËk),	
stratified by fast, moderate, and slow responders as defined by proteomic signature. Vertical lines represent 
the median response time for each group. (C) Individual time to detection profiles (thin lines) and median 
time to detection profiles (thick lines) color coded by fast, moderate, and slow responders as defined by 
proteomic signature. (D) Time to first culture negative status color coded by fast, moderate, and slow 
responders as defined by proteomic signature. Solid lines represent subpopulation with rifapentine exposure 
above the median (AUC > 255 mgh/L) and dashed lines represent subpopulation with rifapentine at or 
below the median (AUC ≤ 255 mgh/L). 
Discussion  
In this study, we have shown that leveraging longitudinal sputum culture results and drug 
exposure and applying advanced nonlinear mixed effect modeling with machine learning 
approaches offer insights into the early response dynamics following anti-TB treatment and help 
identify candidate proteomic signatures that can predict treatment response. We identified SAA1, 
RANTES, and CD40L as candidate proteomic biomarkers that can predict time to detection 
profiles. By integrating proteomic signatures, drug exposure, and clinical risk factors we predicted 
week 8 and week 12 culture conversion status with high AUROC (0.82, 95% CI: 0.76-0.87, and 
0.85, 0.78-0.92, respectively). Week 8 proteomic levels were the top predictors of response time 
compared to baseline or ratio of week 8 to baseline levels. Although only baseline and week 8 
proteomic levels were available in the train and test datasets, earlier proteomic data in the 
independent dataset suggest that levels after only 2 weeks of treatment may have potential to 
predict treatment response.  
The proteomic signatures identified in this study are predictors of treatment response as 
defined by response time in time to detection profiles from the MGIT assay. This is not the same 
as showing an effect on clinical outcome, namely treatment failure or relapse. However, these time 
to detection profiles are used to define intermediate biomarkers in current Phase 2 trials, such as 
culture status after 8 weeks of treatment and time to culture conversion, to predict clinical 
outcomes. We also showed that categorizing participants into slow, moderate, and fast responders 
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defined by proteomic signatures are risk factors of time to first negative culture status and time to 
stable culture conversion. Therefore, we anticipate that treatment response as predicted by the 
proposed proteomic signatures are correlated with clinical outcomes. Furthermore, we have 
validated our proteomic signatures in cured participants and plan to validate them in failed and 
relapse participants when data becomes available.    
The top predictor of response time in the two proteomic signatures we identified was week 
8 levels of SAA1, an acute phase protein mainly expressed in the lung and produced in response 
to infection, tissue injury, and malignancy.31 SAA1 and CRP, a similar acute phase protein, have 
been associated with baseline severity of TB disease and bacterial burden and have shown 
significant decreases during anti-TB treatment.11,17,18,20,32 In this study, we showed that lower 
levels of SAA1 at week 8 was associated with faster response times; consistent with anticipated 
improvements of acute phase protein response to TB treatment. In addition, week 8 levels of 
RANTES or CD40L were capable to differentiate participants with the slowest response times. In 
TB, RANTES has a protective role in M. tuberculosis infection by forming granulomas, limiting 
pathogen growth, and preventing lung tissue damage 33 Interestingly, the relationship between 
RANTES levels and treatment response have differed among ethnic populations (i.e. African, 
Eurasian, and Asian) and comorbidities (i.e. HIV co-infection) and RANTES polymorphisms have 
been associated with increased risk of TB.34-39 CD40-CD40L pathway has been identified as a 
critical mechanism for generation of antigen specific T-helper-17 cells that produce IL-17 
responses which have emerged as an important role for protecting and controlling immunity to 
TB.40 Although these markers have been associated with treatment response in TB patients, there 
use alone or in combination with clinical risk factors have not shown sufficient predictive value 
for clinical use.20 Instead, in this study, we found that integrating serially-collected culture data, 
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drug exposure parameters, clinical risk factors and proteomic biomarkers substantially improved 
the predictions of early treatment response.  
Based on variable importance, week 8 proteomic levels were primarily the top predictors 
of response times and contributes the largest model improvements by reducing root mean squared 
errors (Appendix Table A.6).  This may suggest that monitoring when biomarker levels are within 
normal levels may indicate when patients are in a recovery phase. In this study, participants 
without TB (i.e. healthy controls) were not included to assess normal ranges of biomarker levels. 
However, recent studies that have monitored longitudinal profiles of inflammatory markers show 
treated and survived TB patients approach normal ranges observed in healthy controls.10,41-46 
Blood-based biomarkers would provide even more value if levels before week 8 can predict 
treatment outcomes. In the independent dataset with proteomic levels measured at weeks 2 and 4, 
participants predicted to be fast responders already had median proteomic levels below the week 
8 split thresholds identified in the CART analysis (Figure 4.3). Similar decreasing patterns of 
inflammatory markers in TB patients have been shown during the first 2 weeks of treatment with 
levels plateauing to normal ranges by 8 weeks.10,41-46 Blood-based biomarkers that can reliability 
predict treatment response within the first 2 weeks of treatment would greatly increase efficiency 
of clinical care and regimen development and provide major advantages over sputum-based 
approaches.  
In the independent dataset, 80% of participants were predicted to be fast to moderate 
responders but 20% were still predicted to be slow responders despite having been cured. In a 
recent study that used Positron Emission Tomography-Computed Tomography (PET-CT) scans to 
monitor treatment response in patients, the heterogenous nature of disease pathology and prognosis 
during treatment was illustrated and similar PET-CT patterns of active disease at diagnosis were 
identified in bacteriologically cured patients at the end of treatment.47 Interestingly, many cured 
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individuals developed new lesions during treatment, and 68% of cured individuals had persistent 
pulmonary inflammation even one year after the completion of therapy. This may explain, in part, 
the small portion of cured participants predicted to be slow responders and the relatively high 
levels of inflammatory markers in a small portion of cured participants (5/30 above SAA1 split 
threshold) through week 52 (at least 6 months of follow-up) (Figure 4.3). Participants who failed 
treatment or relapsed are not yet part of the independent dataset, but we hypothesize that a larger 
proportion of these participants will have sustained high levels of proteomic levels and will be 
categorized as slow responders.   
There were limitations in our study. First, the two proteomic signatures identified in this 
study were not uniform potentially implying that signatures may predict differently for each 
regimen or may depend on available drug exposure and clinical data. PK data was not available 
for participants who administered standard-dose rifampin limiting our second analysis to a subset 
of the data including only participants who administered rifapentine and making it difficult to 
confirm if the same proteomic signature can predict response after accounting for rifampin 
exposure. Varying signatures for each regimen would imply poor trial level surrogacy but may 
still be a valuable tool for more individualized treatments. The utility of these proteomic signatures 
as individual- and trial-level surrogates should be further evaluated as part of robust clinical trials 
that test rifamycin- and non-rifamycin-based regimens and collect long term outcomes and PK 
samples. Third, the parent trials for training and testing the model did not have samples from earlier 
timepoints. Based on the longitudinal proteomic data in the independent dataset, we may have 
missed important changes in proteomic levels that have stabilized before week 8. Fourth, our 
population only consist of 10% HIV co-infected individuals so separate analysis for HIV co-
infected individuals was not plausible. The primary strength of our study lies in the integration 
within randomized clinical trials, which provided the infrastructure to conduct measurements 
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rigorously. PK, clinical, radiographic, and bacteriological data were collected using standardized 
forms and methods, acid-fast bacilli smears and cultures were performed at a single quality-
controlled microbiological laboratory, and all biomarker assays including those for the 
independent dataset were done at a single quality-controlled immunology laboratory.  
In conclusion, across 70 host biomarkers evaluated in the largest cohort of diverse TB 
patients enrolled in clinical trials, we identified proteomic signatures that can predict treatment 
response. We found that proteomic levels after 8 weeks of treatment predict treatment response 
but levels after 2 weeks of treatment may be sufficient. Accounting for individual drug exposure 
proved to be valuable in improving the predictive value of proteomic biomarkers and since drug 
exposure and proteomic blood-based biomarkers are easily measurable and available throughout 
treatment, together they have potential to project long term relapse-free outcomes and inform 
individualized dosing or treatment strategies to maximize cure for all.    
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Chapter 5:  Linezolid dosing strategies to minimize adverse events with high-dose, long-term 
treatment for extensively drug-resistant tuberculosis 
Abstract  
Background High-dose linezolid given with bedaquiline and pretomanid has the potential to 
transform treatment of extensively drug resistant tuberculosis, but limited information is available 
about linezolid dosing to optimize treatment and minimize toxicity. We evaluated linezolid clinical 
trial data to provide model-based dosing recommendations to minimize toxicity. 
Methods Pharmacokinetic-toxicodynamic modeling and simulations were performed with 
longitudinal data from 104 participants in the Nix-TB trial (NCT02333799) (treatment duration, 6 
months; follow-up, 24 months after treatment completion). All participants initially administered 
a linezolid dosage of 1200 mg once daily or 600 mg twice daily. Dose adjustments were allowed 
per discretion of the investigator to manage linezolid toxicity. Linezolid pharmacokinetic profiles 
that accounted for individual dosing histories were predicted from the pharmacokinetic model and 
used as inputs to drive models for hemoglobin levels, platelet counts, and peripheral neuropathy 
scores. Final models were used to simulate and compare pharmacokinetics and safety outcomes 
following daily doses of 1200 mg linezolid as well as alternative dosing strategies.  
Results Linezolid pharmacokinetics had nonlinear elimination, with AUC 2.7-fold greater at 1200 
mg once daily than 600 mg once daily. Toxicity profiles were similar between 1200 mg once daily 
vs 600 mg twice daily. Linezolid pharmacokinetics predicted anemia, thrombocytopenia, and 
peripheral neuropathy (p<0.001). Regarding severe anemia, simulations indicated that: i) the 
median time to onset of severe anemia was 9 (90% CI: 9-11) weeks; ii) hemoglobin levels at 
pretreatment and week 4 could be used to predict severe anemia (AUROC=0.91 (0.88-0.93); iii) a 
greater than 10% decrease in hemoglobin at week 4 would have maximum sensitivity (82%) and 
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specificity (84%) for prediction; iv) a dose reduction to 600 mg triggered by this simple marker 
would prevent 63% (49-74) cases and v) recovery time to normal levels was 6 weeks (6-8) after 
dose adjustment. Severe peripheral neuropathy mostly occurred after 4 to 6 months of treatment 
and reversed within 6 months after linezolid dosage reductions or discontinuation. Less than 1% 
of severe thrombocytopenia was predicted at linezolid dosages of 1200 mg daily. 
Conclusions Simple monitoring and biomarker-guided dose-adjustment strategies have great 
potential to anticipate and avoid toxicities associated with the use of high dose linezolid-containing 
regimens in patients with extensively drug resistant tuberculosis.  
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Introduction  
The WHO estimated that in 2017 there were approximately 500,000 cases of multi-drug 
resistant tuberculosis (MDR-TB), including 9% of the people who had extensively drug resistant 
TB (XDR-TB). Treatment success rates in XDR-TB patients is low, at around 34%, and it has been 
urged that new drugs and regimens are desperately needed to improve cure rates.1  
Linezolid is one of the most potent repurposed agents for the treatment of drug resistant 
TB that has been shown to be efficacious against MDR and XDR-TB when added to failing 
regimens. In a recent meta-analysis with 12,030 MDR-TB patients, treatment with linezolid 
significantly reduced mortality and increased treatment success compared to failure or relapse.2 
Based on this evidence, a rapid communication published in 2018 from the WHO prioritized its 
use for MDR-TB.3 In the Phase 3 Nix-TB trial (NCT02333799) that evaluated high-dose linezolid 
(1200 mg daily) in combination with bedaquiline and pretomanid (BPaL) for 6 months to treat 
XDR and treatment intolerant or non-responsive (TI/NR) MDR-TB, 102 of 109 (94%) of enrolled 
participants completed treatment (all surviving participants), and 98 (90%) had culture negative 
status at 6 months post treatment, exceeding the 34% success rate currently reported by WHO.1,4,5   
Based on the efficacy and safety data from the Nix-TB trial, the FDA approved BPaL for 
treatment of XDR-TB and TI/NR MDR-TB.4,5 However, the use of linezolid is controversial 
because of concerns over safety and tolerability. In the Nix-TB trial, adverse events including 
peripheral neuropathy (81% of participants), anemia (37%), and thrombocytopenia (6%) resulted 
in substantial frequencies of participants who required linezolid discontinuation (28%), 
interruption (46%), or dose reduction (39%). The mean maximum interruption of linezolid 
administration because of an adverse event was 38 days. Nevertheless, the hematological and 
neuropathy adverse events were generally reversible leading to the approved recommended 
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starting dose and duration for linezolid in the combination regimen of 1200 mg daily for 26 weeks, 
with dose adjustments for any known linezolid adverse reactions.4,5  
Another review of linezolid treatment for MDR-TB and XDR-TB showed adverse events 
in 55% of patients at all doses investigated (range, 300 to 1200 mg daily).6 Although linezolid 
trough levels have been associated with linezolid-related adverse events in XDR-TB patients, 40% 
of patients with trough levels < 2 mg/L develop an adverse event.7 Despite the narrow therapeutic 
range, linezolid is among the most effective drugs for treatment of MDR-TB and XDR-TB.4,5 
Therefore, it is important to define optimal dosages, treatment durations, and best clinical practices 
for the use of linezolid in TB. However, limited information is available about the optimal time 
and extent of linezolid dosage adjustments required to optimize efficacy and minimize adverse 
events. 
In this study, we quantitatively characterized the relationship between linezolid dose, 
plasma concentrations and the time course of all major toxicities (anemia, thrombocytopenia, and 
peripheral neuropathy) using longitudinal long-term data from the Nix-TB trial. Then, we provided 
model-based recommendations about optimal dosing to minimize adverse events. 
Methods  
Study design  
Data from the Nix-TB clinical trial that evaluated the BPaL regimen after 6-months of 
treatment in participants with pulmonary XDR-TB or TI/NI MDR-TB was used in this study. The 
Nix-TB study enrolled participants presenting with one of the following three pulmonary TB 
conditions: i. XDR-TB with documented resistance to isoniazid, rifamycins, a fluoroquinolone and 
an injectable, ii. MDR-TB with documented non-response to treatment with best available regimen 
for 6 months or more prior to enrollment who in the opinion of the investigator have been adherent 
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to treatment and will be adherent to study regimen (TI MDR-TB), or iii. MDR-TB with 
documented intolerance to p-aminosalicylic acid, ethionamide, aminoglycosides or 
fluoroquinolones (NR MDR-TB). All pulmonary TB conditions must have documented culture 
positive results for Mycobacterium Tuberculosis within 3 months prior to screening. Males or 
nonpregnant females of at least 14 years of age and 30 kg body weight were included in the study. 
Participants were required to provide consent to HIV testing. Additional inclusion and exclusion 
criteria details are available in the original study protocol.4 
Participants were treated for 6 months with bedaquiline at 400 mg once daily (QD) for 2 
weeks then 200 mg three times per week, pretomanid at 200 mg QD, and linezolid 1200 mg daily 
at 600 mg twice daily (BID; according to initial protocol) or 1200 mg QD (according to amended 
protocol) schedules. The protocol was amended to require all participants to begin treatment with 
linezolid at the 1200 mg QD dosage because toxicity was thought to be caused by mitochondrial 
toxicity and may be lessened by lowering the time the linezolid concentration is greater than the 
threshold for mitochondrial toxicity.4 For suspected linezolid-induced toxicities, linezolid was 
dose reduced, interrupted, or discontinued while participants remained on bedaquiline and 
pretomanid. Time, duration, and dose reductions of all dose adjustments for each individual were 
recorded and used for our analysis. Pretreatment levels were defined as measurements made before 
the first dose of BPaL taken. All participants provided pre-dosing pharmacokinetic (PK) samples 
at week 2, 8, and 16 and a subset of participants provided intensive PK samples at week 16 with 
samples collected at pre-dose and 0.5, 1, 2, 4, 8, 12, 12.5, 13, 14, 16, 20 and 24 hours after dosing. 
PK for bedaquiline, bedaquiline metabolite M2, and pretomanid were also available but not used 
for the current analysis.   
Complete blood counts including hemoglobin level and platelet count were performed at 
pretreatment, weekly up to week 16 and at week 20 and 26 of treatment, and peripheral neuropathy 
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screening was performed at pretreatment, weeks 4, 8, 12, 16, 20, and 26 during treatment and 
months 3, 6, 12, and 24 after completion of treatment. Subject elicited symptoms (i. interference 
with walking or sleeping, ii. pain, aching or burning in feet, iii. “pins and needles” in feet or legs, 
iv. numbness (lack of feeling) in feet or legs), perception of vibration (left and right foot), and deep 
tendon reflexes (left and right foot) were collected at each peripheral neuropathy screen. 
The investigators were responsible for defining and eliciting adverse events by observing 
the participants and recording adverse events observed by themselves or reported by the 
participants during the trial. Severity of adverse events were made per the Division of 
Microbiology and Infectious Disease (DMID) Adult Toxicity table.8 
Of the 109 enrolled patients, 88 patients were included in the model development process. 
An additional 16 patients who were still in the study at time of model development were used for 
external validation of the final population models. Five patients had unverifiable dosing histories, 
hence were not included.  
Additional information on study design and data collection is available in the original 
publication.4  
Population pharmacokinetic-toxicodynamic modeling  
Population PK modeling started with simple one or two compartment distribution models 
with linear elimination and first order absorption. More complex models with respect to absorption 
and elimination (nonlinear elimination) were then tested to identify the best model for our 
population. Between subject variability was modeled exponentially and residual variability was 
modeled with a proportional error model.  
It was critical to investigate drug dosing and schedule information as potential predictors 
of toxicity response. Therefore, the focus in the PK-toxicodynamic modeling was on investigating 
the potential for dynamic linezolid concentration-time profiles, which take into account individual 
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dose reductions and dose interruptions, as the drug exposure variable to predict hemoglobin level, 
platelet count, and peripheral neuropathy scores. A sequential approach was used to develop PK-
toxicodynamic models. First, empirical Bayesian estimates of PK parameters were used to estimate 
individual concentration-time profiles taking into account dose adjustments. Then, instantaneous 
linezolid concentrations were input for the toxicity models to drive response as a covariate with 
linear, Emax, or sigmodal Emax relationships. 
Hemoglobin levels and platelet counts were characterized with delayed response models. 
Mechanistic, semi-mechanistic, and more empirical indirect models were tested separately for each 
hemoglobin level and platelet count model. The effect of instantaneous linezolid concentrations 
was included by inhibiting the first-order proliferative rate of progenitor cells (mechanistic or 
semi-mechanistic models) or more empirically the zero-order synthesis rate of response in an 
indirect model. The most mechanistic model that supported the data for each hematological 
response was used. Between subject variability was modeled exponentially in each model. 
Additive and/or proportional error models were explored to explain residual unexplained 
variability.  
As several participants had increased hemoglobin levels at the end of BPaL treatment 
compared to pretreatment (73/88, 83%), we modeled hemoglobin levels obtained from participants 
of other trials without linezolid (OFLOTUB (NCT00216385)9, REMoxTB (NCT00864383)10, and 
RIFAQUIN (ISRCTN 44153044)11) to describe the resolution of anemia upon starting anti-TB 
treatment (data not shown). Empirical models (i.e., linear, exponential, logistic growth models) 
were tested to fit the independent dataset. The model that described hemoglobin profiles in the 
absence of linezolid was included in the Nix-TB hemoglobin model as an additional synthesis rate 
of response (Figure 5.1).    
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For peripheral neuropathy modeling, the maximum score of four subject-elicited symptom 
questions was used. The four symptom questions were based on: i.) interference with walking, ii.) 
pain, aching, or burning in feet or legs, iii.) pins and needles in feet or legs, and iv.) numbness in 
feet or legs. Participants were asked to rank each symptom from 0 (normal) to 10 (worst/severe) 
for up to 24 months post treatment. The maximum scores were grouped into four categories for 
modeling: normal (maximum score 0), minimal (1-3), modest (4-7) and severe (8-10). A 
proportional odds model was used to describe the proportion of scores over time, with a 
distributional effect compartment to account for the generally delayed onset of neuropathy. 
Additional information on proportional odds modeling used in this analysis is available in 
Appendix Text A.1.  
Covariates (age, sex, weight, BMI and HIV status) were tested as predictors of model 
parameters that describe PK, hemoglobin levels, platelet counts, and peripheral neuropathy scores 
using an automated stepwise covariate modeling procedure. This method involves stepwise testing 
of linear and nonlinear relationships in a forward inclusion (p < 0.01) and backward exclusion (p 
< 0.001) procedure. Model evaluation was performed throughout the model development process 
by evaluating goodness-of-fit plots, visual predictive checks, and bootstrap estimates and 
confidence intervals. Additional information on the model structures, differential equations, and 
final model estimates are available in Figure 5.1, Appendix Text A.1, and Appendix Table A.7 - 
Appendix Table A.13.  
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Model-based simulations  
The final PK-toxicodynamic models were used to perform 1000 simulations for 500 
patients over 6 months for hematological toxicities and 24 months (6 months of treatment and 18 
months of recovery) for peripheral neuropathy. Simulations assessed steady-state PK (area under 
the concentration-time curve over 24 hours, AUC, maximum concentrations, Cmax, and minimum 
concentrations, Cmin); probability of ≥ grade 3 hematological toxicities according to the DMID 
Adult Toxicity table (severe anemia, hemoglobin < 8 g/dL; severe thrombocytopenia, platelets < 
50x109 platelets/L)8; probability of peripheral neuropathy graded scores; management and 
reversibility of toxicities; and attainment of efficacy targets. Normal levels were based on DMID 
table for hematological toxicities (hemoglobin level ≥ 10.6 g/dL; platelet count, ≥ 100 ×109/L). 
We considered linezolid dosages of 600 mg or 1200 mg total daily (BID or QD) for 6 
months. Strategies to manage toxicities were investigated with linezolid dosage reductions to 600 
mg or 300 mg total daily or discontinuations. Anemia management strategies involved monitoring 
weekly hemoglobin and steady-state linezolid trough concentrations. To assess reversal of 
peripheral neuropathy, the first occurrence of a modest or severe score was considered an event, 
and a dose adjustment was made at the time of the event via simulations. Following the dose 
adjustment, the time of reversal was defined as the time of the first of two consecutive minimal or 
normal scores. The distribution of the time from the event to reversed neuropathy was determined.  
Although efficacy outcomes are not evaluated in this report, to allow some judgment of the 
potential impact of linezolid dosage adjustments, two PK-based pharmacodynamic targets for 
linezolid were assessed using free-drug concentrations in the simulations: i)  ratio of the free area 
under the concentration-time curve over 24 hours (fAUC) to minimum inhibitory concentration 
(MIC) (fAUC/MIC) > 100, and ii) time above MIC (TMIC).12,13 MIC of 0.5 mg/L and protein 
binding fraction of 31% were used.14-17  
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Statistical analysis  
Separate Cox regression analysis was performed to identify predictors associated with the 
time to first occurrence of an investigator-reported peripheral neuropathy, anemia, and 
thrombocytopenia adverse event. Participant characteristics (HIV status, BMI, weight, age, and 
sex) and linezolid exposure (steady state AUC, Cmax, or Cmin and observed trough after 2 weeks of 
treatment)  were assessed as predictors for each investigator-reported adverse event. Hemoglobin 
levels at pretreatment, week 1, 2, and 4 were assessed as predictors of investigator-reported anemia 
adverse events. Area under the receiver operating characteristic curve (AUROC) was used to 
assess model discrimination. Data management, statistical analysis and visualization were 
performed using the R software (v3.4.1). Pharmacokinetic and safety data were characterized 
based on a population nonlinear mixed effects modelling approach using the software NONMEM 
7.4.1.   
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Results  
Participant and data characteristics  
There were no significant differences in participant characteristics or pretreatment 
hemoglobin levels, platelet counts, or peripheral neuropathy scores between participants who 
initially had 600 mg BID vs 1200 QD linezolid dosages. Approximately half of the participants 
(50/104) were HIV co-infected (Table 5.1).  Median levels of hemoglobin levels increased from 
12.1 (range: 7.4-16.1) at pretreatment to 13.5 (9.5-19.4) at the end of treatment (Table 1, P < 
0.001), and platelet counts decreased from 354 (137-1083) at pretreatment to 262 (116-840) at the 
end of treatment (Table 5.1).  
Population model development  
Linezolid pharmacokinetics was best described by a two-compartment disposition model 
with nonlinear (Michaelis-Menten) elimination. No covariates were included in the final model to 
describe variability in PK. Hemoglobin levels were best described with an indirect model (Figure 
5.1). Instantaneous linezolid concentrations that account for individual dosing histories were 
shown to inhibit the synthesis rate of hemoglobin with a maximum inhibition of 100% and a half-
maximal inhibitory concentration (IC50) of 7.7 mg/L. A logistic growth model that empirically 
described the hemoglobin levels without linezolid was included in the Nix-TB hemoglobin model 
as an additional synthesis rate of response. Platelet counts were best described with a semi-
mechanistic hematological toxicity model (Figure 5.1). Instantaneous linezolid concentrations 
were shown to inhibit the proliferation rate for the stem-cell-like platelet-progenitor cell 
compartment with 8% maximum inhibition and IC50 of 4.1 mg/L. Peripheral neuropathy scores 
were described by a proportional odds model with probabilities driven by linezolid concentrations 
in an effect compartment to describe the 2- to 3-month delay in onset. Model details are available 
in Figure 5.1, Appendix Text A.1 and Appendix Table A.7 - Appendix Table A.13. Each model 
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described its respective data reasonably well, as shown by the visual predictive checks with model-
development data and external-validation data (Figure 5.2).  
Table 5.1 Participant characteristics and summary of data available for linezolid dosing model development 
and external validation in extensively drug-resistant tuberculosis.  
 Model development External Validation 
Initial Dose  600 BID  1200 QD 1200 QD 
Participant characteristics  
N 42 46 16 
Males [N (%)] 23 (55) 23 (50) 7 (43) 
Age (y) [median (range)] 31 (18-55) 36 (21-60) 36 (17-48) 
Weight (kg) [median (range)] 59 (29-112) 54 (33-89) 54 (32-106) 
BMI (kg/m2) [median (range)] 19.8 (12.4-41.1) 19.7 (13.6-36.1) 18.9 (15.1-38.9) 
HIV positive [N (%)] 18 (42) 25 (54) 7 (43) 
Creatinine clearance (ml/min) [med (range)]a  102 (46-167) 104 (42-180) 107 (43-179) 
Dose adjustments   
Participants with dose adjustment  38 (90) 40 (87) 10 (90) 
Time of first dose adjustment (days) [med 
(range)] 
61.5 (18-174) 75.5 (9-170) 60.5 (13-153) 
Pharmacokinetic data   
Participants in PK substudy [N (%)] 16 (38) 4 (8) 5 (31) 
Total evaluable PK samples [n]  243 154 100 
Hemoglobin data   
No. of Hb samples per participant [med 
(range)] 
19 (5-24) 19 (10-24) 20 (17-24) 
Total evaluable Hb samples [n] 773 835 319 
Pretreatment Hb (g/dL) [median (range)] 12.4 (8.5-16.1) 11.8 (8.7-15.6) 12.1 (7.4-13.9) 
End of treatment Hb (g/dL) [median (range)]b 13.6 (9.8-19.4) 13.7 (9.5-17.0) 12.8 (11.2-16.8) 
Platelet data   
No. of platelet samples per participant [med 
(range)] 
19 (5-24) 19 (9-24) 19 (16-24) 
Total evaluable platelet samples [n] 761 816 315 
Pretreatment Platelet (109 platelets/L) [median 
(range)] 
354 (137-1045) 348 (188-1083) 436 (139-730) 
End of treatment Platelet (g/dL) [median 
(range)]c 
254 (116-840) 262 (175-478)  312 (167-409) 
Peripheral Neuropathy data   
No. of neuropathy scores per participant 
[median (range)] 
10 (2-14) 8 (3-11) 10 (10-13) 
Total evaluable neuropathy scores [n] 418  382 170 
No. of participants without neuropathy at 
pretreatment [N (%)]d 
32 (76) 31 (67) 16 (100) 
No. of participants with minimal neuropathy 
at pretreatment [N (%)]d 
5 (12) 5 (11) 0 (0) 
No. of participants with modest neuropathy at 
pretreatment [N (%)]d 
4 (10) 10 (22) 0 (0) 
No. of participants with severe neuropathy at 
pretreatment [N (%)]d 
1 (2) 0 (0) 0 (0) 
Hb, hemoglobin; BMI, body mass index, HIV: human immunodeficiency virus  
aCalculated with Cockcroft-Gault equation using serum creatine levels and ideal body weight. Creatinine 
clearance missing for two participants in the external validation dataset.  
bEnd of treatment hemoglobin levels missing for 7 participants in model development dataset.  
cEnd of treatment platelet counts missing for 8 participants in model development dataset.  
dBased on maximum of four subject elicited symptom questions. 
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Figure 5.2 Linezolid pharmacokinetic model and pharmacokinetic-toxicodynamic models: observed data 
and visual predictive checks. Left panel shows the observed data (points or thin solid line) and median 
(proportion for (D)) of the observed data (thick solid line) stratified by initial dosage (red = 600 mg BID, 
blue = 1200 mg QD). Middle panel shows the visual predictive checks for model development data. For 
(A), (B), and (C), the solid black line is the median and dashed black lines show the 5th and 95th percentiles 
of the observed data. The shaded areas are the 95% confidence intervals of the 95th, median, and 5th 
percentiles of the model predicted simulations, respectively. For (D) the solid black line is the observed 
proportion and the shaded area is the 95% prediction interval of model predicted simulations. Right panel 
shows the visual predictive checks for external validation data. Solid black line is the median (proportion 
for (D)) of the observed data and the shaded area is the 95% prediction interval of model predicted 
simulations. (A) pharmacokinetic model, (B) pharmacokinetic-toxicodynamic model for hemoglobin 
levels, (C) pharmacokinetic-toxicodynamic model for platelet counts, and (D) pharmacokinetic-
toxicodynamic model for peripheral neuropathy severe symptom scores (based on maximum of four 
symptom scores). Additional predictive checks for peripheral neuropathy normal, minimal, and modest 
symptom scores available in Appendix Table A.14. LLOQ, lower limit of quantification; Rx, treatment   
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In each toxicity model, predicted instantaneous linezolid concentrations that accounted for 
individual dosing histories and interindividual variation had better predictions of longitudinal 
toxicity profiles than models that included observed week 2 trough levels (Table 5.2).  Participant 
characteristics did not predict the potency of linezolid exposure or pretreatment toxicity levels 
(final models described in Appendix Table A.7 - Appendix Table A.13).  
Table 5.2 Linezolid drug exposure as a predictor of linezolid-induced toxicities in participants with 
extensively drug-resistant tuberculosis.  
 
Effect of linezolid dosages on toxicity and efficacy   
Simulations were performed to predict PK and toxicity profiles following 1200 and 600 
mg total daily doses. The simulated AUC at steady state was similar between BID vs QD dosing 
at the same total daily doses. Higher maximum linezolid concentrations and lower minimum 
concentrations were observed with QD than BID dosages. The AUC at linezolid 1200 mg QD was 
2.7 (90% CI: 2.6-2.8) times greater than 600 mg QD because of nonlinear clearance in the model 
(Figure 5.3 and Table 5.3). In simulations, ≥ 99% of participants treated with 1200 mg total daily 
met the target of fAUC/MIC > 100, but 600 mg total daily resulted in 19% (600 mg QD, median 
fAUC/MIC: 134) or 26% (300 mg BID, median fAUC/MIC: 124) of participants below this target 
(Table 5.3). 
Toxicity profiles were not substantially different between BID and QD dosing at the same 
total daily dose. However, simulations showed higher frequencies of severe anemia and severe 
 Anemiaa Thrombocytopeniaa Peripheral 
Neuropathya 
Hemoglobinb Plateletsb Peripheral 
Neuropathy 
Scoresb 
Instantaneous 
linezolid 
concentrations 
Not 
tested 
Not tested Not tested P << 0.001 P <<< 
0.001 
P << 0.001 
Week 2 
linezolid  
troughs  
P = 0.2 P = 0.2 P =0.9 P = 0.4  P << 
0.001 
P = 0.9 
P values for inclusion of covariates as predictors of time to first occurrence of investigator-reported clinical 
event in Cox regression analysisa or as predictors of longitudinal hemoglobin levels, platelet counts, and 
peripheral neuropathy scores in the PK-toxicodynamic modelsb. 
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peripheral neuropathy scores but no differences in platelet toxicity with total daily linezolid of 
1200 mg vs 600 mg (Figure 5.3 and Table 5.3).  
 
Figure 5.3 Simulated pharmacokinetic and toxicity profiles after linezolid total daily doses of 600 mg or 
1200 mg. (A) Simulated pharmacokinetic profiles. Solid blue lines represent the typical patient (median of 
simulations) and the shaded areas the 90% prediction interval. Red solid line represents an MIC of 0.5 
mg/L. (B) Simulated hemoglobin profiles. Solid blue lines represent the typical patient and the shaded areas 
the 90% prediction intervals. Red dashed line represents a DMID definition of Grade 2 toxicity (hemoglobin 
levels < 9.5 mg/L) and red solid line represents a DMID definition of Grade 3 toxicity (hemoglobin levels 
< 8.0 mg/L). (C) Simulated platelet profiles. Solid blue lines represent the typical patient (median of 
simulations) and the shaded areas the 90% prediction intervals. Red solid line represents the DMID 
definition of Grade 3 toxicity (platelet levels < 50x109 platelets/L).  (D) Simulated expected proportions of 
severe peripheral neuropathy maximum scores. Simulated proportions of normal, minimal, and modest 
score available in Appendix Figure A.6.   
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Management of anemia  
At least 1 investigator-reported anemia adverse event was reported in 35 of the 88 model 
development participants (40%) (median time to first anemia event, 8 weeks (90% CI: 7-10)). 
Hemoglobin levels after 4 weeks of linezolid treatment had higher AUROC for predicting reported 
anemia adverse events than hemoglobin levels at earlier timepoints (pretreatment, 1 week, or 2 
weeks), linezolid exposure parameters (steady state AUC, Cmax, or Cmin and observed trough after 
2 weeks of treatment)  or participant characteristics  (Figure 5.4A and Appendix Table A.15). In 
simulations with the hemoglobin toxicity model, the median time to onset of severe anemia was 9 
weeks (90% CI: 9-11), and the AUROC for predicting model-simulated severe anemia was also 
higher for hemoglobin levels after 4 weeks than linezolid trough concentrations (Figure 5.4B). The 
threshold of 10% decrease in hemoglobin levels at 4 weeks vs pretreatment had the highest 
combination of sensitivity and specificity in identifying severe anemia (both > 0.80) (Figure 5.4C). 
With this threshold as a trigger for linezolid dosage reduction from 1200 to 600 mg QD to 
minimize severe anemia, simulations showed that the frequency of severe anemia events could 
potentially be decreased by a median of 63% from 16% to 6% (Figure 5.5 and Table 5.3). In the 
patients that meet the trigger and dose is reduced to 600 mg QD, the median recovery to 
pretreatment hemoglobin levels was 9 weeks (90% CI: 9-12)  and to normal levels was 6 weeks 
(90% CI: 6-8). Decreasing the linezolid dosage from 1200 to 600 mg QD did not substantially 
affect efficacy targets (Table 5.3).  Dosage adjustments to 300 mg once daily or discontinuation 
yielded similar results (data not shown). 
Management of thrombocytopenia 
Five of 88 model development participants (6%) had an investigator-reported 
thrombocytopenia adverse event, with only one being severe (1%). Simulations with the platelet 
toxicity model also showed that the frequency of severe thrombocytopenia was less than 1% for 
138 
 
linezolid dosages of 600 mg or 1200 mg total daily. Management strategies for severe 
thrombocytopenia were not further investigated because of the low frequency in the clinical trial 
and model simulations.   
 
Figure 5.4 Predictors of anemia associated with linezolid treatment (BPaL regimen). (A) ROC curves for 
univariate models that predict investigator-reported anemia adverse events. (B) ROC curves for simulated 
prediction of severe anemia (as defined by DMID Grade 3 or higher toxicity; hemoglobin levels < 8 g/dL) 
using the hemoglobin population model (C) Simulated sensitivity and specificity rates to predict severe 
anemia for management strategies using various hemoglobin percent change thresholds at week 4.  
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Figure 5.5 Proposed management strategy to predict and minimize severe anemia associated with linezolid 
treatment (BPaL regimen) for extensively drug-resistant tuberculosis. (A) Decision tree algorithm. (B) 
Simulated steady state pharmacokinetic profiles after implementing anemia toxicity management strategies 
for initial linezolid 1200 mg QD dosage. (C) Simulated hemoglobin level profiles after implementing 
anemia toxicity management strategy for initial linezolid 1200 mg QD dosage. Solid blue lines represent 
typical participant (median of simulations); shaded areas represent 90% prediction interval.   
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Management of peripheral neuropathy 
The distribution of maximum scores from 104 participants (88 model development + 16 
external validation) shows that some pretreatment peripheral neuropathy was present, the 
frequency of peripheral neuropathy increased from 3 to 6 months after beginning BPaL treatment, 
and the majority of participants who have completed two years post treatment follow-up reversed 
or improved (Figure 5.6A). Observed data and simulations showed that peripheral neuropathy had 
reversed in most participants within 2 to 6 months after linezolid dosage reductions to 600 mg or 
300 mg daily or discontinuations, but improvement continued for up to 1 year or more (Figure 
5.6C-Figure 5.6E). In simulations, greater decreases in linezolid dosages were associated with 
slightly faster times to reversal of neuropathy, but linezolid discontinuation did not provide a 
substantial advantage over dosage reduction. Most severe neuropathy occurred toward the end of 
treatment (4 to 6 months after treatment initiation), but severe neuropathy persisted in 3 of 85 
participants (4%) 1 year and 1 of 43 participants (2%) 2 years after treatment completion (based 
on available data at time of analysis) (Figure 5.6A).  In the three participants with severe 
neuropathy at 1 year after treatment completion, peripheral neuropathy was no longer severe at 2 
years after treatment completion (Figure 5.7). However, one participant had increasing maximum 
neuropathy scores even at the end of the 2 year follow up with a severe score in interference with 
walking and moderate score in numbness to the feet and legs (Figure 5.8).  
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Figure 5.7 Distribution of subject-elicited peripheral neuropathy symptom scores at 18 and 32 months 
associated with linezolid treatment (BPaL regimen) for extensively drug resistant tuberculosis. (A) Scores 
at 18 months after start of treatment (1 year after treatment completion). (B) Scores at 32 months after start 
of treatment (2 years after treatment completion). (C) Profiles of peripheral neuropathy scores over time for 
4 participants with persistent severe peripheral neuropathy at 18 and 32 months after start of treatment. 
Colored bar at the bottom of each plot represent linezolid dosage pattern over 6 months.  
 
 
Figure 5.8 Peripheral neuropathy symptom scores over time for one participant with persistent and 
increasing peripheral neuropathy. Left panel shows maximum peripheral neuropathy score based on 
individual scores shown in middle and right panels. Participant D in Figure 5.7.  
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Discussion  
In this study, we have identified dosing and patient management strategies that may permit 
safe administration of linezolid without substantial expected reduction in efficacy. We developed 
the first population PK-toxicodynamic models describing anemia, thrombocytopenia, and 
peripheral neuropathy associated with high-dose linezolid as part of the FDA-approved, 6-month 
BPaL regimen in patients with XDR- and TI/NR-MDR TB. Model simulations suggest comparable 
toxicity rates for QD and BID dosing, but higher rates for higher daily doses. We found that 
pretreatment and week 4 hemoglobin levels can potentially be used to guide early dose adjustments 
to prevent severe anemia, and peripheral neuropathy typically improved after linezolid dosage 
reductions.    
The 2-compartment population PK model with nonlinear Michaelis-Menten elimination 
provided the optimal description of the PK data. The degree of nonlinearity in the model, with 2.7-
fold greater AUC at 1200 mg QD than 600 mg QD, was similar to that observed in a 
noncompartmental PK analysis in TB patients, which showed 2.5-fold greater AUC at 1200 mg 
daily than 600 mg daily,18,19 However, others have also shown linear PK behavior and higher 
elimination at increased linezolid dosages in TB patients.20-22 Furthermore, it is unknown whether 
differences in protein binding when linezolid is administered with strong protein binders such as 
bedaquiline may alter linezolid PK properties. In other non-TB patients, decreased renal function 
may increase linezolid concentrations, but inclusion of a linear elimination pathway did not 
improve our model.23 Overall, based on our simulations, the typical participant AUC at 600 mg 
and 1200 mg daily doses are consistent with previous analyses of linezolid in TB patients.12,24 
For anemia, thrombocytopenia, and peripheral neuropathy, linezolid PK was the only 
predictor of toxicity potency (Table 5.2, final models described in Appendix Table A.7 - Appendix 
Table A.13). Linezolid troughs have previously been shown to predict linezolid adverse events. 
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One study with XDR-TB patients showed that mean mitochondrial function, which is associated 
with linezolid-induced toxicities, decreased with increasing linezolid troughs. In the previous 
study, a clinically-defined adverse event developed in all patients with linezolid trough level > 2 
mg/L but in less than half of the patients with trough level < 2 mg/L.7 In our analysis, linezolid 
trough levels at steady state predicted toxicity to platelets but not anemia or peripheral neuropathy, 
and use of dynamic linezolid profiles accounting for dosage adjustments better predicted all three 
toxicities (Table 5.2). The low predictive power of linezolid trough levels in our analysis may be 
explained, in part, by the higher median linezolid trough level (5.7 mg/L) observed at week 2 than 
the threshold of 2 mg/L cited previously.7  
Delays between linezolid initiation and onset of toxicity were identified both for anemia, 
thrombocytopenia and peripheral neuropathy. Hemoglobin was described with an indirect 
response model that assumes hemoglobin levels are at steady state before treatment onset, decrease 
during treatment, and return to steady state when linezolid is discontinued. However, the median 
hemoglobin levels increased from 12.1 g/dL at pretreatment to 13.5 g/dL at end of treatment (Table 
5.1); consistent with previous findings that preexisting anemia may resolve with anti-TB treatment, 
representing a paradoxical contrast between the effects of linezolid on hemoglobin levels from 
toxicity vs TB improvement.25,26 A logistic growth function was included as a synthesis component 
in hemoglobin response in the model to account for increasing hemoglobin levels after starting 
BPaL treatment (Figure 5.1). 
The present models and simulations may be used in the development of treatment protocols 
and best clinical practices that are needed for linezolid-related toxicities, which are observed at all 
currently-tested linezolid dosages. Although hematologic and nonhematologic toxicities may be 
reversible and manageable,5 predictions for optimal treatment methods may help prevent the 
development of adverse events, especially at linezolid dosages of 1200 mg daily that may be 
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required to treat TB. Investigator-reported events and simulations showed that anemia was 
observed after 8 to 9 weeks of daily linezolid at high doses. Therefore, treatment changes for 
hemoglobin toxicity should begin before 2 months after starting linezolid therapy. Although 
linezolid concentration-time profiles affected toxicity, use of linezolid trough levels at 2 weeks 
had low AUROC for predicting severe anemia (0.56 (90% CI: 0.52-0.60), Figure 5.4) and changes 
in hemoglobin level at 4 weeks vs pretreatment better predicted the development of severe anemia 
(0.91 (90% CI: 0.88-0.93), Figure 5.4). This suggest that the effect of linezolid concentrations on 
hemoglobin levels may be modulated by high variability in individual sensitivity to linezolid 
potency (coefficient of variation for half-maximal inhibitory concentration, IC50, 47%; Appendix 
Table A.10). Therefore, close monitoring of hemoglobin levels is needed for early identification 
of linezolid-induced anemia, with weekly monitoring. Changes in hemoglobin level after 1, 2, and 
4 weeks of linezolid therapy was evaluated for practical application but we found that changes at 
4 weeks optimized the ROC curve for predicting anemia (Figure 5.4Figure 5.4B). The threshold 
of >10% decrease in hemoglobin level at 4 weeks after starting linezolid may optimize the 
sensitivity (0.82) and specificity (0.84) of the hemoglobin level in predicting anemia and may 
prevent 63% of occurrences of severe anemia, with a false-positive rate of only 13% of participants 
who would undergo unnecessary dosage adjustments.  
Severe thrombocytopenia rarely occurred in the Nix-TB trial (1%) so management 
strategies were not evaluated in the present study. However, weekly monitoring of platelet counts 
is still recommended because platelets counts did decrease during treatment (median 354 x 109/L 
at pretreatment vs 262 x 109/L at end of treatment, Table 5.1), although, were still above normal 
levels. 
The most frequent investigator-reported adverse event in the Nix-TB trial was peripheral 
neuropathy but was frequently reversible with linezolid dosage reductions and discontinuation at 
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the discretion of the Nix-TB investigators. Although simulations showed that more aggressive 
dosage reductions were associated with faster reversal of neuropathy (Figure 5.6), most 
participants had neuropathy reversal within 2 to 6 months after dosage reduction or 
discontinuation. Therefore, close monitoring of symptoms included in the neuropathy score, with 
at least monthly documentation, is necessary for early detection of peripheral neuropathy. Dosage 
adjustments (reduction or discontinuation) may depend on a combination of peripheral neuropathy 
severity and treatment efficacy. Analysis of optic neuropathy was not included in the present study 
but is justified because optic neuritis was reported in 2 participants.  
Although favorable efficacy of linezolid has been observed at all daily doses tested, it may 
be difficult to define optimal treatment interventions for linezolid because adverse events may 
occur regardless of daily dose and treatment duration.6,24 The present simulations showed that 
administration of linezolid at lower daily doses reduced the occurrence of adverse events but may 
compromise treatment efficacy or risk the development of acquired resistance because 19% to 
26% of participants did not reach the fAUC/MIC > 100 efficacy target at 600 mg daily dosages 
(Table 5.3).  Further study in the Phase 3 ZeNix trial (NCT03086486), which is a successor trial 
to Nix-TB that will evaluate 4 parallel treatment groups with varied linezolid daily doses (600 and 
1200 mg) and duration (9 and 26 wk), may further clarify the optimal daily dose and duration of 
linezolid in BPaL combination therapy for XDR-TB, pre-XDR-TB, or TI/NR MDR-TB.27 
Strengths of the present study include the composition of participants from South Africa, 
which has among the highest national TB burdens globally,28 and a high percentage of participants 
with HIV coinfection. The data used from the Phase 3 Nix-TB trial was rich; including up to 3 PK 
trough levels per participant, intensive 24-hour PK sampling from 25 participants, a median of 19 
hemoglobin levels and platelet counts per participant for 6 months on treatment, and a median of 
10 peripheral neuropathy scores per participant for up to 2 years after completion of treatment 
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(Table 5.1).4 Therefore, the exposure-toxicity relationships that were defined in our models enable 
unique evidence-based recommendations about treatment to predict and prevent linezolid-related 
toxicity.  
Limitations of the present study include the evaluation of linezolid as a component of BPaL 
combination therapy in XDR-TB and TI/NR MDR, which may limit generalizability to other 
combination therapies or TB populations. As the analyses were limited to data from the Nix-TB 
trial, we did not consider management for anemia, thrombocytopenia and peripheral neuropathy 
other than linezolid dosage reduction. In addition, we did not model the effects of dose adjustments 
on treatment efficacy or benefit-to-risk ratio, and the predicted benefits must be interpreted with 
caution because of potential loss of efficacy that may exceed the benefit of linezolid dosing 
reduction or discontinuation. Although this limitation may be mitigated, in part, by the results of 
our simulations that showed persistent achievement of PK-based efficacy targets (Table 5.3), 
evaluation of the recommended treatment adjustments is justified in future trials.  
In conclusion, the present study provides recommendations for linezolid dosage 
adjustments based on data-driven models and simulations that may help clinicians predict and 
minimize toxicity from high-dose long-term linezolid treatment for XDR-TB and TI/NR MDR 
TB. Model simulations showed that hemoglobin toxicity may be prevented by responding to 
decreased hemoglobin levels in the early weeks after linezolid initiation. Linezolid-induced 
peripheral neuropathy frequently was reversible, but no dose adjustments were identified to 
prevent neuropathy. The quantitative strategies for linezolid toxicities may be applicable toward 
evaluating toxicity profiles of other antimycobacterial treatment combinations.  
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Chapter 6:  Conclusions 
The work presented in this dissertation improved the understanding of treatment response 
following anti-TB treatment. Quantitative, model-based tools were developed to provide evidence-
based recommendations on optimal treatment regimens and strategies that i.) maximize durable 
cure in all patients, ii.) maximize success of late stage regimen development, and iii.) minimize 
safety concerns associated with a highly potent, but toxic, high-dose linezolid-containing regimen. 
In the patient-pooled analysis of recent Phase 3 treatment shortening trials described in 
Chapter 1 and 2, semi-parametric and parametric survival analysis was performed to identify and 
quantify major risk factors of treatment outcomes and predict optimal treatment regimens that 
maximize cure rates for stratified risk groups. An integrated suite of six pragmatic baseline and 
on-treatment risk factors were identified. A risk stratification algorithm based on these risk factors 
effectively stratified patients into low, moderate, and high risk groups and a clinical simulation 
tool provided predictions of optimal treatment regimens. These tools can greatly benefit TB 
patients who can now be assigned optimal treatment regimens to maximize cure rates based on 
their phenotypes. In these analysis, minimal non-adherence and missed doses were also 
significantly associated with high risk of poor outcomes. These findings provide evidence to 
support 7-days-a-week administration for standard-dose rifampin-based regimens.     
To help ensure that the most promising novel regimens are brought through the TB regimen 
development process, we provide a clinical trial simulation tool that can be used to design optimal 
clinical trials. The tool integrates the most studied and broadly acceptable intermediate biomarkers 
assessed in Phase 2B trials, treatment duration, and patient risk factors to predict Phase 3 clinical 
outcomes. Model simulations suggested that potent TB regimens with culture conversion hazard 
ratios of 3 may still undertreat high risk groups when using a one-duration-fits-all approach. We 
provide optimal trial designs for innovative stratified medicine approaches and adjuvant 
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immunotherapeutic strategies that have potential to increase cure rates for all patients. We have 
developed a framework that can be extended and adapted to provide more precise predictions of 
cure rates and further facilitate decisions when more quantitative and sensitive biomarkers are 
discovered and more data from Phase 3 trials testing novel regimens become available.   
A major challenge in TB regimen development process has been the poor sensitivity of 
current Phase 2 culture-based intermediate biomarkers to predict clinical outcomes. In Chapter 4, 
proteomic biomarkers, which are quantitative, easy to collect, and available throughout treatment, 
were evaluated with pharmacokinetic data as predictors of early treatment response by applying 
advanced nonlinear mixed effect modeling with machine learning approaches. The integration of 
proteomic biomarkers, pharmacokinetic data, and clinical risk factors improved predictions of 
treatment response compared to use of these markers alone. As both drug exposure and proteomic 
biomarkers are easily measurable and available throughout treatment, they can be potentially used 
to efficiently predict long-term relapse-free outcomes and inform individualized dosing or 
treatment strategies to maximize cure for all patients.  
In Chapter 5, we provide recommendations for linezolid dosage adjustments based on data-
driven models and simulations that may help predict and minimize toxicity from high-dose long-
term linezolid treatment for XDR-TB and TI/NR MDR-TB. Model simulations showed that 
hemoglobin toxicity may be prevented by responding to decreased hemoglobin levels in the early 
weeks after linezolid initiation. Linezolid-induced peripheral neuropathy frequently was reversible 
and monthly documentation of neuropathic symptoms can prompt linezolid dosage adjustments to 
markedly decrease the occurrence of adverse events.  
In summary, we used quantitative, model-based approaches to characterize treatment 
response in TB patients and provide evidence-based tools that can be used to improve TB cure. 
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Overall, the presented work has contributed to identifying shorter, efficacious, and better-tolerated 
oral regimens for TB that bring us closer to ending the global TB epidemic.  
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Appendix  
Appendix Text A.1  
A proportional odds model was developed to describe the likelihood of occurrence of the 
peripheral neuropathy scores over time in the study. The likelihood was estimated using logit 
transformations to constrain values between 0 and 1 as shown in the equations below:  ÔGFB = 	b 
Ô = 	 %z‚Ò|X1 + %z‚Ò|X 
where b	represents the estimated value of the logit parameter for a particular score for peripheral 
neuropathy and	Ô is the likelihood of a patient experiencing that score. Because there are several 
possible ordered categorical scores (i.e., 0 = normal, 1 = minimal, 2 = modest, 3 = severe.) the 
logits were calculated from values which were coded as shown below:  àø = bø àw = àø + bw 
where bø is the logit of a score greater than or equal to	1 and bw is the additive logit of a score 
greater than or equal to	 2 for possible ordered categorical scores of 0, 1, or 2. à\ would then be 
used to calculate the likelihoods as shown below:  
Ô\ = 	 %Yfl1 + %Yfl 
where Ô\ is the likelihood of having greater than or equal to a score ê.  
The probability of a particular score was then calculated as follows:  ^98rk = 1 − Ôø ^98rø = Ôø − Ôw ^98rw = Ôw 
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where ^98rk, ^98rø, and ^98rw are the probabilities of score 0, 1, and 2, respectively.  
 
Because repeated scores are available for each individual over time an inter-individual error term 
was added to the logits as follows:  ÔGFB = 	b + 	Í 
where 	Í = H(0, Úw) and Úw is estimated.  
The linezolid drug exposure effect, EFF, was added to the logit terms as follows:  ÔGFB = 	b + =uu + 	Í 
where EFF function can be described using a linear (=uu≤:\A>?), Emax (=uu⁄vÅÛ), or sigmoidal 
Emax  (=uu~|Ò&⁄vÅÛ) relationship.  
An additional effect compartment was included in the model to account for delays between 
initiation of linezolid treatment and increased probability of peripheral neuropathy. The transfer 
of plasma concentration into the effect compartment was described by the following differential: j;⁄j/ = 6Ak(;Ù −	;⁄) 
where 6Ak is the first order effect compartment rate and Cp is linezolid concentration in central 
compartment at time t. The apparent drug concentration in the effect compartment (;⁄) was then 
used to describe the effective linezolid concentration in the drug effect functions [e.g., =uu =
⁄vÅÛx ıˆ˜˜⁄x Ëkıˆ˜˜¯x ıˆ˜˜].  
Participant characteristics (age, sex, weight, BMI, and HIV status) were tested as additional 
covariates on the logits in an additive manner as shown below:  ÔGFB = 	b + =uu + 	;G](I) + Í 
where ;G](I) is the covariate relationship of interest. In the untransformed domain, this translates 
to a proportional effect on probability.  
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Appendix Table A.1 Definitions of favorable and unfavorable outcomes per clinical trials used in Chapter 
1. Outcomes defined as favorable are shown in green and outcomes defined as unfavorable are shown in 
red. Refer to trial protocols for exact criteria/definition for each outcome category. N refers to number of 
study participants in MITT analysis population** with corresponding outcome. 
Trial  Outcome  N 
OFLOTUB Favorable  1090* 
By end of treatment, died  14 
By end of treatment, adverse event  2 
By end of treatment, drop-out  52 
By end of treatment, consent withdrawn 16 
By end of treatment, treatment failureǁ  28 
After end of treatment, TB-recurrence, two positive culture¶,ǁ 119 
After end of treatment, TB-recurrence, one positive culture¶,ǁ 21 
After end of treatment, culture negative/unk∫,ǁ 8 
REMoxTB Culture-negative status at 18 mo.  1166 
Unable to produce sputum  2 
Unable to produce sputum at 18 mo. But culture negative status 
earlier  
115 
Missing data on LJ culture at 18 mo. And MGIT negative 40 
6-mo. treatment phase†, nonviolent death  18 
6 mo. treatment phase, adverse reaction  42 
6 mo. treatment phase, withdrawal of consent  34 
6 mo. treatment phase, relocation  10 
6 mo. treatment phase, other investigator decision  7 
6 mo. treatment phase, no completion of treatment  29 
6-mo. treatment phase, treatment failure, culture confirmedǁ 8 
6 mo. treatment phase, treatment failure, not culture confirmedǁ 9 
Follow up, relapse after culture negative statusǁ 123 
Follow up, retreated for tuberculosisǁ 59 
Follow up, no culture negative status everǁ 3 
Follow up, no culture negative status at last visitǁ 7 
Follow up, death from tuberculosis or respiratory distressǁ 2 
RIFAQUIN Favorable  302 
During treatment, death  1 
During treatment, change in treatment due to adverse event  3 
During treatment, lost to follow up 11 
During treatment, inadequate treatment 3 
During treatment, other treatment change 21 
During treatment, failure (culture confirmed)ǁ 4 
After treatment, relapse, culture confirmationǁ 23 
After treatment, relapse, limited bacteriologic confirmationǁ  10 
After treatment, culture positive when last seenǁ  2 
After treatment, death due to tuberculosisǁ  1 
DMID 01-
009** 
Microbiological cure   326 
Clinical cure  28 
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Appendix Table A.1 continued 
Trial  Outcome  N 
DMID 01-
009** 
Bacteriological relapse,ǁ  18 
Death  4 
Lost to follow up  9 
Other  1  
*Six study participants were excluded due inability to verify treatment allocation in source 
database  
† In the REMoxTB trial, treatment phase was defined as 32 weeks after randomization.  
∫smear positive/symptoms 
¶Sixteen TB-recurrences included in the primary analysis for the OFLOTUB trial were MIRU 
confirmed reinfections  
ǁIncluded in TB related outcome definition. 
**For DMID 01-009 trial, data corresponds to time to event analysis population from original 
publication.  
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Appendix Table A.3 Univariate Cox proportional hazard analysis for merged MGIT and LJ culture data 
(as used in primary analysis)*, MGIT data only, and LJ data only in the MITT analysis population. 
Univariate results for experimental group study participants 
Variable N unfavorable/ N 
assessable (%) 
Hazard Ratio 
(95% CI)  
P value  
Month 2 culture negative*  248/1478 (17) Reference Reference 
Month 2 culture positive*  115/336 (34) 2.3 (1.9 - 2.9) <0.001 
Month 2 culture negative- 
MGIT data only  
77/583 (13) Reference Reference 
Month 2 culture positive-
MGIT data only  
141/508 (28) 2.3 (1.7 - 3.0) <0.001 
Month 2 culture negative- LJ 
data only  
233/1386 (17) Reference Reference 
Month 2 culture positive-LJ 
data only  
106/319 (33) 2.2 (1.8 - 2.8) <0.001 
 
 
Variable N unfavorable/ N 
assessable (%) 
Hazard Ratio 
(95% CI)  
P value  
Month 2 culture negative* 113/998 (11) Reference Reference 
Month 2 culture positive* 49/285 (17) 1.6 (1.1 - 2.2) 0.007 
Month 2 culture negative- 
MGIT data only  
24/310 (8) Reference Reference 
Month 2 culture positive-
MGIT data only  
42/296 (14) 1.9 (1.1 - 3.1) 0.02 
Month 2 culture negative- LJ 
data only  
108/915 (12) Reference Reference 
Month 2 culture positive-LJ 
data only  
43/261 (16) 1.5 (1.0 - 2.1) 0.04 
* Culture positivity on either media was used for analyses with preference for solid culture if 
available. 
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Appendix Table A.4 Adjusted hazard ratios for time to stable culture conversion. P value for interaction 
between response groups and drug/drug exposure not significant at a P = 0.01 level.   
 
Train  
Dataset 
Test  
Dataset 
Train + Test 
Dataset 
Independent 
Dataset 
Proteomic signature adjusted for drug (rifampin vs rifapentine)  
N 379a 158a 538a 30 
Stable Culture Conversion  
Hazard Ratio  
Median (95% CI)   
  
Moderate responders relative to 
slow responders  1.5 (1.1-2.1) 2.3 (1.3-3.9) 1.6 (1.2-2.2) 1.7 (0.5-5.1) 
Fast responders relative to slow 
responders  2.3 (1.7-3.0) 2.5 (1.6-3.6) 2.3 (1.9-2.9) 2.3 (0.8-6.5) 
Proteomic signature adjusted for drug exposure (rifapentine AUC) and clinical risk factors  
N  236a 99a 335a - 
Stable Culture Conversion  
Hazard Ratio  
Median (95% CI)  
  
 
Moderate responders relative to 
slow responders  1.2 (0.6-2.5) 1.1 (0.4-2.7) 1.1 (0.7-1.9) - 
Fast responders relative to slow 
responders  2.4 (1.2-4.5) 1.7 (0.7-4.0) 2.0 (1.2-3.3) - 
a Two participants in training dataset and one participants in testing dataset missing time to stable culture 
conversion 
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Appendix Table A.6 Relative variable importance for top 5 proteomic predictors in CART analysis. 
Variable importance is calculated as the sum of the decrease in root mean squared error when variable is 
used to split a node. Relative importance is scaled to the most important variable and transformed into a 
percentage.  
Proteomic signature after adjusting for rifamycin drug only   
Variable  Relative Importance (%) 
Week 8 RANTES 100 
Week 8 SAA1 52 
Week 8 CRP  51 
Baseline RANTES 45 
W8 LBP  43 
Proteomic signature after adjusting for rifapentine 
exposure and clinical risk factors 
Variable  Relative Importance (%) 
Week 8 SAA1 100 
Ratio week 8 to baseline SAA1 93 
Week 8 CRP 81 
Week 8 MMP8 78 
Week 8 MMP9  77 
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Appendix Table A.7 Differential equations that describe the final linezolid PK model 
Absorption compartment (A) jAj/ = −6>A 
 
Central compartment (AC) jExj/ = 6>A −
]âEÂExEx]≥ + ˙c ]≥˚ + ]¸Ù E± − ]¸≥ Ex  
 ]âEÂ =	;Ô:\#˙c 
Peripheral compartment (AP) jE±j/ = − ]¸Ù E± + ]¸≥ Ex  
 
A, AC, AP, amounts in absorption, central, and peripheral compartments; Vc, apparent central volume of 
distribution; Vp, apparent peripheral volume of distribution; Q, apparent inter-compartment clearance; ka, 
absorption rate constant; Km, Michaelis-Menten constant; and CLint, Michaelis-Menten intrinsic clearance; 
VMAX= CLintKm, maximum rate of elimination (saturated elimination). Log-normal inter-individual 
variability was tested on ka, Km, CLint, and  ]≥ The following equation was used: :^	 = B]^%IL_Í±–d where :^	 is the estimated parameter for individual, 4; B]^ is the typical value (median) for the parameter, and Í±– 
is the inter-individual random effect reflecting the difference between an individual’s parameter value and 
the population’s typical value where Í±– = H(0,Úw) and Úw is the variance of Í±–, which is estimated in 
model fitting. The coefficient of variation (;]%= 1005˛9/(exp(Úw) − 1)) is reported. A proportional 
model was used to explain residual variability. The following equation was used: :ˇ,!	 = u:,!	(1 + ":,!) 
where :ˇ,!	gêj	u:,!	 are the observed and model predicted dependent variable values, respectively, for 
individual, 4, and sampling timepoint, #; and  ":,! is the unexplained residual error reflecting the difference 
between observed and model predicted data where ":,! = H(0, Îw) and Î is the standard deviation of ":,!, 
which is estimated in the model fitting.   
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Appendix Table A.8 Parameter estimates for final linezolid PK model. CV% is the percent coefficient of 
variation of the parameter’s inter-individual variability, and RSE% is the percent relative standard error of 
the parameter estimate. See Appendix Table A.7 and Chapter 5: for more details on structural and stochastic 
models. 
Parameter (units) Estimate (RSE %) CV % (RSE %) 
Intrinsic clearance, CLint (L/h) 8.5 (3) 5.5 (80) 
Michaelis-Menten Constant, Km (mg/L) 15 (2)  
Volume of distribution, VC (L) 59 (2) 66 (27) 
Rate of absorption, ka, (1/h) 1.6 (1) 146 (20) 
Inter-compartment clearance, Q, (L/h) 1.3 (1)  
Peripheral Volume, Vp, (L) 31.3 (4)  
Standard deviation of proportional residual 
error, Î  0.29 (18)  
Inter-occasion variability for CLint (CV%) 28 (10)  
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Appendix Table A.9 Differential equations that describe the final linezolid dosing hemoglobin model 
Hemoglobin 
compartment (Hb) 
  	 j$rj/ = 6:\(1 − =uu{%(;±)) −	6[¥#$r	 +	B3B?>#A$r(B3B≥>Ù −$rB3B≥>Ù ) 
 =uu{%(;±) = =âEÂ;Ù{|zzF;50{|zz + ;Ù{|zz 
 
Hb, hemoglobin level; kout, first order hemoglobin elimination rate constant; kin, zero-order hemoglobin 
synthesis rate constant, which equals the product of pretreatment hemoglobin, BASEHb and kout; TRTrate, 
rate of increase in hemoglobin, and TRTcap, maximum hemoglobin level, for logistic growth function 
describing improved hemoglobin levels upon initiating anti-TB treatment; EFFHb(Cp), linezolid 
concentration-response relationship; ;Ù, concentration of linezolid at time t; EMAX, maximum inhibitory 
effect;  F;50, concentration to reach half maximal inhibitory effect; $FÔÔ, Hill coefficient that describes 
the shape of the curve. Log-normal inter-individual variability was tested on kout, TRTrate, TRTcap, EMAX, 
and IC50. The following equation was used: :^	 = B]^%IL_Í±–d where :^	 is the estimated parameter for 
individual, 4; B]^ is the typical value (median) for the parameter, and Í±– is the inter-individual random 
effect reflecting the difference between an individual’s parameter value and the population’s typical value 
where Í±– = H(0,Úw) and Úw is the variance of Í±–, which is estimated in model fitting. The coefficient 
of variation (;]%= 1005˛9/(exp(Úw) − 1)) is reported. Correlations between random effects, g and r, 
were predicted using the following formula: Ú>,% (Ú>w + Ú%w& ), where Ú>w is the variance of parameter g, Ú%w is the variance of parameter r, and Ú>,% is the covariance between parameter	g and r. An additive 
model was used to explain residual variability. The following equation was used: :ˇ,!	 = u:,!	 + ":,! where :ˇ,!	gêj	u:,!	are the observed and model predicted dependent variable values, respectively, for individual, 4, and sampling timepoint, #; and  ":,! is the unexplained residual error reflecting the difference between 
observed and model predicted data where ":,! = H(0, Îw) and Î is the standard deviation of ":,!, which is 
estimated in the model fitting.  
 
  
172 
 
Appendix Table A.10 Parameter estimates for final linezolid dosing hemoglobin model. CV% is the 
percent coefficient of variation of the parameter’s inter-individual variability, and RSE% is the percent 
relative standard error of the parameter estimate. Sex was implemented into the model to explain the 
fractional decrease in pretreatment hemoglobin levels using the following linear relationship: àE"={%,¤⁄vÅz⁄ = 	àE"={%(1 − b¤⁄vÅz⁄). See Appendix Table A.9 and Chapter 5: for more details on 
structural and stochastic models. 
Parameter (units) Estimate (RSE %) CV % (RSE %) 
Pretreatment hemoglobin, BASEHb (g/dL) 13 (2) 12 (9) 
1/rate of elimination of hemoglobin [1/6[¥# ] (h) 3685 (9) 97 (8) 
Logistic growth rate for treatment 
progression*1000, TRTrate*1000 (1/h) 
0.44 (18) 52 (20) 
Logistic growth capacity for treatment 
progression, TRTcap (g/dL) 
19 (7) 28 (21) 
IC50 (mg/L) 7.7 (11) 47 (23) 
EMAX (%) 100 FIX  
HILL Coefficient  10 FIX  
Fractional decrease in baseline hemoglobin for 
females, b¤⁄vÅz⁄  0.10 (21)  
Standard deviation of additive residual error, Î 
(g/dL) 
0.70 (6)  
Correlations between random effects:    
 TRTrate and TRTcap -0.65 (21)  
 TRTrate and 1/6[¥# -0.48 (17)  
 1/6[¥# and IC50  -0.57 (20)  
 
  
173 
 
Appendix Table A.11 Differential equations that describe the final linezolid dosing platelet model 
Progenitor cell 
compartment (Prol) 
  	 j^98'j/ = 6Ù?[≤^98'(1 − =uu±≤>#A≤A#(;±))(;497k ;497⁄ )( − 6#?^98' 
 =uu±≤>#A≤A#(;±) = =âEÂ;Ù(/){|zzF;50{|zz + ;Ù(/){|zz 
 
Transit compartment 1 jB9gê54/øj/ = 6#?^98' −	6#?B9gê54/ø 
 
Transit compartment 2 jB9gê54/wj/ = 6#?B9gê54/ø −	6#?B9gê54/w 
 
Transit compartment 3 jB9gê54/)j/ = 6#?B9gê54/w −	6#?B9gê54/) 
 
Circulating cells 
(Platelets) (Circ) 
j;497j/ = 6#?B9gê54/) −	6≥:?≥;497 
 
Prol, amount of proliferative/progenitor cells; Transit x, transit compartments representing cell maturation 
process; Circ, circulation compartment; kprol, first-order proliferation rate constant, assumed equal to ktr; 
ktr, first-order transit rate constant; MTT, mean transit time = (No. transit compartments+1)/ktr; kcirc, first-
order rate of elimination from circulation compartment; Circo, baseline platelet level; and Ó homeostatic 
feedback parameter; EFFPlatelet(Cp), linezolid concentration-response relationship; ;Ù(/), concentration of 
linezolid at time t; EMAX, maximum inhibitory effect;  F;50, concentration to reach half maximal 
inhibitory effect; $FÔÔ, Hill coefficient that describes the shape of the curve. Log-normal inter-individual 
variability was tested on kout, TRTrate, TRTcap, EMAX, and IC50. The following equation was used: :^	 =B]^%IL_Í±–d where :^	 is the estimated parameter for individual, 4; B]^ is the typical value (median) for 
the parameter, and Í±–  is the inter-individual random effect reflecting the difference between an 
individual’s parameter value and the population’s typical value where Í±– = H(0,Úw) and Úw  is the 
variance of Í±– , which is estimated in model fitting. The coefficient of variation ( ;]% = 1005˛9/(exp(Úw) − 1)) is reported. Correlations between random effects, g and r, were predicted using 
the following formula: Ú>,% (Ú>w + Ú%w& ), where Ú>w is the variance of parameter g, Ú%w is the variance of 
parameter r, and Ú>,% is the covariance between parameter	g and r. A proportional model was used to 
explain residual variability. The following equation was used: :ˇ,!	 = u:,!	(1 + ":,!) where :ˇ,!	gêj	u:,!	are 
the observed and model predicted dependent variable values, respectively, for individual, 4, and sampling 
timepoint, #; and  ":,! is the unexplained residual error reflecting the difference between observed and 
model predicted data where ":,! = H(0, Îw) and Î is the standard deviation of ":,!, which is estimated in 
the model fitting.   
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Appendix Table A.12 Parameter estimates for final linezolid dosing platelet model CV% is the percent 
coefficient of variation of the parameter’s inter-individual variability and RSE% is the percent relative 
standard error of the parameter estimate. See Appendix Table A.11 and Chapter 5: for more details on 
structural and stochastic models. 
Parameter (units) Estimate (RSE %) CV % (RSE %) 
Pretreatment platelet, Circ0 (109/L) 340 (6) 31 (10) 
Mean transit time, MTT = (4/ktr) (h) 144 (8) 9 (26) 
Homeostatic feedback parameter, Ó 0.28 (13)  
IC50 (mg/L)  4.1 (18) 105 (11) 
EMAX (%) 8 (14) 49 (13) 
HILL coefficient  3.1 (9)   
Standard deviation of proportional residual error, Î  0.17 (4)  
Correlations between random effects:    
 Circ0 and MTT 0.36 (50)  
 Circ0 and IC50  -0.48 (16)  
 MTT and IC50  -0.84 (22)  
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Appendix Table A.13 Parameter estimates for final linezolid dosing proportional odds peripheral 
neuropathy model. SD is the standard deviation of the base logit parameter’s inter-individual variability 
and RSE% is the percent relative standard error of the parameter estimate. See Appendix Text A.1 for more 
details on structural and stochastic models. 
Parameter (units) Estimate (RSE %) SD (RSE)  
Base logit value for score ≥ 1 -1.3 (22) 1.7 (11) 
Additive base logit value for score ≥ 4 -1.1 (11) 
Additive base logit value for score ≥ 8 -1.9 (9) 
First order effect compartment rate, ke0 (1/h) 5.9E-5 (3)  
Maximum effect of effect compartment concentrations on 
increasing logit, EMAX  
3.4 (23)  
Half maximal effect compartment concentration, ECE50 
(mg/L) 
1.3 (33)  
HILL coefficient for sigmoidal effect on logit 4.9 (33)  
 
 
Appendix Table A.14 Observed and model simulated proportions of maximum subject-elicited symptom 
scores for peripheral neuropathy over time after treatment with BPaL regimen. Simulations show median 
and 95% prediction interval.  
Time (months) Score Observed Proportion  Simulated Proportion  
[Median (95% PI)] 
0 Normal, 0 0.76 0.78 (0.69-0.86) 
0 Minimal, 1-3 0.10 0.11 (0.06-0.18) 
0 Modest, 4-7 0.13 0.08 (0.04-0.15) 
0 Severe, 8-10 0.01 0.03 (0-0.06) 
3 Normal, 0 0.58 0.56 (0.48-0.66) 
3 Minimal, 1-3 0.18 0.16 (0.10-0.25) 
3 Modest, 4-7 0.18 0.18 (0.12-0.24) 
3 Severe, 8-10 0.06 0.09 (0.04-0.15) 
6 Normal, 0 0.31 0.41 (0.31-0.50) 
6 Minimal, 1-3 0.23 0.17 (0.12-0.23) 
6 Modest, 4-7 0.28 0.23 (0.17-0.33) 
6 Severe, 8-10 0.18 0.17 (0.12-0.28) 
19 Normal, 0 0.52 0.55 (0.43-0.63) 
19 Minimal, 1-3 0.23 0.15 (0.10-0.25) 
19 Modest, 4-7 0.20 0.19 (0.10-0.30) 
19 Severe, 8-10 0.04 0.11 (0.04-0.17) 
32 Normal, 0 0.60 0.67 (0.58-0.81) 
32 Minimal, 1-3 0.12 0.14 (0.06-0.22) 
32 Modest, 4-7 0.26 0.12 (0.07-0.22) 
32 Severe, 8-10 0.02 0.07 (0.02-0.12) 
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Appendix Table A.15 Area under the receiver operating characteristic curves for univariate models for 
prediction of reported anemia adverse events after treatment with BPaL regimen 
Model  AUROC (90% 
confidence interval) 
BMI 0.50 (0.39-0.61) 
Weight 0.51 (0.37-0.60) 
HIV status  0.53 (0.43-0.63) 
Sex 0.54 (0.55-0.64) 
Age 0.58 (0.46-0.69) 
Pretreatment Hb levels 0.56 (0.44-0.67) 
Week 1 Hb levels 0.53 (0.44-0.67) 
Percent change in Hb at Week 1 0.50 (0.38-0.53) 
Week 2 Hb levels 0.63 (0.52-0.74) 
Percent change in Hb at Week 2 0.62 (0.51-0.73) 
Week 4 levels  0.73 (0.64-0.82) 
Percent change in Hb at Week 4 0.71 (0.61-0.81) 
Observed linezolid troughs, week 2 0.52 (0.41-0.63) 
Simulated SS Cmin 0.61 (0.51-0.72) 
Simulated SS CMAX  0.62 (0.51-0.72) 
Simulated SS AUC24 0.60 (0.49-0.70) 
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Appendix Figure A.1 Univariate Cox proportional hazard analysis with X-Ray measurements in the MITT 
analysis population for the experimental group in pooled patient-level analysis. Measurements collected at 
baseline are shown in the top panel and measurements collected at the end of treatment are shown in the 
bottom panel. Cavity size at baseline was collected in the RIFAQUIN trial. Disease Extent, Disease Grade, 
and Lung Zone Score was collected in the OFLOTUB trial. Hazard ratios with 95% Wald confidence 
interval are reported.  
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Appendix Figure A.2 Univariate Cox proportional hazard analysis with X-Ray measurements in the MITT 
analysis population for the control group in pooled patient-level analysis. Measurements collected at 
baseline are shown in the top panel and measurements collected at the end of treatment are shown in the 
bottom panel. Cavity size at baseline was collected in the RIFAQUIN trial. Disease Extent, Disease Grade, 
and Lung Zone Score was collected in the OFLOTUB trial. Hazard ratios with 95% Wald confidence 
interval are reported.  
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Appendix Figure A.3 Kaplan-Meier visual predictive checks for final model describing TB-related 
outcomes stratified by covariates of interest: (A) number of treatment days, (B) baseline smear grade, (C) 
month 2 culture status, (D) HIV status, (E) baseline cavitation status, (F) sex, (G) clinic site, (H) inclusion 
of isoniazid, and (I) BMI. 
 
Appendix Figure A.4 Kaplan-Meier visual predictive checks for final model describing TB-related 
outcomes stratified by risk groups: low risk (left panel), medium risk (center panel), high risk (right panel) 
as defined by target cure rate of 93% at 18 months since start of treatment. 
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Appendix Figure A.5 Kaplan Meier visual predictive checks for final model describing non-TB-related 
outcomes stratified by age.    
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Appendix Figure A.6 Simulated proportions of peripheral neuropathy scores following various linezolid 
dosage administrations in BPaL regimen 
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